Ictrp Covid-19

TrialID Last Refreshe Public title
A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019

NCT042462 3-Feb-20 Novel Coronavirus (2019-nCoV)
A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane

ChiCTR200 17-Feb-20 Oxygenation in Patients with Severe Novel Coronavirus Pneumonia (COVID-19)
Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus

ChiCTR200 17-Feb-20 Pneumonia (COVID-19)
A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel

ChiCTR200 17-Feb-20 Coronavirus Pneumonia 2019 (COVID-19)
A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of

ChiCTR200 17-Feb-20 Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)
Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel

ChiCTR200 17-Feb-20 coronavirus pneumonia (COVID-19)
Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of
ChiCTR200 17-Feb-20 Acute Novel Coronavirus Pneumonia (COVID-19)
Clinical study of a novel high sensitivity nucleic acid assay for novel coronavirus
ChiCTR200 17-Feb-20 pneumonia (COVID-19) based on CRISPR-cas protein
Study on convalescent plasma treatment for severe patients with novel coronavirus
ChiCTR200 17-Feb-20 pneumonia (COVID-19)
Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of
ChiCTR200 17-Feb-20 Children with Novel Coronavirus Pneumonia (COVID-19)
Study for the key issues of the diagnosis and treatment of novel coronavirus
ChiCTR200 17-Feb-20 pneumonia (COVID-19) based on the medical imaging
Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in
ChiCTR200 17-Feb-20 Treatment of Novel Coronavirus Pneumonia (COVID-19)
ChiCTR200 17-Feb-20 Analysis of clinical characteristics of severe novel coronavirus pneumonia (COVID-19)
Randomized controlled trial for TCM syndrome differentiation treatment impacting
quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-
ChiCTR200 17-Feb-20 19)
A multicenter, randomized, controlled trial for integrated chinese and western
medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the
ChiCTR200 17-Feb-20 'Truncated Torsion' strategy
A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-
Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-
ChiCTR200 17-Feb-20 19)
Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay

NCT042456 17-Feb-20 for 2019-nCoV
The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus
NCT042528 17-Feb-20 Infection
NCT042559 17-Feb-20 2019-nCoV Outbreak and Cardiovascular Diseases
A Survey of Psychological Status of Medical Workers and Residents in the Context of

NCT042603 17-Feb-20 2019 Novel Coronavirus Pneumonia
Clinical study for the changes in mental state of medical staff in the department of
radiotherapy in a comprehensive tertiary hospital in Zhejiang Province during the
ChiCTR200 17-Feb-20 epidemic of novel coronavirus infection (COVID-19)
Imaging Features and Mechanisms of Novel Coronavirus Pneumonia (COVID-19): a
ChiCTR200 17-Feb-20 Multicenter Study
A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate
ChiCTR200 17-Feb-20 Injection in the treatment of patients with pneumonia (COVID-19)
Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus
(CoVID-19) infections: a prospective, open-label, multicenter randomized controlled
ChiCTR200 17-Feb-20 clinical study
Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused

NCT042605 17-Feb-20 by Novel Coronavirus
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected

NCT042614 17-Feb-20 Pneumonia
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and

NCT042619 17-Feb-20 Lopinavir/Ritonavir for Novel Coronavirus Infection
An observational study for Xin-Guan-1 formula in the treatment of novel coronavirus

Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus
ChiCTR200 17-Feb-20 pneumonia (COVID-19): a single arm clinical trial
Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-

ChiCTR200 17-Feb-20 Throughput Mass Spectrometry Analysis With Exhaled Breath
A randomized, open-label study to evaluate the efficacy and safety of low-dose

ChiCTR200 17-Feb-20 corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)
A comparative study on the sensitivity of nasopharyngeal and oropharyngeal

ChiCTR200 17-Feb-20 swabbing for the detection of SARS-CoV-2 by real-time PCR
A multicenter, randomized, controlled trial for integrated Chinese and western
medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19)
ChiCTR200 17-Feb-20 based on the ' Internal and External Relieving -Truncated Torsion' strategy
A randomized controlled trial for Traditional Chinese Medicine in the treatment for
ChiCTR200 17-Feb-20 Novel Coronavirus Pneumonia (COVID-19)
A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the

ChiCTR200 17-Feb-20 treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)
Study for construction and assessment of early warning score of the clinical risk of
ChiCTR200 17-Feb-20 novel coronavirus (COVID-19) infected patients
A medical records based study of novel coronavirus pneumonia (COVID-19) and

ChiCTR200 17-Feb-20 influenza virus co-infection
An open, prospective, multicenter clinical study for the efficacy and safety of
ChiCTR200 17-Feb-20 Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19)
Chinese medicine prevention and treatment program for novel coronavirus

ChiCTR200 17-Feb-20 pneumonia (COVID-19): a perspective, sing-arm trial
The efficacy and safety of carrimycin treatment in patients with novel coronavirus
ChiCTR200 17-Feb-20 pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial
Application of Regulating Intestinal Flora in the Treatment of Severe Novel

ChiCTR200 17-Feb-20 Coronavirus Pneumonia (COVID-19)
Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in

ChiCTR200 17-Feb-20 Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19)
A real world study for traditional Chinese Medicine in the treatment of novel
Chinese medicine prevention and treatment program for novel coronavirus
pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled
ChiCTR200 17-Feb-20 trial
Chinese medicine prevention and treatment program for suspected novel coronavirus
pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled
Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia

ChiCTR200 17-Feb-20 (COVID-19)
A randomized, open and controlled clinical trial for traditional Chinese medicine in the
ChiCTR200 17-Feb-20 treatment of novel coronavirus pneumonia (COVID-19)
A randomized controlled trial for honeysuckle decoction in the treatment of patients

ChiCTR200 17-Feb-20 with novel coronavirus (COVID-19) infection
Psychological survey of frontline medical staff in various regions of China during the
ChiCTR200 17-Feb-20 epidemic of novel coronavirus pneumonia (COVID-19)
Community based prevention and control for Chinese medicine in the treatment of
novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed
ChiCTR200 17-Feb-20 population
Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in
the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a
ChiCTR200 17-Feb-20 randomized controlled trial
Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental
Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent
ChiCTR200 17-Feb-20 Period
Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality
of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent
ChiCTR200 17-Feb-20 Period: a Randomized Controlled Trial
Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus

ChiCTR200 17-Feb-20 Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19)
A randomized, open-label, controlled clinical trial for azvudine in the treatment of

ChiCTR200 17-Feb-20 novel coronavirus pneumonia (COVID-19)
An observational study on the clinical characteristics, treatment and outcome of novel

Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia
A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-

ChiCTR200 17-Feb-20 Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)
Clinical study for the integration of traditional Chinese and western medicine in the
Traditional Chinese medicine cooperative therapy for patients with novel coronavirus
ChiCTR200 17-Feb-20 pneumonia (COVID-19): a randomized controlled trial
A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in
ChiCTR200 17-Feb-20 the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)
Clinical study for the remedy of M1 macrophages target in the treatment of novel
Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the
Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using
ChiCTR200 17-Feb-20 Chinese Medicine Technology and its Clinical Application Evaluation
Ba-Bao-Dan in the adjuvant therapy of novel coronavirus pneumonia (COVID-19)
ChiCTR200 17-Feb-20 patients
Study for clinical characteristics and distribution of TCM syndrome of novel

A randomized controlled trial of integrated TCM and Western Medicine in the

ChiCTR200 17-Feb-20 treatment of severe novel coronavirus pneumonia (COVID-19)
A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in
ChiCTR200 17-Feb-20 the treatment of new coronavirus pneumonia (COVID-19)
The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-
19) patients treated in square cabin hospital: a prospective, randomized controlled
Clinical Application of ECMO in the Treatment of Patients with Very Serious

ChiCTR200 17-Feb-20 Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19)
Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus
A single arm study for evaluation of integrated traditional Chinese and western
ChiCTR200 17-Feb-20 medicine in the treatment of novel coronavirus pneumonia (COVID-19)
Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a

ChiCTR200 17-Feb-20 Randomized Controlled Trial
ChiCTR200 17-Feb-20 Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients
Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus

A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated
capsules combined with vitamin C tablets in the treatment of common novel
coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral
ChiCTR200 17-Feb-20 treatment to evaluate
Study for the Effect of Novel Coronavirus Pneumonia (COVID-19) on the Health of
ChiCTR200 17-Feb-20 Different People
Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel
ChiCTR200 25-Feb-20 coronavirus pneumonia (COVID-19) and clinical application demonstration
Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with
ChiCTR200 25-Feb-20 antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)
Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of
ChiCTR200 17-Feb-20 Novel Coronavirus Pneumonia (COVID-19)
Risks of Death and Severe cases in Patients with 2019 Novel Coronavirus Pneumonia
Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus

A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen
Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia
A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus

Safety and effectiveness of human umbilical cord mesenchymal stem cells in the
treatment of acute respiratory distress syndrome of severe novel coronavirus
Impact of vitamin D deficiency on prognosis of patients with novel coronavirus

Study for Mental health and psychological status of doctors, nurses and patients in
novel coronavirus pneumonia (COVID-19) designated hospital and effect of
ChiCTR200 17-Feb-20 interventions
Epidemiological investigation and clinical characteristics analysis of novel coronavirus

Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus

A clinical observational study for Xin-Guan-2 formula in the treatment of suspected

Construction of Early Warning and Prediction System for Patients with Severe /
ChiCTR200 17-Feb-20 Critical Novel Coronavirus Pneumonia (COVID-19)
Clinical study for community based prevention and control strategy of novel
ChiCTR200 17-Feb-20 coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population
Clinical study for safety and efficacy of Favipiravir in the treatment of novel
Study for application of simplified cognitive-behavioral therapy for related emergency
psychological stress reaction of medical providers working in the position of
ChiCTR200 25-Feb-20 treatment and control of novel coronavirus pneumonia (COVID-19)
A multicenter study for efficacy of intelligent psychosomatic adjustment system
intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients
ChiCTR200 25-Feb-20 with mild to moderate anxiety and depression
Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of
severe and critically novel coronavirus pneumonia(COVID-19): a randomized
ChiCTR200 17-Feb-20 controlled clinical trial
Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-

ChiCTR200 17-Feb-20 19)
A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil,
Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still
ChiCTR200 17-Feb-20 positive on virus detection under the current antiviral therapy
A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir
combined with thymosin a1 in the treatment of novel coronavirus pneumonia
Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV

NCT042685 24-Feb-20 Immunoregulatory Therapy for 2019-nCoV
Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy

ChiCTR200 25-Feb-20 severe novel coronavirus pneumonia (COVID-19)
Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia

ChiCTR200 17-Feb-20 (COVID-19) in Children
A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir
alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus
A prospective, open-label, multiple-center study for the efficacy of chloroquine

ChiCTR200 17-Feb-20 phosphate in patients with novel coronavirus pneumonia (COVID-19)
Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of
ChiCTR200 17-Feb-20 Acute Novel Coronavirus Pneumonia (COVID-19)
Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-

ChiCTR200 25-Feb-20 19): a multicenter, randomized, open-label, controlled trial
A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult
A single arm study for combination of traditional Chinese and Western Medicine in
ChiCTR200 17-Feb-20 the treatment of novel coronavirus pneumonia (COVID-19)
Randomized controlled trial for traditional Chinese medicine in the prevention of

ChiCTR200 17-Feb-20 novel coronavirus pneumonia (COVID-19) in high risk population
A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian

ChiCTR200 17-Feb-20 oral solution in the treatment of ovel coronavirus pneumonia (COVID-19)
A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the
Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases
ChiCTR200 17-Feb-20 of Novel Coronavirus Pneumonia (COVID-19)
Study for the TCM syndrome characteristics of novel coronavirus pneumonia (COVID-
ChiCTR200 17-Feb-20 19)
Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel
ChiCTR200 25-Feb-20 A cross-sectional study of novel coronavirus pneumonia (COVID-19) patients in ICU
Randomized controlled trial for safety and efficacy of Favipiravir in the treatment of
ChiCTR200 25-Feb-20 novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir
Recommendations of Integrated Traditional Chinese and Western Medicine for
Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan
ChiCTR200 17-Feb-20 Province
Randomized, open-label, controlled trial for evaluating of the efficacy and safety of
Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel
ChiCTR200 17-Feb-20 coronavirus pneumonia (COVID-19) patients
Study for establishment of correlation between virological dynamics and clinical

ChiCTR200 25-Feb-20 features in noveal coronavirus pneumonia (COVID-19)
Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body

ChiCTR200 25-Feb-20 construction and psychological state for female at different ages
A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and
Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia
The effect of shadowboxing for pulmonary function and quality of life in patients with
ChiCTR200 17-Feb-20 novel coronavirus pneumonia (COVID-19) in rehabilitation period
Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia

ChiCTR200 25-Feb-20 (COVID-19): a multicentre, randomized controlled trial
Study on ultrasonographic manifestations of new type of novel coronavirus

ChiCTR200 25-Feb-20 pneumonia (covid-19) in non-critical stage of pulmonary lesions
Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute
NCT042445 24-Feb-20 Respiratory Failure
The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of

ChiCTR200 25-Feb-20 Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)
A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated
convalescent plasma in the treatment of novel coronavirus pneumonia patient
A medical records based study for acute kidney injury in novel coronavirus
The effect of pulmonary rehabilitation for pulmonary function and quality of life in
ChiCTR200 17-Feb-20 patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period
Combination of traditional Chinese medicine and western medicine in the treatment

ChiCTR200 17-Feb-20 of common type novel coronavirus pneumonia (COVID-19)
A multi-center study on the efficacy and safety of suramin sodium in adult patients
ChiCTR200 25-Feb-20 with novel coronavirus pneumonia (COVID-19)
Clinical comparative study of PD-1 mAb in the treatment of severe and critical
ChiCTR200 25-Feb-20 patients with novel coronavirus pneumonia (COVID-19)
Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the

ChiCTR200 25-Feb-20 treatment of Novel coronavirus pneumonia (COVID-19)
Multicenter randomized controlled trial for rhG-CSF in the treatment of novel

Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel

Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus

A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel

Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-

NCT042695 24-Feb-20 novel Coronavirus(nCOV) Pneumonia
Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus
pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled
Development of anti-2019-nCoV therapeutic antibody from the recovered novel

ChiCTR200 25-Feb-20 coronavirus pneumonia patients (COVID-19)
A multicenter, randomized, open, parallel controlled trial for the evaluation of the
effectiveness and safety of Xiyanping injection in the treatment of common type
A clinical research for the changes of Blood cortisol ACTH level and adrenal
morphology in blood cortisol to guide the application of individualized hormone in
ChiCTR200 25-Feb-20 severe novel coronavirus pneumonia (COVID-19) patients
Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical

Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment
ChiCTR200 25-Feb-20 severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)
Assessment of cardiac function in patients with Novel Coronavirus Pneumonia

ChiCTR200 25-Feb-20 (COVID-19) by echocardiography and its new techniques
A Prospective Randomized Controlled Trial for Home Exercise Prescription
Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College
ChiCTR200 25-Feb-20 Students
A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and
safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel
ChiCTR200 25-Feb-20 coronavirus pneumonia patients (COVID-19)
A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir
ChiCTR200 25-Feb-20 Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)
An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and
integrated traditional Chinese and Western medicine in the treatment of novel
ChiCTR200 25-Feb-20 coronavirus infection (COVID-19)
Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel

ChiCTR200 25-Feb-20 Coronavirus Infection (COVID-19)
A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in

ChiCTR200 25-Feb-20 the treatment of novel coronavirus pneumonia (COVID-19)
Study for the effect of early endotracheal intubation on the outcome of novel
ChiCTR200 25-Feb-20 coronavirus pneumonia (COVID-19) patients
Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel
ChiCTR200 25-Feb-20 Humanistic Care in Healthcare Workers in Novel Coronavirus Pneumonia (COVID-19)
Study on anxiety of different populations under novel coronavirus (COVID-19)

ChiCTR200 25-Feb-20 infection
Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life
in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized
ChiCTR200 25-Feb-20 Controlled Trial
A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-
ChiCTR200 25-Feb-20 Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)
Feature of Multiple Organs in Ultrasound Investigation for Clinical Management and

ChiCTR200 25-Feb-20 Prognostic Evaluation of Novel Coronavirus Pneumonia (COVID-19)
A randomized controlled trial for the efficacy of Dao-Yin in the prevention and
ChiCTR200 25-Feb-20 controlling novel coronavirus pneumonia (COVID-19)
Comparative study for integrate Chinese and conventional medicine the the
ChiCTR200 25-Feb-20 treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province
Study for the correlation between the incidence and outcome of novel coronary
ChiCTR200 25-Feb-20 pneumonia (COVID-2019) and ovarian function in women
Correalation between anxiety as well as depression and gut microbiome among staff
ChiCTR200 25-Feb-20 of hospital during the novel coronavirus pneumonia (COVID-19) outbreak
ChiCTR200 25-Feb-20 Humanistic Care in Patients With Novel Coronavirus Pneumonia (COVID-19)
A multicenter randomized controlled trial for ozone autohemotherapy in the

A randomized controlled trial for the efficacy of ozonated autohemotherapy in the

ChiCTR200 25-Feb-20 treatment of Novel Coronavirus Pneumonia (COVID-19)
The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19):
ChiCTR200 25-Feb-20 a multicenter, randomized, double blinded, placebo-controlled trial
A clinical study for the efficacy and safety of Adalimumab Injection in the treatment of
ChiCTR200 25-Feb-20 patients with severe novel coronavirus pneumonia (COVID-19)
Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of
ChiCTR200 25-Feb-20 severe novel coronavirus pneumonia (COVID-19)
A multicenter, randomized, open and controlled trial for the efficacy and safety of
ChiCTR200 25-Feb-20 Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)
Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus

ChiCTR200 25-Feb-20 pneumonia (COVID-19) patients(randomized open-label control clinical trial)
Clinical study for the diagnostic value of pulmonary ultrasound for novel coronavirus
Study for the effects on medical providers' infection rate and mental health after
performing different anesthesia schemes in cesarean section for novel coronavirus
ChiCTR200 25-Feb-20 pneumonia (COVID-19) puerperae
Clinical observation and research of Severe acute respiratory syndrome coronavirus

ChiCTR200 25-Feb-20 2(COVID-19) infection in perinatal newborns
Early warning prediction of patients with severe novel coronavirus pneumonia

ChiCTR200 25-Feb-20 (COVID-19) based on multiomics
Descriptive study on the clinical characteristics and outcomes of novel coronavirus
ChiCTR200 25-Feb-20 pneumonia (COVID-19) in cardiovascular patients
A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic
acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-
ChiCTR200 25-Feb-20 19)
A clinical study for probiotics in the regulation of intestinal function and microflora
ChiCTR200 25-Feb-20 structure of novel coronavirus pneumonia (COVID-19)
A prospective, randomized, open label, controlled trial for chloroquine and

ChiCTR200 25-Feb-20 hydroxychloroquine in patients with severe novel coronavirus pneumonia (COVID-19)
A prospective, open label, randomized, control trial for chloroquine or
hydroxychloroquine in patients with mild and common novel coronavirus pulmonary
ChiCTR200 25-Feb-20 (COVIP-19)
Clinical study for infusing convalescent plasma to treat patients with new coronavirus
Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by
Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in

ChiCTR200 25-Feb-20 female vaginal secretions
A medical records based analysis for the clinical characteristics of novel coronavirus
ChiCTR200 25-Feb-20 pneumonia (COVID-19) in immunocompromised patients
The clinical application and basic research related to mesenchymal stem cells to treat
A prospective, multicenter, open-label, randomized, parallel-controlled trial for
probiotics to evaluate efficacy and safety in patients infected with 2019 novel
A prospective, randomized, open-label, controlled clinical study to evaluate the
preventive effect of hydroxychloroquine on close contacts after exposure to the Novel
The COVID-19 Mobile Health Study (CMHS), a large-scale clinical observational

ChiCTR200 25-Feb-20 registration study using nCapp
Effect of Novel Coronavirus Pneumonia (COVID-19) on the Mental Health of College

ChiCTR200 25-Feb-20 Students
A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-
ChiCTR200 25-Feb-20 Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)
NCT042576 2-Mar-20 Severe 2019-nCoV Remdesivir RCT
Optimization Protocal of Integrated Traditional Chinese and Western Medicine in the

ChiCTR200 25-Feb-20 Treatment for Novel Coronavirus Pneumonia (COVID-19)
Clinical study of novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of

A randomized controlled Trial for therapeutic efficacy of Recombinant Human
Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus
Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel

Study for mental health status and influencing factors of nurses during epidemic
ChiCTR200 25-Feb-20 prevention of novel coronavirus pneumonia (COVID-19)
A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in
ChiCTR200 25-Feb-20 the treatment of Novel Coronavirus Pneumonia (COVID-19)
NCT042526 2-Mar-20 Mild/Moderate 2019-nCoV Remdesivir RCT
Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of

NCT042563 2-Mar-20 COVID-19
NCT042733 2-Mar-20 Efficacy and Safety of Corticosteroids in COVID-19
The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New
NCT042735 2-Mar-20 Coronavirus (COVID-19) Pneumonia
NCT042703 2-Mar-20 Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel
NCT042736 2-Mar-20 Coronavirus Severe Pneumonia
NCT042759 2-Mar-20 The COVID-19 Mobile Health Study (CMHS)
A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of
ChiCTR200 2-Mar-20 Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform
Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus
ChiCTR200 25-Feb-20 pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial
NCT042798 2-Mar-20 The Investigation of the Neonates With or With Risk of COVID-19
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With

NCT042752 2-Mar-20 2019-nCoV Pneumonia
NCT042753 2-Mar-20 Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia
NCT042791 2-Mar-20 Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu
NCT042805 2-Mar-20 Fingolimod in COVID-19
Application of rehabilitation and Lung eight-segment exercise in front-line nurses in

ChiCTR200 2-Mar-20 the prevention of novel coronavirus pneumonia (COVID-19) epidemic
A randomized, double-blind, placebo-controlled trial for evaluation of the efficacy
and safety of bismuth potassium citrate capsules in the treatment of patients with
ChiCTR200 2-Mar-20 novel coronavirus pneumonia (COVID-19).
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the
NCT042735 2-Mar-20 Treatment of Severe COVID-19
Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition
NCT042743 2-Mar-20 Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool
NCT042754 2-Mar-20 Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia
Research and Development of Diagnostic Assistance Decision Support System for

ChiCTR200 2-Mar-20 novel coronavirus pneumonia (COVID-19) Based on Big Data Technology
Novel Coronavirus Infected Disease (COVID-19) in children: epidemiology, clinical

ChiCTR200 2-Mar-20 features and treatment outcome
Application of Rehabilitation and Lung Eight-segment Exercise in Home Rehabilitation

ChiCTR200 2-Mar-20 of Survivors from novel coronavirus pneumonia (COVID-19)
Application of rehabilitation lung exercise eight-segment exercise in patients with
ChiCTR200 2-Mar-20 novel coronavirus pneumonia (COVID-19)
A Comparative Study for the Effectiveness of ''triple energizer treatment'' Method in

ChiCTR200 2-Mar-20 Repairing Lung Injury in Patients with Novel coronavirus pneumonia (COVID-19)
Clinical observation and research of multiple organs injury in severe patients with
ChiCTR200 2-Mar-20 Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)
Construction and application of non-contact doctor-patient interactive diagnosis and
treatment mode of moxibustion therapy for novel coronary pneumonia (COVID-19)
ChiCTR200 2-Mar-20 based on mobile internet
Construction of a Bio information platform for novel coronavirus pneumonia (COVID-

ChiCTR200 2-Mar-20 19) patients follow-up in Anhui
Identification and Clinical Treatment of Severe novel coronavirus pneumonia (COVID-

ChiCTR200 2-Mar-20 19) Patients
Clinical research of 6-minute walk training on motor function of novel coronavirus

ChiCTR200 2-Mar-20 pneumonia (COVID-19)
Clinical application of inhaled acetylcysteine solution in the treatment of novel

ChiCTR200 2-Mar-20 coronavirus pneumonia (COVID-19)
Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus

NCT042797 2-Mar-20 Infection
Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship
NCT042797 2-Mar-20 With Clinical Manifestations
NCT042802 2-Mar-20 NK Cells Treatment for Novel Coronavirus Pneumonia
Combination of Tocilizumab, IVIG and CRRT in severe patients with novel coronavirus
Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the

ChiCTR200 2-Mar-20 treatment of children with novel coronavirus pneumonia (COVID-19)
Multiomics study and emergency plan optimization of spleen strengthening clearing
damp and stomach therapy combined with antiviral therapy for novel coronavirus
ChiCTR200 2-Mar-20 microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)
A randomized, open-label controlled trial for the efficacy and safety of Pirfenidone in
ChiCTR200 2-Mar-20 patients with severe and critical novel coronavirus pneumonia (COVID-19)
Clinical study for a new type of Gastroscope isolation mask for preventing and
ChiCTR200 2-Mar-20 controlling the novel coronavirus pneumonia (COVID-19) Epidemic period
Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of
ChiCTR200 2-Mar-20 Novel Coronavirus Pneumonia (COVID-19)
Efficacy of Traditional Chinese Medicine in the Treatment of Novel Coronavirus

ChiCTR200 2-Mar-20 Pneumonia (COVID-19): a Randomized Controlled Trial
Investigation and analysis of psychological status of hospital staff during the novel
ChiCTR200 2-Mar-20 coronavirus pneumonia (COVID-19) epidemic
A single-center, single-arm clinical trial for azvudine in the treatment of novel

A medical records based analysis for antiviral therapy effect on novel coronavirus
ChiCTR200 2-Mar-20 pneumonia COVID-19 patients
Clinical study for combination of anti-viral drugs and type I interferon and
inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia
ChiCTR200 2-Mar-20 (COVID-19)
Clinical study for individualized nutritional assessment and supportive treatment of

ChiCTR200 2-Mar-20 novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau
ChiCTR200 2-Mar-20 Analysis of clinical characteristics of novel coronavirus pneumonia (COVID-19)
A survey of mental health of first-line medical service providers and construction of

ChiCTR200 2-Mar-20 crisis intervention model for novel coronavirus pneumonia (COVID-19) in Xiangyang
Umbilical cord mesenchymal stem cells (hucMSCs) in the treatment of high risk novel
ChiCTR200 2-Mar-20 coronavirus pneumonia (COVID-19) patients
Correlation between imaging characteristics and laboratory tests of new coronavirus

Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel
Clinical observation and research plan of novel coronavirus pneumonia (COVID-19)

ChiCTR200 2-Mar-20 patients
Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus

ChiCTR200 2-Mar-20 pneumonia (COVID-19) wind-heat syndrome
Exploration and Research for a new method for detection of novel coronavirus
ChiCTR200 2-Mar-20 (COVID-19) nucleic acid
A study for the key technology of mesenchymal stem cells exosomes atomization in
ChiCTR200 2-Mar-20 the treatment of novel coronavirus pneumonia (COVID-19)
Cancelled due to lack of participants Study for the Impact of

ChiCTR200 2-Mar-20 Novel Coronavirus Pneumonia (COVID-19) to the Health of the elderly People
Study for continuous renal replacement therapy with adsorption filter in the
ChiCTR200 2-Mar-20 treatment of the novel coronavirus pneumonia (COVID-19)
ICU healthcare personnel burnout investigation during the fight against novel
Health related quality of life and its influencing factors among front line nurses caring
ChiCTR200 2-Mar-20 patients with new coronavirus pneumonia (COVID-19) from two hospitals in China
Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of

ChiCTR200 2-Mar-20 novel coronavirus pneumonia (COVID-19): a randomized, open and controlled trial
Study for evaluation of integrated traditional Chinese and Western Medicine in the
ChiCTR200 2-Mar-20 treatment of Novel Coronavirus Pneumonia (COVID-19)
A prospective randomized controlled trial for the home exercise prescription
intervention in nursing students during epidemic of novel coronary pneumonia
Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping
ChiCTR200 2-Mar-20 Injection for Novel Coronavirus Pneumonia (COVID-19)
Cancelled due to lack of patient Medical records based study for
epidemiological and clinical characteristics of 2019 novel coronavirus pneumonia
ChiCTR200 2-Mar-20 (COVID-19) in Chongqing
Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel
ChiCTR200 2-Mar-20 coronavirus pneumonia (COVID19)
Clinical research of pulmonary rehabilitation in survivors due to severe or critial novel
A multicenter, randomized, controlled trial for efficacy and safety of hydrogen

ChiCTR200 2-Mar-20 inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients
ChiCTR200 2-Mar-20 The coagulation function of novel coronavirus pneumonia (COVID-19) patients
Cancelled due to lack of patient A Medical Records

ChiCTR200 2-Mar-20 Based Study for Construction and Analysis of Diagnosis Predictive&
Single arm study for exploration of chloroquine phosphate aerosol inhalation in the
ChiCTR200 2-Mar-20 treatment of novel coronavirus pneumonia (COVID-19)
Research for Risks Associated with Novel Coronavirus Pneumonia (COVID-19) in the
ChiCTR200 2-Mar-20 Hospital Workers and Nosocomial Prevention and Control Strategy
Cancelled due to lack of patient Clinical study on the safety and effectiveness
of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel
A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in
the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-
ChiCTR200 2-Mar-20 19)
A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric
Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and
ChiCTR200 2-Mar-20 moderate novel coronavirus pneumonia (COVID-19)
The treatment status and risk factors related to prognosis of hospitalized patients
with novel coronavirus pneumonia (COVID-19) in intensive care unit, Hebei, China: a
ChiCTR200 2-Mar-20 descriptive study
Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia

Cancelled due to lack of patient Clinical

ChiCTR200 2-Mar-20 study for the effect and
Cancelled due to lack of patient A study for the efficacy of

ChiCTR200 2-Mar-20 hydroxychloroquine for mild and moderate COVID-19 infectious diseases
A prospective clinical study for recombinant human interferon alpha 1b spray in the
ChiCTR200 2-Mar-20 prevention of novel coronavirus (COVID-19) infection in highly exposed medical staffs.
A randomized, open-label, controlled trial for the safety and efficiency of Kesuting
syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus
Retracted due to lack of patient A multicenter, randomized, open
label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets
ChiCTR200 2-Mar-20 and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm
Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus

ChiCTR200 2-Mar-20 pneumonia: a randomized controlled trial
Quality of life among Chinese residents during and after novel coronavirus pneumonia
ChiCTR200 2-Mar-20 (COVID19) outbreak: an online survey
Cancelled by the investigator Study for the water extract of soybean in the
ChiCTR200 2-Mar-20 treatment of patients with novel coronavirus pneumonia (COVID-19)
A randomized, open, parallel-controlled clinical trial on the efficacy and safety of

ChiCTR200 2-Mar-20 Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)
A Retrospective Study for Preventive Medication in Tongji Hospital During the

ChiCTR200 2-Mar-20 Epidemic of Novel Coronavirus Pneumonia (COVID-19)
Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with
Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus
ChiCTR200 2-Mar-20 Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial
Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with
Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia
ChiCTR200 2-Mar-20 (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial
Comparative effectiveness and safety of ribavirin plus interferon-alpha,
lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus
ChiCTR200 2-Mar-20 interferon-alphain in patients with mild to moderate novel coronavirus pneumonia
NCT042766 9-Mar-20 Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel
NCT042521 9-Mar-20 Coronavirus
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined
With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild
NCT042737 9-Mar-20 Novel Coronavirus Pneumonia (COVID-19)
A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating

NCT042769 9-Mar-20 Severe Novel Coronavirus Pneumonia
NCT042865 9-Mar-20 The Clinical Study of Carrimycin on Treatment Patients With COVID-19
The immediate psychological impact of novel coronavirus pneumonia (COVID-19)

ChiCTR200 9-Mar-20 outbreak on medical students in anesthesiology and how the cope
Cancelled due to lack of patient Medical records based study for
Heart-type fatty acid-binding protein on prognosis of novel coronavirus pneumonia
Critical ultrasound in evaluating cardiopulmonary function in critical patients infected

ChiCTR200 9-Mar-20 with 2019 novel coronavirus pneumonia (COVID-19)
Research on peripheral immunity function monitoring and its clinical application in

ChiCTR200 9-Mar-20 patients with novel coronavirus pneumonia (COVID-19)
Clinical study of nano-nose and its extended technology in diagnosis of novel

Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus

ChiCTR200 9-Mar-20 Pneumonia (COVID-19) by Ebastine
Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel

Novel coronavirus pneumonia (COVID-19) antiviral related liver dysfunction: a

ChiCTR200 9-Mar-20 multicenter, retrospective, observational study
A medical records based study for the safety of artificial liver cluster nursing in
ChiCTR200 9-Mar-20 critically ill patients with novel coronavirus pneumonia (COVID-19)
A clinical study about the diagnosis and prognosis evaluation of novel coronacirus
pneumonia (COVID-19) based on viral genome, host genomic sequencing, relative
ChiCTR200 9-Mar-20 cytokines and other laboratory indexes.
Research for the mechanism of improvement of novel coronavirus pneumonia

ChiCTR200 9-Mar-20 (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy
A retrospective study on virus typing, Hematological Immunology and case Review of

ChiCTR200 9-Mar-20 novel coronavirus infected and convalescent patients (COVID-19)
Detection of coronavirus in simultaneously collecting tears and throat swab samples

ChiCTR200 9-Mar-20 collected from the patients with novel coronavirus pneumonia (COVID-19)
NCT042816 9-Mar-20 A New Screening Strategy for 2019 Novel Coronavirus Infection
A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus
NCT042829 9-Mar-20 Infection
NCT042840 9-Mar-20 CT Scores Predict Mortality in 2019-nCoV Pneumonia
The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients
NCT042851 9-Mar-20 With COVID-19
Extracorporeal blood purification therapy using Li's Artifical Liver System for patients
ChiCTR200 9-Mar-20 with severe novel coronavirus pneumonia (COVID19) patient
A single-center, single-arm clinical trial for azvudine in the treatment of novel

Retrospective study for integrate Chinese and conventional medicine treatment of

ChiCTR200 9-Mar-20 novel coronavirus pneumonia (COVID-19) in Hu'nan province
To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated
capsules combined with hydrogen-rich water in the treatment of novel coronavirus
Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma
ChiCTR200 9-Mar-20 in the treatment of severe critical cases
ChiCTR200 9-Mar-20 Risk Factors for Outcomes of Novel Coronavirus Pneumonia (COVID-19)
Study for timing of mechanical ventilation for critically ill patients with novel
coronavirus pneumonia (COVID-19): A medical records based retrospective Cohort
ChiCTR200 9-Mar-20 study
An open and controlled clinical study to evaluate the efficacy and safety of Ganovo
ChiCTR200 9-Mar-20 combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)
Novel coronavirus pneumonia (COVID-19) epidemic survey of medical students in

ChiCTR200 9-Mar-20 various provinces and municipalities throughout the country
Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia
ChiCTR200 9-Mar-20 (COVID-19): a randomized, open, controlled trial
The clinical value of corticosteroid therapy timing in the treatment of novel

ChiCTR200 9-Mar-20 coronavirus pneumonia (COVID-19): a prospective randomized controlled trial
A Randomized Controlled Trial for the Influence of TCM Psychotherapy on Negative
Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on
ChiCTR200 9-Mar-20 Network Platform
Efficacy and safety of lipoic acid injection in reducing the risk of progression in
ChiCTR200 9-Mar-20 common patients with novel coronavirus pneumonia (COVID-19)
A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel

ChiCTR200 9-Mar-20 Coronavirus Pneumonia (COVID-19)
Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients

ChiCTR200 9-Mar-20 with Novel Coronavirus Pneumonia (COVID-19)
ChiCTR200 9-Mar-20 Psychological Intervention of Children with Novel Coronavirus Disease (COVID-19)
A medical records based study for Comparing Differences of Clinical Features and
Outcomes of Novel Coronavirus Pneumonia (COVID-19) Patients between Sichuan
ChiCTR200 9-Mar-20 Province and Wuhan City
Study for the route of ocular surface transmission of novel coronavirus pneumonia
ChiCTR200 9-Mar-20 (COVID-19) infection and related eye diseases
Study for the risk factors of critically ill patients with novel coronavirus pneumonia
Early risk stratification of the Novel coronavirus infected diseases (COVID-19): a

ChiCTR200 9-Mar-20 multicenter retrospective study (ERS-COVID-19 study)
Study for the key technique of integrative therapy of Novel Coronavirus Pneumonia
ChiCTR200 9-Mar-20 (COVID-19): the TCM symptoms and treatment regulation
Clinical study for the effects of ACEIs/ARBs on the infection of novel coronavirus
ChiCTR200 9-Mar-20 pneumonia (CoVID-19)
HUMSCs and Exosomes Treating Patients with Lung Injury following Novel
A Multicenter, Long- term Follow-up and Registration Study for Myocardial Injury and
ChiCTR200 9-Mar-20 Prognosis of Novel coronavirus pneumonia (COVID-19)
Cancelled by the investigator Influence of nasal high-fow preoxygenation
on video laryngoscope for emergency intubation in patients with critical novel
Cancelled due to lack of patient Effect of early pulmonary training on

ChiCTR200 9-Mar-20 lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients
Survey for sleep, anxiety and depression status of Chinese residents during the
ChiCTR200 9-Mar-20 outbreak of novel coronavirus infected disases (COVID-19)
Randomized, open, blank controlled trial for the efficacy and safety of recombinant
human interferon alpha 1beta in the treatment of Wuhan patients with novel
Cytosorb in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus
ChiCTR200 9-Mar-20 Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)
Cancelled, due to modify the protocol A single-center, open-
label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2
ChiCTR200 9-Mar-20 inactivated convalescent plasma in the treatment&
Protective factors of mental resilience in first-line nurses with novel coronavirus

Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of
ChiCTR200 9-Mar-20 the Novel Coronavirus Pneumonia (COVID-19)
oXiris Membrane in Treating Critically Ill Hospitalized Adult Patients with novel
A Medical Based Retrospective Real World Study for Assessment of Effectiveness of
Comprehensive Traditional Chinese Medicine in the treatment of Novel Coronavirus
ChiCTR200 9-Mar-20 Pneumonia (COVID-19)
A pilot study for Integrated Chinese and Western Medicine in the treatment of non-
ChiCTR200 9-Mar-20 critical novel coronavirus pneumonia (COVID-19)
Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in

ChiCTR200 9-Mar-20 epicenter Wuhan, China
Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital
of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel
Study for using multiomics in the diagnosis and treatment of novel coronavirus
Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in
combination with mesenchymal stem cells: a prospective, single blind, randomized
ChiCTR200 9-Mar-20 controlled clinical trial
A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound
Interferon (rSIFN-co) in the Treatment of 2019 Novel Coronavirus (2019-nCoV)
ChiCTR200 9-Mar-20 Infected Pneumonia
The investigation of cytokine expression profile of novel coronavirus pneumonia

ChiCTR200 9-Mar-20 (COVID-19) and its clinical significance
Application of flash glucose monitoring to evaluate the effect of blood glucose
ChiCTR200 9-Mar-20 changes on prognosis in patients with novel coronavirus pneumonia (COVID-19)
A medical records based study for the clinical characteristics of anesthesia novel
coronavirus pneumonia (COVID-19) patients during perioperative period and
ChiCTR200 9-Mar-20 assessment of infection and mental health of Anesthesiology Department
Recommendations of Integrated Traditional Chinese and Western Medicine for Novel

Research for Traditional Chinese Medicine Technology Prevention and Control of

ChiCTR200 9-Mar-20 Novel Coronavirus Pneumonia (COVID-19) in the Community Population
A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen
Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-
A randomized, controlled open-label trial to evaluate the efficacy and safety of
lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-
A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule

ChiCTR200 9-Mar-20 /Granule in the treatment of novel coronavirus pneumonia (COVID-19)
NCT042887 16-Mar-20 Eculizumab (Soliris) in Covid-19 Infected Patients
Convalescent plasma for the treatment of severe and critical novel coronavirus
ChiCTR200 9-Mar-20 pneumonia (COVID-19): a prospective randomized controlled trial
Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by

NCT042615 16-Mar-20 2019-nCoV ( HC-nCoV )
Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused
NCT042522 16-Mar-20 by 2019-nCoV
Clinical Application and Theoretical Discussion of Fu-Zheng Qing-Fei Thought in

ChiCTR200 16-Mar-20 Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)
Retrospective and Prospective Study for Nosocomial infection in Stomatology
Department under the Background of novel coronavirus pneumonia (COVID-19)
ChiCTR200 16-Mar-20 epidemic period
Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus

ChiCTR200 16-Mar-20 pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial
Study for effects of crisis intervention based on positive psychology for medical staffs
ChiCTR200 16-Mar-20 working in the novel coronavirus pneumonia (COVID-19) field
Clinical and CT imaging Characteristics of novel coronavirus pneumonia (COVID-19):

ChiCTR200 16-Mar-20 An Multicenter Cohort Study
Correlation analysis of blood eosinophil cell levels and clinical type category of novel
ChiCTR200 16-Mar-20 coronavirus pneumonia (COVID-19): a medical records based retrospective study
Development and application of a new intelligent robot for novel coronavirus (2019-
ChiCTR200 16-Mar-20 nCOV) oropharygeal sampling
Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19

NCT042988 16-Mar-20 Pneumonia
Evaluation on the effect of Chushifangyi prescription in preventing novel coronavirus

Open-label, observational study of human umbilical cord derived mesenchymal stem
cells in the treatment of severe and critical patients with novel coronavirus
ChiCTR200 16-Mar-20 Traditional Chinese Medicine for novel coronavirus pneumonia (COVID-19)
A medical records based study for investigation of dynamic profile of RT-PCR test for
ChiCTR200 16-Mar-20 SARS-CoV-2 nucleic acid of novel coronavirus pneumonia (COVID-19) patients
Study for the virus molecular evolution which driven the immune-pathological
responses and the protection mechanisms of novel coronavirus pneumonia (COVID-
ChiCTR200 16-Mar-20 19) patients
A medical based analysis for influencing factors of death of novel coronavirus

ChiCTR200 16-Mar-20 pneumonia (COVID-19) patients in Wuhan third hospital
Clinical study for bronchoscopic alveolar lavage in the treatment of critically trachea
ChiCTR200 16-Mar-20 intubation patients with new coronavirus pneumonia (COVID-19)
Evaluation of Ganovo (Danoprevir ) Combined With Ritonavir in the Treatment of

NCT042917 16-Mar-20 Novel Coronavirus Infection
NCT042923 16-Mar-20 Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
NCT042938 16-Mar-20 Efficacy and Safety of IFN-a2ÃŸ in the Treatment of Novel Coronavirus Patients
Analysis for the mental health status of residents in Jingzhou during the outbreak of
ChiCTR200 16-Mar-20 the novel coronavirus pneumonia (COVID-19) and corresponding influencing factors
NCT042908 16-Mar-20 Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.
NCT042923 16-Mar-20 Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the
NCT042955 16-Mar-20 Treatment of New Coronavirus Infection Pneumonia (General and Severe)
NCT042966 16-Mar-20 Medical Masks vs N95 Respirators for COVID-19

Clinical observation and evaluation of traditional Chinese medicine in the treatment
of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of
ChiCTR200 16-Mar-20 Integrated Chinese&Western Medicine
A medical records based study for clinical outcomes and follow-up of novel
ChiCTR200 16-Mar-20 coronavirus pneumonia (COVID-19) patients
Retrospective analysis of epidemiology and transmission dynamics of patients

ChiCTR200 16-Mar-20 confirmed with Coronavirus Disease (COVID-19) in Hong Kong
A clinical multicenter study for the occurrence, development and prognosis of novel
Study for the effect of external diaphragmatic pacing assisted invasive ventilation and
ChiCTR200 16-Mar-20 weaning in patients with severe novel coronavirus pneumonia (COVID-19)
Study for the physical and mental health status of medical workers under the novel
ChiCTR200 16-Mar-20 coronavirus pneumonia (COVID-19) epidemic
Evaluation of the protective effect of dexmedetomidine on patients with severe novel

Factors associated with death in patients with novel coronavirus pneumonia (COVID-
ChiCTR200 16-Mar-20 19)
Mental Health and Its Correlates Among Chinese Adolescents Exposed to the Novel
NCT042997 16-Mar-20 Coronavirus Disease 2019
Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to

ChiCTR200 16-Mar-20 nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)
Exploratory study for Immunoglobulin From Cured COVID-19 Patients in the
ChiCTR200 16-Mar-20 Treatment of Acute Severe novel coronavirus pneuvirus (COVID-19)
Preliminary screening of novel coronavirus pneumonia (COVID-19) by special

ChiCTR200 16-Mar-20 laboratory examination and CT imaging before surgery
A multicenter retrospective study of rheumatic patients with novel coronavirus

A medical records based study for epidemic and clinical features of novel coronavirus
ChiCTR200 16-Mar-20 pneumonia (COVID-19) in Ningbo First Hospital
Development of warning system with clinical differential diagnosis and prediction for
severe type of novel coronavirus pneumonia (COVID-19) patients based on artificial
ChiCTR200 16-Mar-20 intelligence and CT images
Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western

ChiCTR200 16-Mar-20 medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy
Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus
Pneumonia (COVID-19) Fibrosis: a prospective exploratory experimental medical
ChiCTR200 16-Mar-20 study
Clinical research and preparation development of qingfei detoxification decoction

ChiCTR200 16-Mar-20 (mixture) for prevention and treatment of novel coronavirus pneumonia (COVID-19)
Study for the pathogenesis and effective intervention of mood disorders caused by
ChiCTR200 16-Mar-20 the novel coronavirus pneumonia (COVID-19)
Development and application of novel coronavirus pneumonia (COVID-19) intelligent

ChiCTR200 16-Mar-20 image classification system based on deep learning
Clinical study for the efficacy of Mesenchymal stem cells (MSC) in the treatment of
ChiCTR200 16-Mar-20 severe novel coronavirus pneumonia (COVID-19)
Epidemiological Characteristics and Antibody Levels of novel coronavirus pneumonia

ChiCTR200 16-Mar-20 (COVID-19) of Pediatric Medical Staff working in Quarantine Area
Establishment of an early warning model for maternal and child vertical transmission
ChiCTR200 16-Mar-20 of COVID-19 infection
Clinical characteristics and outcomes of 483 mild patients with novel coronavirus
pneumonia (COVID-19) in Wuhan, China during the outbreak: A single-center,
ChiCTR200 16-Mar-20 retrospective study from the mobile cabin hospital
Retrospective study for the efficacy of ulinastatin combined with ''clear lung
ChiCTR200 16-Mar-20 detoxification soup'' in the treatment of novel coronavirus pneumonia (COVID-19)
Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia

ChiCTR200 16-Mar-20 (COVID-19): a Randomized Controlled Clinical Trial
Study for the therapeutic effect and mechanism of traditional Chinese medicine in the
A medical records based study for sedation and Analgesia Usage in critically ill
Retrospective analysis of digestive system symptoms in 600 cases of novel

ChiCTR200 16-Mar-20 coronavirus pneumonia (COVID-19) in Guanggu district, Wuhan
A medical records based study for the value of Lymphocyte subsets in the diagnose
ChiCTR200 16-Mar-20 and treatment of novel coronavirus pneumonia (COVID-19)
An artificial intelligence assistant system for suspected novel coronavirus pneumonia

ChiCTR200 16-Mar-20 (COVID-19) based on chest CT
Investigation on psychological status of novel coronavirus pneumonia (COVID-19)

ChiCTR200 16-Mar-20 rehabilitation patients in Zhengzhou City and research on coping strategies
Establishment and validation of Premonitory model of deterioration of the 2019 novel
ChiCTR200 16-Mar-20 corona virus pneumonia (COVID-19)
clinical study for hemodynamics and cardiac arrhythmia of novel coronavirus

ChiCTR200 16-Mar-20 pneumonia (COVID-19) patients
Multicenter clinical study of evaluation of multi-organ function in patients with novel

ChiCTR200 16-Mar-20 coronavirus pneumonia (COVID-19) by ultrasound
Collection and analysis of clinical data in severe and critically ill patients with novel
Impact of Novel Coronavirus Pneumonia (COVID-19) Epidemic Period on the
Management of investigator-initiated clinical trial and the resilience of medical
ChiCTR200 16-Mar-20 service providers
Detection of SARS-CoV-2 in EPS / semen of patients with novel coronavirus

Clinical validation and application of high-throughput novel coronavirus (2019-nCoV)

ChiCTR200 16-Mar-20 screening detection kit
The analysis of related factors on improving oxygenation status by endotracheal
intubation ventilation in severe patients suffered from novel coronavirus pneumonia
ChiCTR200 16-Mar-20 (COVID-19): a single center and descriptive study in Wuhan
A retrospective study of clinical drug therapy in patients with novel coronavirus

Analysis of risk factors affecting prognosis of elderly patients infected with novel
ChiCTR200 16-Mar-20 coronavirus pneumonia (COVID-19): a single-center retrospective observational study
A clinical trial for Ulinastatin Injection in the treatment of patients with severe novel
A Medical Records Based analysis for Risk Factors for Outcomes After Respiratory
ChiCTR200 16-Mar-20 Support in Patients with ARDS Due to Novel Coronavirus Pneumonia (COVID-19)
Nutritional risk assessment and outcome prediction of critically ill novel coronavirus
ChiCTR200 16-Mar-20 pneumonia (COVID-19) patients
A medical records based analysis of clinical evidence of human-to-human

ChiCTR200 16-Mar-20 transmission of 2019 novel coronavirus pneumonia (COVID-19) by conjunctival route
Continuous renal replacement therapy (CRRT) alleviating inflammatory response in
severe patients with novel coronavirus pneumonia (COVID-19) associated with renal
ChiCTR200 16-Mar-20 injury: A Prospective study
Medical records based study for the accuracy of SARS-CoV-2 IgM antibody screening
ChiCTR200 16-Mar-20 for diagnosis of novel coronavirus pneumonia (COVID-19)
Characteristics, prognosis, and treatments effectiveness of critically ill patients with

ChiCTR200 16-Mar-20 Novel Coronavirus Pneumonia (COVID-19)
Observational Study for Prone Position Ventilation and Conventional Respiratory

ChiCTR200 16-Mar-20 Support in ARDS Patients with Novel Coronavirus Pneumonia (COVID-19)
Cancelled by the investigator Study on levels of inflammatory factors in
peripheral blood of patients with novel coronavirus pneumonia (COVID-19) and their
ChiCTR200 16-Mar-20 diagnostic and prognostic value
A study for clinical characteristics of novel coronavirus pneumonia (COVID-19)

ChiCTR200 16-Mar-20 patients follow-up in Guangxi
Clinical characteristics and prognosis of cancer patients with novel coronavirus

Quantitative CT characteristic estimate the severity of novel coronavirus pneumonia

A medical records based study for clinical characteristics of novel coronavirus
ChiCTR200 16-Mar-20 Clinical characteristics and treatment of novel coronavirus pneumonia (COVID-19)
Study for the Psychological Status of Medical Staff of Otolaryngology Head and Neck
Surgery in Hubei Province under the Epidemic of novel coronavirus pneumonia
Clinical Research for Traditional Mongolian Medicine in the treatment of novel

A medical records based analysis for risk factors for death in patients with Novel
A prospective cohort study for comprehensive treatment of Chinese medicine in the

ChiCTR200 16-Mar-20 treatment of convalescent patients of novel coronavirus pneumonia (COVID-19)
Analysis of the incidence and risk factors of ARDS in patients with Novel Coronavirus
ChiCTR200 16-Mar-20 Pneumonia (COVID-19).
Cross sectional study of dialysis treatment and mental status under the outbreak of
ChiCTR200 16-Mar-20 novel coronavirus pneumonia (COVID-2019) in China
The value of CD4 / CD8 cells, CRP / ALB and APCHEII in novel coronavirus pneumonia
Application of blood purification in the treatment of novel coronavirus pneumonia

ChiCTR200 16-Mar-20 Retrospective study on novel coronavirus pneumonia (COVID-19) in Tibetan Plateau
Cancelled by the investigator Application of cas13a-mediated RNA

ChiCTR200 16-Mar-20 detection in the assay of novel coronavirus nucleic acid (COVID-19)
Research for the influence of epidemic of novel coronavirus pneumonia (COVID-19)

ChiCTR200 16-Mar-20 on sleep, psychological and chronic diseases among different populations
Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and

ChiCTR200 16-Mar-20 severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''
A medical records based study for clinical characteristics of 2019 novel coronavirus
ChiCTR200 16-Mar-20 pneumonia (COVID-19) in Zhejiang province, China
A medical records based study for characteristics, prognosis of ederly patients with
ChiCTR200 16-Mar-20 Novel Coronavirus Pneumonia (COVID-19) in Wuhan area
ChiCTR200 16-Mar-20 Auscultatory characteristics of novel coronavirus pneumonia (COVID-19)
Prognosis Investigation and Intervention Study on Patients with novel coronavirus

ChiCTR200 16-Mar-20 pneumonia (COVID-19) in recovery period Based on Community Health Management
A medical records based analysis of the Incidence and Risk Factors of Ventilator-
associated Pneumonia in ARDS Patients with Novel Coronavirus Pneumonia (COVID-
ChiCTR200 16-Mar-20 19)
Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the

ChiCTR200 16-Mar-20 Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)
A clinical study for effectiveness and safety evaluation for recombinant chimeric
ChiCTR200 16-Mar-20 COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia
Randomized controlled trial for Chloroquine Phosphate in the Treatment of novel

Exploration of the Clinical Characteristics of Patients with Novel Coronavirus
Pneumonia (COVID-19) and Its Differences from Patients with Severe Influenza A and
ChiCTR200 16-Mar-20 MERS
A comparative study for the sensitivity of induced sputum and throat swabs for the
detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus
Plasma of the convalescent in the treatment of novel coronavirus pneumonia (COVID-

ChiCTR200 16-Mar-20 19) common patient: a prospective clinical trial
A multi-center, open-label observation study for psychological status and intervention
efficacy of doctors, nurses, patients and their families in novel coronavirus pneumonia
ChiCTR200 16-Mar-20 (COVID-19) designated hospitals
Study for immune cell subsets in convalescent patients with novel coronavirus
Efficacy and safety of tozumab combined with adamumab(Qletli) in severe and critical
A medical records based study for risk assessment and treatment timing of invasive
ChiCTR200 16-Mar-20 fungal infection in novel coronavirus pneumonia (COVID-19) critical patients
Shedding of SARS-CoV-2 in human semen and evaluation of reproductive health of

ChiCTR200 16-Mar-20 novel coronavirus pneumonia (COVID-19) male patients
A retrospective cohort study for integrated traditional Chinese and western medicine
in the treatment of 1071 patients with novel coronavirus pneumonia (COVID-19) in
ChiCTR200 16-Mar-20 Wuhan
A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy
and safety of Ixekizumab combined with conventional antiviral drugs in patients with
A randomized, parallel controlled open-label trial for the efficacy and safety of
Prolongin (Enoxaparin Sodium Injection) in the treatment of adult patients with novel
Study for the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in
ChiCTR200 16-Mar-20 treatment of novel coronavirus pneumonia (COVID-19) adult common patients
ChiCTR200 16-Mar-20 Novel coronavirus pneumonia (COVID-19) associated kidney injury in children
Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus
ChiCTR200 16-Mar-20 pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial
The effects of prevention and control measures on treatment and psychological status
ChiCTR200 16-Mar-20 of cancer patients during the novel coronavirus pneumonia (COVID-19) outbreak
ChiCTR200 16-Mar-20 Cohort study of Novel Coronavirus Infected Diseases (COVID-19) in children
The prediction value of prognosis of novel coronavirus pneumonia (COVID-19) in
elderly patients by modified early warning score (MEWS): a medical records based
ChiCTR200 16-Mar-20 retrospective observational study
An anaesthesia procedure and extubation strategy for reducing patient agitation and
cough after extubation that can be used to prevent the spread of Novel Coronavirus
ChiCTR200 16-Mar-20 Pneumonia (COVID-19) and other infectious viruses in the operating Room
Cancelled by the investigator Epidemiological research of novel coronavirus
pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined
ChiCTR200 16-Mar-20 with low-dose chest CT screening in primary hospital
Cancelled by the investigator Clinical trial for umbilical cord blood CIK
and NK cells in the treatment of mild and general patients infected with novel
Cancelled due to lack of patients Investigation on Mental Health
Status and Psychological Intervention of Hospitalized Patients with Novel Coronavirus
Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel
Medical records based study for the correlation between Chinese medicine certificate
ChiCTR200 16-Mar-20 and lung image of novel coronavirus pneumonia (COVID-19)
Medical records based study for the correlation between Chinese medicine certificate
ChiCTR200 16-Mar-20 and lung image of novel coronavirus pneumonia (COVID-19)
A medical records based real world study for the characteristics and correlation
mechanism of traditional Chinese medicine combined with western medicine in the
ChiCTR200 16-Mar-20 treatment of patients with novel coronavirus pneumonia (COVID-19)
Cancelled by the investigator A multicentre, randomized, controlled trial for the
Ba-Duan-Jin in the adjunctive treatment of patients with common type novel
Cancelled by the investigator Mechanism of novel coronavirus
pneumonia (COVID-19) virus with silent latent immune system induced by envelope
ChiCTR200 16-Mar-20 protein and vaccine development
Cancelled by the investigator Study for sleep status of medical staffs of

ChiCTR200 16-Mar-20 hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)
Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of

Cancelled by the investigator Randomized controlled trial for the efficacy of
dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus
Application of TCM Nursing Scheme in Patients with Novel Coronavirus Pneumonia

Cancelled by the investigator Clinical Study of NK Cells in the Treatment of Novel

Cancelled by the investigator Study for the Effectiveness and Safety
of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus
Multicenter study for the treatment of Dipyridamole with novel coronavirus

Clinical study for Lopinavir and Ritonavir in the treatment of novel coronavirus
Cancelled by investigator Single arm study for the efficacy and safety of GD31
ChiCTR200 16-Mar-20 in patients with novel coronavirus pneumonia (COVID-19)
Study for meditation assists for the rehabilitation of patients with novel coronaviruse
Cancelled by the investigator Efficacy and safety of chloroquine
phosphate inhalation combined with standard therapy in the treatment of novel
Cancelled by the investigator Study on the effect of human placenta biological
preparation on the defense of immune function against novel coronavirus pneumonia
Cancelled by the investigator An observational study of high-dose
Vitamin C in the treatment of severe and critical patients with novel coronavirus
Cancelled by the investigator A randomized, double-blind, parallel,
controlled trial for comparison of phosphoric chloroquine combined with standard
ChiCTR200 16-Mar-20 therapy and standard therapy in mild/common patients with novel coronavirus p
Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum

ChiCTR200 16-Mar-20 samples and pharyngeal swabs-a prospectively diagnostic test
Cancelled by investigator A randomized, open-label, controlled and single-center
trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent
ChiCTR200 16-Mar-20 plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient
Cancelled by the investigator A randomized controlled trial for high-dose
Vitamin C in the treatment of severe and critical novel coronavirus pneumonia
ChiCTR200 16-Mar-20 (COVID-19) patients
Cancelled by the investigator A randomized, double-blind, parallel, controlled
trial for comparison of phosphoric chloroquine combined with standard therapy and
standard therapy in mild/common patients with novel coronavirus pneumonia
Cancelled by the investigator A randomized, double-blind, parallel, controlled
trial for comparison of phosphoric chloroquine combined with standard therapy and
ChiCTR200 16-Mar-20 standard therapy in serious/critically ill patients with novel coronavirus pneumoni
Cancelled by the investigator Clinical Study of Cord Blood NK Cells
Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel
Cancelled by the investigator Clinical Study for Umbilical Cord Blood
Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-
ChiCTR200 16-Mar-20 19)
Cancelled by the investigator Study for the false positive rate of IgM / IgG
ChiCTR200 16-Mar-20 antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients
The effect of Gymnastic Qigong Yangfeifang on functional recovery and quality of life
ChiCTR200 16-Mar-20 in patients with mild novel coronavirus pneumonia (COVID-19)
Cancelled by the investigator Clinical Study for Umbilical Cord Blood Plasma in
ChiCTR200 16-Mar-20 the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)
Cancelled by the investigator Clinical Study for Cord Blood Mesenchymal

ChiCTR200 16-Mar-20 Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)
Cancelled by investigator A cox regression analysis of prognosis of

NCT040613 23-Mar-20 Sero-epidemiological Survey of England in 2019/2020
Study for epidemiology, diagnosis and treatment of novel coronavirus pneumonia

NCT042517 23-Mar-20 Washed Microbiota Transplantation for Patients With 2019-nCoV Infection
Clinical Study of Arbidol Hydrochloride Using for Post-exposure Prophylaxis of 2019-

ChiCTR200 16-Mar-20 nCoV in High-risk Population Including Medical Staff
NCT042727 23-Mar-20 Prognositc Factors in COVID-19 Patients Complicated With Hypertension
A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and

NCT042612 23-Mar-20 Ritonavir for 2019-nCoV Pneumonia
NCT042634 23-Mar-20 The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
NCT042645 23-Mar-20 Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia
Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure
*Due to COVID-19 Outbreak in United States the Investigators Have Paused All In-
NCT042261 23-Mar-20 person Enrollment and Will Re-evaluate on May 1st*
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon

NCT042548 23-Mar-20 Atomization in the 2019-nCoV Pneumonia
Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for

NCT042876 23-Mar-20 Patients With COVID-19
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral

NCT042550 23-Mar-20 Therapy in the 2019-nCoV Pneumonia
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured

NCT042648 23-Mar-20 Patients
NCT042833 23-Mar-20 Study for Novel Coronavirus Pneumonia (NCP)
Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort
NCT042858 23-Mar-20 Study
NCT042768 23-Mar-20 Immunity and Safety of Covid-19 Synthetic Minigene Vaccine
NCT042789 23-Mar-20 Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent

NCT042834 23-Mar-20 SARS-CoV-2 Infection
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in
Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard
NCT042927 23-Mar-20 of Care Treatment
NCT042807 23-Mar-20 Adaptive COVID-19 Treatment Trial
Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease
NCT042881 23-Mar-20 2019(COVID-19)
NCT042936 23-Mar-20 Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus
NCT043027 23-Mar-20 Expanded Access Remdesivir (RDV; GS-5734â„¢)
NCT042910 23-Mar-20 The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19
NCT042929 23-Mar-20 Prognostic Factors of Patients With COVID-19
NCT042997 23-Mar-20 Safety and Immunity of Covid-19 aAPC Vaccine
NCT043026 23-Mar-20 Accurate Classification System for Patients With COVID-19 Pneumonitis
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in

NCT042928 23-Mar-20 Participants With Severe Coronavirus Disease (COVID-19)
NCT043035 23-Mar-20 Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild

NCT043076 23-Mar-20 Coronavirus Disease (COVID-19)
NCT043083 23-Mar-20 Tetrandrine Tablets Used in the Treatment of COVID-19
Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the

NCT043040 23-Mar-20 COVID-19 Epidemic
NCT043043 23-Mar-20 A Pilot Study of Sildenafil in COVID-19
NCT043060 23-Mar-20 Blood Donor Recruitment During Epidemic of COVID-19
Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-

NCT043064 23-Mar-20 19.
Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal
NCT043025 23-Mar-20 Stem Cells
NCT043054 23-Mar-20 Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
NCT043055 23-Mar-20 Social Media Use During COVID-19
NCT043108 23-Mar-20 Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
NCT043051 23-Mar-20 Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia-RCT
NCT043063 23-Mar-20 Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease

NCT043102 23-Mar-20 2019
Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring
NCT043111 23-Mar-20 Hospitalization
Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring

NCT043120 23-Mar-20 Hospitalization
NCT043122 23-Mar-20 NO Prevention of COVID-19 for Healthcare Providers
NCT043124 23-Mar-20 Myocardial Damage in COVID-19
NCT043133 23-Mar-20 Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-

NCT043067 23-Mar-20 19
NCT043081 23-Mar-20 Influence of the COvid-19 Epidemic on STRESS
NCT043116 23-Mar-20 Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress
NCT043121 23-Mar-20 Sequential Oxygen Therapy Strategy for Patients With COVID-19
Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection

NCT043113 23-Mar-20 System
The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-
NCT043130 23-Mar-20 CoV-2
NCT043142 23-Mar-20 Mechanisms to Morbidity and Mortality for Covid-19
Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With

NCT043152 23-Mar-20 COVID-19
NCT043131 23-Mar-20 Phase I Clinical Trial in Healthy Adult
Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The

NCT043158 23-Mar-20 Italian Registry on Coronavirus in Pregnancy.
Mesenchymal Stem Cell NestCellÂ® to Treat Patients With Severe COVID-19
NCT043159 23-Mar-20 Pneumonia
Clinical Performance of the VivaDiag â„¢ COVID-19 lgM / IgG Rapid Test in Early
NCT043167 23-Mar-20 Detecting the Infection of COVID-19
Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza

NCT043139 23-Mar-20 Pneumonitis Using Chest X-Rays
NCT043148 23-Mar-20 Adverse Events Related to Treatments Used Against Coronavirus Disease 2019
Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA

NCT043158 23-Mar-20 Trial)
NCT043159 23-Mar-20 Trial of Treatments for COVID-19 in Hospitalized Adults
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults
NCT043129 23-Mar-20 Positive for SARS-CoV-2 Infection
The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of

NCT043142 23-Mar-20 Treatment of Severe Patients With Novel Coronavirus Pneumonia
NCT043168 23-Mar-20 Mechanisms for Organ Dysfunction in Covid-19
NCT043170 23-Mar-20 Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)
NCT043162 23-Mar-20 Acute Kidney Injury in Patients Hospitalized With COVID-19
NCT043170 23-Mar-20 CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment
ChiCTR200 23-Mar-20 The relationship between Vitamin D andnovel coronavirus pneumonia (COVID-19)
NCT043163 23-Mar-20 Norwegian Coronavirus Disease 2019 Study
Does point-of-care testing for coronavirus in hospital improve patient care compared
ISRCTN149 23-Mar-20 to laboratory testing?
Can hydroxychloroquine and coronavirus swabbing reduce hospital admission or

ISRCTN865 23-Mar-20 death for older patients with suspected coronavirus infection?
A medical records based study of peripheral blood T lymphocyte subsets in patients

ChiCTR200 23-Mar-20 with novel coronavirus pneumonia (COVID-19)
ChiCTR200 23-Mar-20 Study for the impact on fetus and neonates of vertical transmission of 2019-nCoV
Prospective exploratory clinical research on the efficacy and safety of pirfenidone

ChiCTR200 23-Mar-20 capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)
Application of radiology in the prevention and control system of emergency

ChiCTR200 23-Mar-20 respiratory infectious diseases
Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for
ChiCTR200 23-Mar-20 Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)
ChiCTR200 23-Mar-20 Study for metagenomics of patients with novel coronavirus pneumonia (COVID-19)
ChiCTR200 23-Mar-20 A prognosis study of novel coronavirus pneumonia (COVID-19)
A medical records based study for Tou-Jie-Qu-Wen Granules in the Treatment of mild
ChiCTR200 23-Mar-20 and moderate patients with novel coronavirus pneumonia (COVID-19)
A medical records based study for the value of Upper Respiratory Tract Virus
Detection in the assessment of rehabilitation of novel coronavirus pneumonia
ChiCTR200 23-Mar-20 (COVID-19) patient
Psychological Support for Diagnosed Patients with novel coronavirus pneumonia

Effect of Auricular point pressing on insomnia of novel coronavirus pneumonia

ChiCTR200 23-Mar-20 (COVID-19) patients: a randomized controlled trial.
A medical records based study for the diagnosis and prognosis prediction AI model of
Internet based Solution Focused Brief Therapy treating adolescent anxiety under the
ChiCTR200 23-Mar-20 novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial
Perioperative immune prediction and intervention of tumor patients undergoing

ChiCTR200 23-Mar-20 surgery during the novel coronavirus pneumonia (COVID-19) outbreak period
A Study for SARS-COV-2 RNA Level in Blood and Excrement of Novel Coronavirus
ChiCTR200 23-Mar-20 Pneumonia (COVID-19) Convalescent Patients
A Randomized Controlled Trial for Favipiravir Tablets Combine With Chloroquine

ChiCTR200 23-Mar-20 Phosphate in the Treatment of Novel Coronavirus Pneumonia (COVID-19)
Psychological Responses of Medical Staff during the Metaphase of novel coronavirus

ChiCTR200 23-Mar-20 pneumonia (COVID-19) Outbreak in Hubei, China
Correlation of T lymphocytes level and clinical severity in novel coronavirus

ChiCTR200 23-Mar-20 pneumonia (COVID-19) patients: a medical records based retrospective study
A Medical Records Based Retrospective Study for Clinical Characteristics, Treatments

ChiCTR200 23-Mar-20 and Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19) in WuHan
A RCT for Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia
A medical records based study for clinical features and prognosis of severe patients
ChiCTR200 23-Mar-20 with novel coronavirus pneumonia (COVID-19) in Huanggan, Hubei in Huanggang.
A medical records based study for clinical application of extracorporeal membrane
oxygenation in the treatment of severe respiratory failure patients with novel
Effects of different VTE prevention methods on the prognosis of hospitalized patients

ChiCTR200 23-Mar-20 with novel coronavirus pneumonia (COVID-19)
Clinical efficacy of TCM syndrome differentiation in the treatment of severe/critical
type of novel coronavirus pneumonia (COVID-19): a prospective, observational, one-
ChiCTR200 23-Mar-20 arm clinical study
Developing and evaluating of artificial intelligence triage system for suspected novel
ChiCTR200 23-Mar-20 coronavirus pneumonia (COVID-19): a retrospective study
Myocardial injury and arrythmias in the novel coronavirus pneumonia (COVID-19)

ChiCTR200 23-Mar-20 patients
Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune
ChiCTR200 23-Mar-20 response and guidance for vaccine design
Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general
ChiCTR200 23-Mar-20 type novel coronavirus pneumonia (COVID-19)
Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide
ChiCTR200 23-Mar-20 (CAS001) in the treatment of novel coronavirus pneumonia (COVID-19)
Clinical study of human NK cells and MSCs transplantation for severe novel
Combined diagnostic value of novel coronavirus (2019-CoV) infection detected by NLR

ChiCTR200 23-Mar-20 and CRP
Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory
function in novel coronavirus pneumonia (COVID-19) patients: a randomized
ChiCTR200 23-Mar-20 controlled trial
Correlation between virological negative conversion and clinical factors and prognosis
ChiCTR200 23-Mar-20 in patients with novel coronavirus pneumonia (COVID-19)
Venous Thrombosis Risk of novel coronavirus pneumonia (COVID-19) Patients: A

ChiCTR200 23-Mar-20 Prospective Study
A real-world study for the Chinese medicines ''Xinguan 2'' and ''Xinguan 3'' in the
A randomized, open-label, controlled trial for Gu-Shen Ding-Chuan-Wan in the
treatment of patients with novel coronavirus pneumonia (COVID-19) at recovery
ChiCTR200 23-Mar-20 phase with Fei-Pi-Qi-Xu Zhen
An observational study for cardiac and pulmonary ultrasound and evaluation of

ChiCTR200 23-Mar-20 treatment of severe patients with novel coronavirus pneumonia (COVID-19)
Clinical investigation and reseach on TCM syndrome of novel coronavirus pneumonia

The treatment and diagnosis plan of integrated traditional Chinese and Western
ChiCTR200 23-Mar-20 medicine for novel coronavirus pneumonia (COVID-19)
A Platform for Rapid Immuno-detection and Emergency Vaccine Development of

ChiCTR200 23-Mar-20 Novel Coronavirus (2019-COV)
A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and
safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel
A Medical Records Based Study for Clinical Characteristic and Outcomes of

ChiCTR200 23-Mar-20 Hospitalized Patients With Novel Coronavirus Pneumonia (COVID-19)
Screening and identification of peripheral blood biomarkers in patients with COVID-19

ChiCTR200 23-Mar-20 infection based on multiomics studies
Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and
dendrobium candidum to nutrition intervention of patients with novel coronavirus
ChiCTR200 23-Mar-20 pneumonia (COVID-19) during convalescence.
Cancelled by the investigator Observation Of Clinical Efficacy And Safety Of
Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia
Study for clinical oral characteristics of patients with novel coronavirus pneumonia
(COVID-19) and Effect of 3% hydrogen peroxide gargle on the Intraoral novel
ChiCTR200 23-Mar-20 coronavirus
A medical records based study for optimization and evaluation of the comprehensive
diagnosis and treatment of novel coronavirus pneumonia (COVID-19) and the
ChiCTR200 23-Mar-20 assessment of risk factors for severe pneumonia
Prospective, open-label, controlled, multicenter cohort study of long-acting interferon

ChiCTR200 23-Mar-20 plus ribavirin in patients with novel coronavirus pneumonia (COVID-19)
A phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine

ChiCTR200 23-Mar-20 (adenoviral vector)
Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed

ChiCTR200 23-Mar-20 by multimodal MRI imaging
A study for the psychological status, social support, and care needs of tumor patients
admitted to a general hospital during the novel coronavirus pneumonia (COVID-19)
ChiCTR200 23-Mar-20 outbreak
Study for the clinical characteristics and digestive system damage of novel
the Efficacy and Safety of Favipiravir for novel coronavirusâ€“infected pneumonia: A

ChiCTR200 23-Mar-20 multicenter, randomized, open, positive, parallel-controlled clinical study
Cancelled by the investigator Clinical guidance of diagnose and treatment for

ChiCTR200 23-Mar-20 novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''
Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in

ChiCTR200 23-Mar-20 patients with critical novel coronavirus pneumonia (COVID-19)
Cancelled by the investigator Clinical study of mesenchymal stem cells in

ChiCTR200 23-Mar-20 treating severe novel coronavirus pneumonia (COVID-19)
Cancelled by the investigator A real world study for Compound Houttuyniae

ChiCTR200 23-Mar-20 Mixture for prevention of novel coronavirus pneumonia (COVID-19)
A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and
safety of recombinant cytokine gene-derived protein injection in combination with
ChiCTR200 23-Mar-20 standard therapy in patients with novel coronavirus infection
A randomized, open label, parallel controlled trial of evaluating the efficacy of
recombinant cytokine gene-derived protein injection for clearing novel coronavirus in
Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized

ChiCTR200 23-Mar-20 controlled, open label, multicenter trial
Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of

EUCTR2020 23-Mar-20 COVID-19 in hospitalized adults
IRCT20100 24-Mar-20 Interferon ÃŸ in treatment of COVID-19
IRCT20200 24-Mar-20 Effect of herbal syrup and solution in treatment of COVID-19
NL8460 23-Mar-20 Biomarkers for prognosis in critically ill COVID-19 patients : a prospective cohort study
a trial of an inhaled antiviral drug to treat or prevent severe respiratory difficulties in

EUCTR2020 23-Mar-20 patients with COVID-19
EUCTR2020 23-Mar-20 Hydroxychloroquine as a treatment for coronavirus disease COVID-19
Identification of host cell respiratory tract cell gene expression and epigenetic pattern
DRKS00021 23-Mar-20 after human SARS-CoV-2 infection
IRCT20100 24-Mar-20 Interferon in treatment of COVID-19
The effect of Noscapine on clinical and pulmonary manifestations of COVID-19

IRCT20160 24-Mar-20 patients
Evaluting the therapeutic and adverse effects of Interferon beta 1-a in patients with
IRCT20151 24-Mar-20 novel Coronavirus(COVID-19)
IRCT20100 24-Mar-20 ?Effect of sofosbuvir/ ledipasvir on COVID-19
Study to Evaluate the Safety and Efficacy of Sofosbuvir/Daclatasvir in Participants

IRCT20200 24-Mar-20 with Moderate to Severe Coronavirus Disease (COVID-19)
TCTR20200 25-Mar-20 ED Response against Covid-19 pandemic
IRCT20100 24-Mar-20 Combination therapy in COVID 19
JPRN-jRCT 23-Mar-20 Triple combination therapy in patients infected with COVID-19
JPRN-jRCT 23-Mar-20 Favipiravir in patients infected with COVID-19
JPRN-jRCT 23-Mar-20 Favipiravir for SARS-CoV-infected patients
ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory

JPRN-UMIN 23-Mar-20 Disease
JPRN-UMIN 23-Mar-20 COVID-19 Registry
Covid-19 preparedness among Emergency Departments: a cross-sectional study in

TCTR20200 25-Mar-20 France.
Scientific title Acronym Primary sp Date registDate registExport dat Source Regweb addre Recruitmen
A Randomized Multicenter
Xiangya Hos ### 20200127 3/25/2020 ClinicalTri https://cl Not recruit
A Medical Records BasedEmergency

Stud ### 20200216 3/25/2020 ChiCTR http://wwwNot Recrui
Construction and AnalysisZhongnan

of Prog H ### 20200217 3/25/2020 ChiCTR http://wwwNot Recrui
A Single-arm Clinical TrialHwaMei

for Hos ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
A Randomized ControlledLonghua
Trial Hos ### 20200216 3/25/2020 ChiCTR http://wwwNot Recrui
Evaluate the effectiveness

Affiliated
of T ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Study for Anti-aging

Guangzhou ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
Development and application

Shenzhen
of S ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Effecacy and safty of convales

The First A ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Trial for Integrated

Children's ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Study for the key issues of

Wuxi
the Peopl ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Study for Traditional

Shanghai U ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
Optimization of treatment
Wuhan
and diagno
Jiny ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Randomized controlled trial

A multicenter, randomized,
Huangshi H ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, open-label,
TheblaFirst A ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
Development of a SimpleBeijing Dit ### 20200126 3/25/2020 ClinicalTri https://cl Recruiting
A Randomized,
ELACOI Guangzhou ### 20200130 3/25/2020 ClinicalTri https://cl Recruiting
Impact of a Novel CoronaQilu Hospi 2/3/2020 20200203 3/25/2020 ClinicalTri https://cl Recruiting
A Survey of Psychologic Huazhong U2/3/2020 20200203 3/25/2020 ClinicalTri https://cl Recruiting
Clinical study for the chaZhejiang Pr ### 20200213 3/25/2020 ChiCTR http://wwwNot Recrui
Imaging Features and Mechanisms
West China ### 20200213 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized, parallel control

Tongji Hos ### 20200211 3/25/2020 ChiCTR http://wwwRecruiting
Efficacy of Chloroquine and

The Fifth A ### 20200211 3/25/2020 ChiCTR http://wwwRecruiting
Effects of Traditional C Beijing 302 ### 20200128 3/25/2020 ClinicalTri https://cl Recruiting
Randomized, Open, Multic

Jieming Q 2/6/2020 20200206 3/25/2020 ClinicalTri https://cl Not recruit
A Randomized, Open-labe
Peking Uni 2/6/2020 20200206 3/25/2020 ClinicalTri https://cl Not recruit
A Randomized, Open-label
First Affil 2/6/2020 20200206 3/25/2020 ClinicalTri https://cl Not recruit
An observational study for

Guangdong
Xin-G 2/8/2020 20200208 3/25/2020 ChiCTR http://wwwNot Recrui
Efficacy and safety of aerosol

Union Hosp2/8/2020 20200208 3/25/2020 ChiCTR http://wwwRecruiting
Early Detection of Novel Co

Shenzhen T ### 20200210 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized, open-labelWuhan
stud Pul 2/9/2020 20200209 3/25/2020 ChiCTR http://wwwNot Recrui
A comparative study on the

Tongji
senHos ### 20200216 3/25/2020 ChiCTR http://wwwNot Recrui
A multicenter, randomized
Huangshi H ### 20200215 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized controlledLonghua
trial f Hos ### 20200216 3/25/2020 ChiCTR http://wwwNot Recrui
A Single-blind, Randomized,
HwaMei
Co Hos ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
Study for construction and

West
asseChina ### 20200216 3/25/2020 ChiCTR http://wwwNot Recrui
Co-infection of novel coronavir

Zhongnan H ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
An open, prospective, multice

Beijing ho 2/5/2020 20200205 3/25/2020 ChiCTR http://wwwRecruiting
Chinese medicine prevention

Zhejiang
and Ct 2/5/2020 20200205 3/25/2020 ChiCTR http://wwwRecruiting
The efficacy and safety ofBeijing

ca You ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
Application of RegulatingThe
Intest
First A ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
Immune Repertoire (TCRThe

& BCR)
First A 2/7/2020 20200207 3/25/2020 ChiCTR http://wwwNot Recrui
A real world study for tradition
Shanghai Pu2/7/2020 20200207 3/25/2020 ChiCTR http://wwwNot Recrui
A prospective randomized
Zhejiang
dou C 2/3/2020 20200203 3/25/2020 ChiCTR http://wwwRecruiting
Chinese medicine prevention

Zhejiang
and Ct 2/3/2020 20200203 3/25/2020 ChiCTR http://wwwRecruiting
Evaluation of Rapid Diagnostic

JiangsuKitIns ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, open and The

control
A randomized controlledNanjing
trial f Se ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Psychological survey of frontl

Guangdong ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Community based prevention

Hubeian
Prov 2/6/2020 20200206 3/25/2020 ChiCTR http://wwwRecruiting
Safety and efficacy of umbi

Xiangyang 2/4/2020 20200204 3/25/2020 ChiCTR http://wwwNot Recrui
Traditional Chinese Medicine

1. Xinhua A 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
Traditional Chinese Medici

1. Xinhua a 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Trial for Tanreqing

Shanghai
Caps Pu ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Wuhan
and diagno
People's
contr H ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
An observational study on
Ningbo
the c Firs ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
A prospective cohort study

Sunfor
Yat se 2/3/2020 20200203 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, open-labelTongji
stud Hos 2/3/2020 20200203 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study for the integra

Shanghai P ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
Traditional Chinese medicine

Dongzhimen
c ### 20200213 3/25/2020 ChiCTR http://wwwNot Recrui
A Real World Study For the

TheEfFirst A 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study of type I macroph

Affiliated 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwRecruiting
Based on Delphi MethodDeyang

to Int ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the pharmacodynam
Sir Run Ru ### 20200214 3/25/2020 ChiCTR http://wwwRecruiting
Study for clinical characteristi

The First A 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized controlledBeijing
trial hos 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
Thecont
Study on Prevention and China

Treatme
Acad ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
Wuhan
and diagno
Babaodan Capsule used for

Enze
theHospi
ad ### 20200213 3/25/2020 ChiCTR http://wwwNot Recrui
The evaluation of integrated

The tFirst H 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
Chinese Herbal medicineDongzhimen

for Seve ### 20200130 3/25/2020 ChiCTR http://wwwRecruiting
Cohort Study of Novel Coronavirus

DepartmentP ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study of nebulizedRenmin

Xiya Hos ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, open, contZhongnan H ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
Effect of Novel Coronavirus

West
Pneumo
China ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
Key techniques of umbilical

Hunan
c yuan ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
Randomized, parallel control,

The 5th Me ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui

Risks of Death and SevereTongji

casesHos
i ### 20200210 3/25/2020 ChiCTR http://wwwRecruiting
Effect evaluation and prognosis

A Multicenter, Randomized,
A clinical study for ''Huo-Shen''

Shenzhen n ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui
Safety and effectiveness of

Impact of vitamin D deficiency

West China
on ### 20200210 3/25/2020 ChiCTR http://wwwNot Recrui
Mental health and psycholog
The Fifth A 2/8/2020 20200208 3/25/2020 ChiCTR http://wwwRecruiting
Epidemiological investigation
The First
an P ### 20200210 3/25/2020 ChiCTR http://wwwRecruiting
Multicenter, randomized,Ruijin
ope Hosp 2/7/2020 20200207 3/25/2020 ChiCTR http://wwwRecruiting
Observational study of Xin-Guan

Guangdong 2/7/2020 20200207 3/25/2020 ChiCTR http://wwwNot Recrui
Construction of Early Warning

The First
a A 2/7/2020 20200207 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for community

Hubei Prov 2/6/2020 20200206 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study on safety and

Theeff
Third 2/6/2020 20200206 3/25/2020 ChiCTR http://wwwRecruiting
Study for application of The Second ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui
A multicenter study for efThe First H ### 20200222 3/25/2020 ChiCTR http://wwwRecruiting
Safety and efficacy of umbil

Xiangyang F2/5/2020 20200205 3/25/2020 ChiCTR http://wwwRecruiting
Therapeutic effect of hydroxychlor

Renmin Hos2/4/2020 20200204 3/25/2020 ChiCTR http://wwwRecruiting
A randomized controlledThe
tr First H 2/3/2020 20200203 3/25/2020 ChiCTR http://wwwNot Recrui
A randomised, open, controll

Zhongnan H2/3/2020 20200203 3/25/2020 ChiCTR http://wwwNot Recrui
Viral Excreti Cov-CONT Institut N 2/5/2020 20200205 3/25/2020 ClinicalTri https://cl Recruiting
Immunoregulatory TheraSoutheast 2/8/2020 20200208 3/25/2020 ClinicalTri https://cl Not recruit
Experimental study of novel

Theco
Clinical Study for Gu-BiaoWuhan

Jie-D Hosp2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
The early use of lopinavirInstitute 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
A prospective, open-label,
ThemuFifth A 2/6/2020 20200206 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study for Human The

Menst
First A 2/7/2020 20200207 3/25/2020 ChiCTR http://wwwRecruiting
Shen-Fu injection in the treat

Peking Univ ### 20200221 3/25/2020 ChiCTR http://wwwNot Recrui
A single-arm, single-center
Zhongnan
cli H ### 20200221 3/25/2020 ChiCTR http://wwwNot Recrui
A single arm study for combina
Hubei Prov 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui

Wuhanfo 1st 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
Tongji
bla Hos 2/7/2020 20200207 3/25/2020 ChiCTR http://wwwRecruiting
A Randomized, Open-Label,
The First A 2/6/2020 20200206 3/25/2020 ChiCTR http://wwwRecruiting
An epidemiology study for

Hubei
TCMInte
syn 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
Study for Traditional Chinese

ChinaMAcad ### 20200129 3/25/2020 ChiCTR http://wwwRecruiting
A cross-sectional study ofWuhan

novel cJin ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for safety and

The Third ### 20200223 3/25/2020 ChiCTR http://wwwRecruiting
Recommendations of Integrate
Hospital o 2/4/2020 20200204 3/25/2020 ChiCTR http://wwwRecruiting
Randomized, open-label,The
conFirst A 2/4/2020 20200204 3/25/2020 ChiCTR http://wwwNot Recrui
Study for establishment of

Peking
cor Univ ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui
Effects of novel coronavirus

Chengdu
p Un ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui
A Randomized Controlled1.Tri
Xinhua a 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
The effect of shadowboxing

1. Xinhua
fo a 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui

Tongde
i Hos ### 20200221 3/25/2020 ChiCTR http://wwwRecruiting
Study on ultrasonographic
Xi'an
mani
Chest ### 20200221 3/25/2020 ChiCTR http://wwwRecruiting
Glucocorticoi Steroids-S Peking Uni ### 20200123 3/25/2020 ClinicalTri https://cl Recruiting
The Value of Critical CareWest

Ul China ### 20200224 3/25/2020 ChiCTR http://wwwRecruiting
A single arm trial to evalua

First Peopl ### 20200221 3/25/2020 ChiCTR http://wwwRecruiting
The risk factor and prognosis

Tongji
ofHos ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
Pulmonary rehabilitation1.Xinhua
to i af 2/2/2020 20200202 3/25/2020 ChiCTR http://wwwNot Recrui
Combination of traditional
Beijing
ch Hos 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
A multi-center study on the
Theeff
First A ### 20200221 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical comparative study

West
of PChina ### 20200220 3/25/2020 ChiCTR http://wwwNot Recrui
Efficacy evaluation of inhGuangxi me ### 20200219 3/25/2020 ChiCTR http://wwwRecruiting
Multicenter randomized The

controlle
Clinical Trial for Recombinant

Renmin
H Hos ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for ozonated

Tianjin
auto Uni ### 20200224 3/25/2020 ChiCTR http://wwwRecruiting
A prospective comparative
Thestudy
Clinical Research Regard ZhiYong P 2/7/2020 20200207 3/25/2020 ClinicalTri https://cl Recruiting

Dongzhimen ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
Development of 2019-nCoV
The therapeutic
First P ### 20200219 3/25/2020 ChiCTR http://wwwNot Recrui
Shanghai Pu ### 20200223 3/25/2020 ChiCTR http://wwwRecruiting
A clinical research for th Tongji Hos ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study on Syndrome

Guangdong
Diff ### 20200224 3/25/2020 ChiCTR http://wwwRecruiting
Study for safety and efficacy

Assessment of cardiac function

Department ### 20200223 3/25/2020 ChiCTR http://wwwRecruiting
A Prospective Randomized
West
ConChina ### 20200222 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized, double-blind
Wuhan Jiny ### 20200219 3/25/2020 ChiCTR http://wwwNot Recrui
Beijing
con Cha ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
An open, controlled clinica

Nanchang N ### 20200219 3/25/2020 ChiCTR http://wwwRecruiting
Chinese Medicine Promotes

Hospital
Rehabi
o ### 20200217 3/25/2020 ChiCTR http://wwwNot Recrui
Renmin
dou Hos ### 20200222 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the effect of early

Union
e Hosp ### 20200222 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Trial for Human Mesenc
Chinese PL ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
The Effect of Humanistic The

CareSecond
i ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
Study on anxiety of different

Shanghai
popu G ### 20200219 3/25/2020 ChiCTR http://wwwRecruiting
Liu-Zi-Jue Qigong and Acupr

Shanghai U ### 20200218 3/25/2020 ChiCTR http://wwwNot Recrui
A study for the intervention

The First A ### 20200221 3/25/2020 ChiCTR http://wwwNot Recrui
Feature of Multiple Organs

Department
in ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
A randomized controlledYueyang
trial f Ho ### 20200218 3/25/2020 ChiCTR http://wwwNot Recrui
Comparative study for integra

Study for the correlation Tongji

betw Hos ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
Correalation between anxiety

The Therapeutic Efficacy the

of PSecond ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
A multicenter randomized
Tianjin
contrHu ### 20200223 3/25/2020 ChiCTR http://wwwRecruiting
A randomized controlledUnion
trial Hosp ### 20200219 3/25/2020 ChiCTR http://wwwRecruiting
The efficacy and safety ofHealth

Tr com ### 20200219 3/25/2020 ChiCTR http://wwwRecruiting
Shanghai
co C ### 20200222 3/25/2020 ChiCTR http://wwwNot Recrui
Umbilical cord Wharton'sThe

JellySixth ### 20200222 3/25/2020 ChiCTR http://wwwNot Recrui
Union
o Hospi ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
Efficacy of therapeutic effect

The First H ### 20200211 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study for the diagnosti

Union Hosp ### 20200222 3/25/2020 ChiCTR http://wwwRecruiting
Study for the effects on me

Clinical observation of the

West
novel
China
c ### 20200217 3/25/2020 ChiCTR http://wwwRecruiting
Early warning prediction Enze

of pati
Hospi ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
Clinical characteristics and
Union
ou Hospi ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
Zhongshan
con ### 20200215 3/25/2020 ChiCTR http://wwwRecruiting
A clinical study for probiotics

Shanghai 1 ### 20200219 3/25/2020 ChiCTR http://wwwNot Recrui
An open randomized controlle

Zhongshan ### 20200218 3/25/2020 ChiCTR http://wwwNot Recrui
An open randomized controll

Zhongshan ### 20200222 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for infusingAffiliated

conv ### 20200221 3/25/2020 ChiCTR http://wwwRecruiting
Clinical trials of mesenchymal

Institute
s ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
Study for nucleic acid detection

A medical records based Department

analys ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
The clinical application and

Second
ba Hos ### 20200220 3/25/2020 ChiCTR http://wwwRecruiting
A prospective, multicenter,
Qingdao Ea ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
A prospective, randomized,
Renmin Hos ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
The COVID-19 Mobile Health

Zhongshan
Study ### 20200220 3/25/2020 ChiCTR http://wwwNot Recrui
Effect of New Coronavirus

West
Pneumon
China ### 20200219 3/25/2020 ChiCTR http://wwwNot Recrui
Union
op Hospi ### 20200213 3/25/2020 ChiCTR http://wwwRecruiting
A Phase 3 Randomized, Do
Capital Med ### 20200131 3/25/2020 ClinicalTri https://cl Recruiting
Optimization Protocal of Hospital

Integ o ### 20200219 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for novel NLRP

The In
A randomized controlledChinese
Tri PL ### 20200218 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study of Chloroquine

Zhongnan
Ph H ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
Study on mental health status

Sichuan Ac ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
A randomized controlledTongji
trial Hos ### 20200217 3/25/2020 ChiCTR http://wwwRecruiting
A Phase 3 Randomized, Do
Capital Med ### 20200131 3/25/2020 ClinicalTri https://cl Recruiting
Registry Stud COVID-19 Beijing Ts 2/1/2020 20200201 3/25/2020 ClinicalTri https://cl Recruiting
Efficacy and Safety of C Beijing Ch ### 20200215 3/25/2020 ClinicalTri https://cl Recruiting
The Efficacy and Safety First Affil ### 20200214 3/25/2020 ClinicalTri https://cl Not recruit
A Multicenter ObservatioBeijing Chi ### 20200211 3/25/2020 ClinicalTri https://cl Not recruit
Clinical Study of Human Wuhan Unio ### 20200214 3/25/2020 ClinicalTri https://cl Not recruit
The COVID-19CMHS Chinese Al ### 20200217 3/25/2020 ClinicalTri https://cl Recruiting
A Clinical Trial Study for tInstitute o 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwNot Recrui
Efficacy and safety of honeys

Hubei Hosp ### 20200217 3/25/2020 ChiCTR http://wwwRecruiting
A Multicenter ObservatioChildren's ### 20200218 3/25/2020 ClinicalTri https://cl Recruiting
Single Center, Single Ar Tang-Du Ho2/6/2020 20200206 3/25/2020 ClinicalTri https://cl Recruiting
A Prospective, RandomizeJiangxi Qi ### 20200217 3/25/2020 ClinicalTri https://cl Not recruit
A Randomized, Placebo-CShuGuang H ### 20200215 3/25/2020 ClinicalTri https://cl Recruiting
Efficacy of Fingolimod First Affil ### 20200220 3/25/2020 ClinicalTri https://cl Recruiting
Application of rehabilitation
A randomized, double-blind
Wuhan Jiny3/1/2020 20200301 3/25/2020 ChiCTR http://wwwNot Recrui
The Efficacy and Safety First Affil ### 20200214 3/25/2020 ClinicalTri https://cl Not recruit
Identifying Critically-i Peking Univ ### 20200216 3/25/2020 ClinicalTri https://cl Not recruit
A Pilot Study BEST-CP Qilu Hospi ### 20200214 3/25/2020 ClinicalTri https://cl Recruiting
Research and Development

KeyofLabora
D 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwRecruiting
Novel Coronavirus Infected

Tongji
Disea
Hos ### 20200229 3/25/2020 ChiCTR http://wwwRecruiting
The Application of Rehabilita

Application of rehabilitation
ThelFirst A 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwRecruiting
A Comparative Study for Hubei

the E Prov 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwRecruiting
Clinical observation and resear

Tongji Hosp3/1/2020 20200301 3/25/2020 ChiCTR http://wwwRecruiting
Study for moxibustion in Hu'nan

the preve
uni ### 20200218 3/25/2020 ChiCTR http://wwwNot Recrui
Construction and applicatio

Hubei Prov ### 20200217 3/25/2020 ChiCTR http://wwwRecruiting
Construction of a Bio informatio

the First A ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
Identification and ClinicalXinyang

Treat Ce ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
the effects of 6-minute walk

Clinical application of inhaled

Union Hosp ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Investigation on Clinica Third Affil ### 20200215 3/25/2020 ClinicalTri https://cl Recruiting
Study on Detection of 20Third Affil ### 20200219 3/25/2020 ClinicalTri https://cl Recruiting
Clinical Investigation o Xinxiang me ### 20200213 3/25/2020 ClinicalTri https://cl Recruiting
The therapeutic efficacy of

thecoSecond 3/2/2020 20200302 3/25/2020 ChiCTR http://wwwNot Recrui

Xiangyang C ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Multiomics study and emerge

Li Caixia ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
microRNA as a marker forNanjing

early dia
Se ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, open-labelTongji
stud Hos ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
West
con China ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui

Affiliated ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
Study on Prevention and China

Treatme
Acad ### 20200227 3/25/2020 ChiCTR http://wwwRecruiting
Investigation and analysisBeijing

of p Ger ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
A single-center, single-arm
Henan
clin Prov3/1/2020 20200301 3/25/2020 ChiCTR http://wwwNot Recrui
A medical records based Lishui
analysis
Cent 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for combinatio

Clinical study on novel coron

Ganzi Hospi ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
Analysis of clinical characteristic

The Second ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
A survey of mental healthXiangyang

of C ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Umbilical cord mesenchymal

Nanjing
s Se ### 20200228 3/25/2020 ChiCTR http://wwwRecruiting
Correlation between imaging

Xianning
charCe ### 20200227 3/25/2020 ChiCTR http://wwwRecruiting

Xiangyang
'Z C ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical observation and research

Efficacy and Safety of Jing-Yin

Shanghai U ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
Exploration and ResearchGanzi

for a Hospi
ne ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
A study for the key technology

Wuxi Fifth ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the Impact of Novel

The Thirte
Cor ### 20200225 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical research programThe

of First A ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
ICU healthcare personnelDepartment

burnout ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
Health related quality of Xiamen

lif Uni ### 20200227 3/25/2020 ChiCTR http://wwwNot Recrui
Evaluation Danorevir sodium

Shanghai
t C ### 20200226 3/25/2020 ChiCTR http://wwwRecruiting
Study for evaluation of integr

First Teach ### 20200225 3/25/2020 ChiCTR http://wwwRecruiting
West
con China ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui
Study of Pinavir / Ritonavir

Fifth
T Peopl ### 20200225 3/25/2020 ChiCTR http://wwwRecruiting
Epidemiological and clinical

Chongqing
cha ### 20200217 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the efficacy of Kanggu

Effect of pulmonary rehabili
West China ### 20200225 3/25/2020 ChiCTR http://wwwNot Recrui
ThecoFourth ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
The coagulation functionPuren

of novel
Hosp
A Medical Records BasedChongqing

Study ### 20200221 3/25/2020 ChiCTR http://wwwRecruiting
Single arm study for explorati

The First H ### 20200218 3/25/2020 ChiCTR http://wwwNot Recrui
Research for Risks Associated

Multicenter, randomized,The
opeFirst A ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
A multicenter, single arm,Central

o So ### 20200225 3/25/2020 ChiCTR http://wwwNot Recrui
A parallel, randomized con

First Affil ### 20200220 3/25/2020 ChiCTR http://wwwNot Recrui
The treatment status andThe

ris Fourth ### 20200226 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Reseach of Acupuncture

Yueyangi Ho ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
Thec First A ### 20200212 3/25/2020 ChiCTR http://wwwNot Recrui
study
Second ### 20200212 3/25/2020 ChiCTR http://wwwNot Recrui
A study on the efficacy and

Chinese PL ### 20200219 3/25/2020 ChiCTR http://wwwNot Recrui
Thec First A ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
The Second ### 20200212 3/25/2020 ChiCTR http://wwwNot Recrui
A study on treatment strategies

Chongqing
of ### 20200129 3/25/2020 ChiCTR http://wwwRecruiting
Quality of life among Chinese

NA r ### 20200226 3/25/2020 ChiCTR http://wwwRecruiting
Cancelled Cancelled ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized, open, parallel-

Tongji Hosp ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
A Retrospective Study forTongji

Prev Hosp ### 20200210 3/25/2020 ChiCTR http://wwwNot Recrui
Evaluation the Efficacy a Peking Univ ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
Evaluation the Efficacy a Peking Univ ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
Comparative effectiveness
Chongqing ### 20200129 3/25/2020 ChiCTR http://wwwRecruiting
An Open-label Randomized
The Univer ### 20200211 3/25/2020 ClinicalTri https://cl Recruiting
Safety and Efficiency o Beijing 302 ### 20200127 3/25/2020 ClinicalTri https://cl Recruiting
Evaluating the Efficacy Second Aff ### 20200214 3/25/2020 ClinicalTri https://cl Recruiting
A Pilot Clinical Study o Ruijin Hosp ### 20200216 3/25/2020 ClinicalTri https://cl Not recruit
The Efficacy and Safety Beijing Yo ### 20200225 3/25/2020 ClinicalTri https://cl Not recruit
The immediate psychological

Westi China 3/8/2020 20200308 3/25/2020 ChiCTR http://wwwRecruiting
Medical records based study

Chongqing
for ### 20200215 3/25/2020 ChiCTR http://wwwNot Recrui
Critical ultrasound in evaluat

Tongji Hos 3/7/2020 20200307 3/25/2020 ChiCTR http://wwwRecruiting
Research on peripheral immunit

Union Hosp3/7/2020 20200307 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study of nano-nose

Anhui
andCanc 3/7/2020 20200307 3/25/2020 ChiCTR http://wwwNot Recrui
Multi-Center Clinical Study

Wuhan
on t Red 3/6/2020 20200306 3/25/2020 ChiCTR http://wwwRecruiting
Efficacy and safety of Ma-Xing-G

Novel coronavirus pneumonia

The First
(COA 3/8/2020 20200308 3/25/2020 ChiCTR http://wwwNot Recrui
Retrospective study to assess

A clinical study about theWest China 3/6/2020 20200306 3/25/2020 ChiCTR http://wwwRecruiting
Research for the mechanism

Tongji
o Hosp3/6/2020 20200306 3/25/2020 ChiCTR http://wwwNot Recrui
A retrospective study on The

viru Third A 3/7/2020 20200307 3/25/2020 ChiCTR http://wwwRecruiting
Detection of coronavirusCentral
in s Th 3/6/2020 20200306 3/25/2020 ChiCTR http://wwwRecruiting
Identification of a New Affiliated ### 20200220 3/25/2020 ClinicalTri https://cl Not recruit
A Randomized, Open-label
Huilan Zha ### 20200210 3/25/2020 ClinicalTri https://cl Recruiting
CT Scores Predict Morta Shanghai G ### 20200222 3/25/2020 ClinicalTri https://cl Not recruit
A Clinical Study to Inve Tasly Pharm ### 20200219 3/25/2020 ClinicalTri https://cl Not recruit
Effecacy and safty of extraco

A single-center, single-arm
The
clin
Retrospective studyfor integr

To evaluate the efficacy an

Huo-Shen-S3/4/2020 20200304 3/25/2020 ChiCTR http://wwwRecruiting
Study on the application The

of convale
Risk Factors for Outcomes

Shandong
of Novel P3/8/2020 20200308 3/25/2020 ChiCTR http://wwwNot Recrui
Study for timing of mechanica

Tongji Hos 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
An open and controlled clini

Shenyang S 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwRecruiting

Xiamen
(C Med3/6/2020 20200306 3/25/2020 ChiCTR http://wwwNot Recrui
Zedoary Turmeric Oil for The

Inject
Second3/5/2020 20200305 3/25/2020 ChiCTR http://wwwRecruiting
The clinical value of cortico

Zhongnan H3/3/2020 20200303 3/25/2020 ChiCTR http://wwwRecruiting
A Randomized Controlled
Dalian
Tr Medi3/2/2020 20200302 3/25/2020 ChiCTR http://wwwNot Recrui
Efficacy and safety of lipoic

Maoming Pe3/2/2020 20200302 3/25/2020 ChiCTR http://wwwRecruiting
A randomized parallel controlled

Shanghai U 3/2/2020 20200302 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Prediction and Interve

Shandong P3/8/2020 20200308 3/25/2020 ChiCTR http://wwwNot Recrui
Psychological Intervention
Tongji
of Chil
Hos 3/7/2020 20200307 3/25/2020 ChiCTR http://wwwRecruiting
Comparative Study for Clinical

West China 3/4/2020 20200304 3/25/2020 ChiCTR http://wwwRecruiting
Study for the route of ocular

Tongji
s Hos 3/4/2020 20200304 3/25/2020 ChiCTR http://wwwRecruiting
Study for the risk factors Tongji

of crit Hos 3/6/2020 20200306 3/25/2020 ChiCTR http://wwwNot Recrui
Early risk stratification ofWest

the China 3/5/2020 20200305 3/25/2020 ChiCTR http://wwwNot Recrui
Key techniques of combination
Clinical study for the effects

Theof
First A 3/2/2020 20200302 3/25/2020 ChiCTR http://wwwNot Recrui
HUMSCs and Exosomes Treating

Hubei Shiy
Pat 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
SARS-CoV-2 Infection on Peking

Myocardi
Univ3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
Influence of nasal high-fow

Thep First A 3/2/2020 20200302 3/25/2020 ChiCTR http://wwwNot Recrui
Effect of early pulmonaryWuhan

train Four ### 20200220 3/25/2020 ChiCTR http://wwwNot Recrui
Survey for sleep, anxiety Renmin

and Hos3/4/2020 20200304 3/25/2020 ChiCTR http://wwwNot Recrui
Randomized, open, blankDepartment3/3/2020

con 20200303 3/25/2020 ChiCTR http://wwwRecruiting
The Effect and Safety of cy

Department3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the clinical characterist

The Third X 3/2/2020 20200302 3/25/2020 ChiCTR http://wwwRecruiting
A single-center, open-label
First peopl ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Protective factors of mental

Theresi
Third A ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the Effectiveness

Affiliated
and 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
The Effect and Safety of oXi

Department3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
The Real World Study to Yueyang

Eval Ho ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
Epidemiological and clinical

Daping
charHos ### 20200226 3/25/2020 ChiCTR http://wwwRecruiting
Recommendations for Diagno

Study for the diagnosis and

Union
treaHosp ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
Severe novel coronavirusDepartment2/5/2020

pn 20200205 3/25/2020 ChiCTR http://wwwRecruiting
A Multicenter, Randomized,
WestC China 2/8/2020 20200208 3/25/2020 ChiCTR http://wwwRecruiting
The investigation of cytokine

Tongji
exHos 2/5/2020 20200205 3/25/2020 ChiCTR http://wwwRecruiting
Application of flash glucose
Shanghai Si 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwNot Recrui
A medical records based D

s epartment ### 20200217 3/25/2020 ChiCTR http://wwwNot Recrui
Recommendations of Integrated
HospitalTo 2/4/2020 20200204 3/25/2020 ChiCTR http://wwwRecruiting
Research for Traditional Chin

Hebei
bla Yili 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized, controlledWuhan
open- Jiny ### 20200123 3/25/2020 ChiCTR http://wwwRecruiting
Hebei
bla Yili 2/1/2020 20200201 3/25/2020 ChiCTR http://wwwRecruiting
Soliris to St SOLID-C19 Hudson Me ### 20200227 3/25/2020 ClinicalTri https://cl Not recruit
Convalescent plasma for China-Japa

the tr ### 20200212 3/25/2020 ChiCTR http://wwwRecruiting
Efficacy and Safety of Shanghai Pu2/6/2020 20200206 3/25/2020 ClinicalTri https://cl Recruiting
Efficacy and DACO-nCo Shanghai Pu ### 20200129 3/25/2020 ClinicalTri https://cl Recruiting
Clinical Application and Theor

Zhengzhou ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Retrospective and Prospective

TongjiSHos ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Favipiravir Combined With

Peking
Toc Univ ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Study of effects of crisis interven

Zhengzhou ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical and CT imaging Characte

Jinling Hos ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Correlation analysis of blood

Tongji
e Hos ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui

The First
of a A ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Analysis of Safety Relat Tongji Hosp ### 20200226 3/25/2020 ClinicalTri https://cl Not recruit
Evaluation on the effect of

TheChus
affilia ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Open-label, observationalThe
stud
First H ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study for TCM Decoction

Xiangyang ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Investigation of dynamic Tongji
profileHos
of ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Study for the virus molecula

Shanghai N ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Analysis of influencing factors

Wuhan of Thir ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical study for bronchoscop

An Open and Controlled CThe Ninth ### 20200227 3/25/2020 ClinicalTri https://cl Recruiting
The Efficacy and Safety Shanghai Pu ### 20200225 3/25/2020 ClinicalTri https://cl Recruiting
Randomized, Open, BlankTongji Hosp ### 20200215 3/25/2020 ClinicalTri https://cl Not recruit
Analysis for the mental heal

Jingzhou M ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Nitric Oxide NOSARSCOXijing Hosp ### 20200227 3/25/2020 ClinicalTri https://cl Not recruit
Clinical Prog 2019-nCoVFujian Prov ### 20200223 3/25/2020 ClinicalTri https://cl Not recruit
Multicenter Clinical Stu Jiangxi Qi 3/3/2020 20200303 3/25/2020 ClinicalTri https://cl Not recruit
Medical Masks Versus N9McMaster U3/3/2020 20200303 3/25/2020 ClinicalTri https://cl Not recruit
Clinical observation and eHubei 672 ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Clinical outcomes and follow-up

Tongji Hos
stud ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Retrospective analysis ofThe

epidChines ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
A clinical multicenter study

Li Lanjuan
on t ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the effect of extern

Department ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the physical andThe

mental
Evaluation of the protective

Department
eff ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Factors associated with death

Beijingpati
An ### 20200316 3/25/2020 ChiCTR http://wwwNot Recrui
Mental Health and Its C University 3/4/2020 20200304 3/25/2020 ClinicalTri https://cl Not recruit
Evaluation of the effect ofHwaMei Hos ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Treatment of Acute Severe
Union
COVID-1
hosp ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Preliminary screening of Corona

Tongren Ho ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
A multicenter retrospective
Tongji
study
Hoso ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Epidemiologic and ClinicalNingbo

features
Firso ### 20200314 3/25/2020 ChiCTR http://wwwNot Recrui
Development of warningZhongnan
system H ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Novel covid-19 pneumonia

Longhua
combi Hos ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Efficacy and Safety of Pirfe

State Key L ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Clinical research and prepar

Affiliated ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Study on the pathogenesis

Tongji
and Hos
e ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui

Hwa Mei
of CO
Ho ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Clinical study on the efficacy

the First A ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Epidemiological Characteristics
Tongji Hos ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Establishment of an earlyTongji
warninHos ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Clinical characteristics a Hubei Canc ### 20200316 3/25/2020 ChiCTR http://wwwRecruiting
Retrospective study for the

Wuhan
e Thir ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Exocarpium Citri Grandis Maoming

Reliev Pe ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Study for the therapeuticThe

effeFirst A ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Sedation and Analgesia Usage

TongjiinHos
Retrospective analysis ofWuhan

diges Thir ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
The value of LymphocyteDepartment

subsets in C ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
An artificial intelligence assist

Investigation on psychological
Zhengzhou ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Establishment and validation
Tongji
ofHos ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
clinical study for hemodynamics

Shanghai
a Fi ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Multicenter clinical studyUnion

of Hosp ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Clinical characteristics of Union

severeHospi ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Impact of Novel Coronavirus

Clinical R ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Detection of SARS-CoV-2Shenzhen
in EPS / H ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
Clinical validation and applicati

The analysis of related faTongji Hos ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
A retrospective study of clinical

Tongji Hosp
dr ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Analysis of risk factors affec

The Third ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Shanghai
co C ### 20200314 3/25/2020 ChiCTR http://wwwRecruiting
Analysis of Risk Factors for

Shandong
O P ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
Nutritional risk assessment

Tongji
and Hos
out ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Ocular dectection of SARS-CoV-2

Tongji hos ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Continuous renal replacemen

Renji Hospi ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Accuracy analysis of SARS-CoV-2

The Third
Ig A ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Characteristics, prognosis,
Tongji
a Hos ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Observational Study for Prone

Shandong P ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
Study on levels of inflammator

The Third A ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
A study for clinical characterist

The People ### 20200314 3/25/2020 ChiCTR http://wwwRecruiting
Screening and Identification

Tongji
of Hos ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Quantitative CT characteristic
Tongjiestim
Hos ### 20200315 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical characteristics of Wuhan
COVID-19
3rd ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Clinical characteristics and

The
treatmen
Second ### 20200315 3/25/2020 ChiCTR http://wwwRecruiting
Risk Factors for Anxiety ofZhongnan

Oto H ### 20200314 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Research for Traditiona

Affiliated ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Analysis of risk factors forShandong

death P ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
A prospective cohort study

Hubei
o Prov ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
Analysis of the incidence Shandong

and ri P ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
Cross sectional study of dialysis

West China ### 20200311 3/25/2020 ChiCTR http://wwwRecruiting
The value of CD4 / CD8 cells,

Cangzhou
CRP P ### 20200314 3/25/2020 ChiCTR http://wwwRecruiting
Application of blood purification

Huashan Ho ### 20200314 3/25/2020 ChiCTR http://wwwRecruiting
Retrospective study on novel

Ganzicoron
Hospi ### 20200311 3/25/2020 ChiCTR http://wwwNot Recrui
Application of cas13a-mediated
Affiliated
RN ### 20200311 3/25/2020 ChiCTR http://wwwRecruiting
Research for the influence

Xiyuan
of Hos ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
Diagnosis and treatment The

of no
Clinical characteristics of Zhejiang

2019 H ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Characteristics, prognosisTongji
of Hos ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Auscultatory characteristics
Shanghai
of novFi ### 20200312 3/25/2020 ChiCTR http://wwwNot Recrui
Prognosis Investigation and

Hubei Prov ### 20200311 3/25/2020 ChiCTR http://wwwRecruiting
Analysis of the IncidenceShandong

and P ### 20200313 3/25/2020 ChiCTR http://www.chictr.or
Clinical Application of ECMO

Shandong P ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
A clinical study for effectiv

Shenzhen T ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study of Chloroquine

Zhongnan
Phos H ### 20200311 3/25/2020 ChiCTR http://wwwRecruiting
Exploration of the ClinicalShandong P ### 20200313 3/25/2020 ChiCTR http://wwwRecruiting
A comparative study for the

Affiliated ### 20200312 3/25/2020 ChiCTR http://wwwNot Recrui
Convalescent plasma for China-Japa

the trea ### 20200310 3/25/2020 ChiCTR http://wwwRecruiting
A multi-center, open-label
Ningbo Firs ### 20200310 3/25/2020 ChiCTR http://wwwNot Recrui
Study on immune cell subsets

The Third
in coA ### 20200310 3/25/2020 ChiCTR http://wwwRecruiting
Tozumab combined withShanghai

adam G 3/8/2020 20200308 3/25/2020 ChiCTR http://wwwRecruiting
Risk assessment and treatment

Tongji Hos
t ### 20200311 3/25/2020 ChiCTR http://wwwNot Recrui
Shedding of SARS-CoV-2 Tongji

in human
Med
s ### 20200311 3/25/2020 ChiCTR http://wwwRecruiting
A retrospective cohort study

Wuhan Hosp ### 20200311 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, blinded, con

Xiangya Hos ### 20200310 3/25/2020 ChiCTR http://wwwRecruiting
A randomized, parallel cont

The Third ### 20200310 3/25/2020 ChiCTR http://wwwNot Recrui
An evaluative clinical studUnion Hospi ### 20200310 3/25/2020 ChiCTR http://wwwNot Recrui
COVID-19 infection associated

Department3/9/2020
kidney 20200309 3/25/2020 ChiCTR http://wwwNot Recrui
Efficacy and safety of honeys

Hubei Hosp3/6/2020 20200306 3/25/2020 ChiCTR http://wwwRecruiting
The effects of preventionPeking

a Univ3/9/2020 20200309 3/25/2020 ChiCTR http://wwwRecruiting
Cohort study of Novel Coronavirus

Wuhan Chil3/9/2020
I 20200309 3/25/2020 ChiCTR http://wwwRecruiting
The prediction value of progno

The Sixth A 3/9/2020 20200309 3/25/2020 ChiCTR http://wwwNot Recrui
An anaesthesia procedure
Liaocheng
a 3/9/2020 20200309 3/25/2020 ChiCTR http://wwwNot Recrui
Epidemiological researchGuangzhou
of 3/7/2020 20200307 3/25/2020 ChiCTR http://www.chictr.or
Clinical trial for umbilical The Second ### 20200228 3/25/2020 ChiCTR http://wwwNot Recrui
Investigation on Mental Health

Yongchuan 3/2/2020 20200302 3/25/2020 ChiCTR http://www.chictr.or
Efficacy and safety of Xue-Bi-Ji

Jingzhou Fi 3/1/2020 20200301 3/25/2020 ChiCTR http://wwwRecruiting
Medical records based study
Xiyuan
f Hos 3/8/2020 20200308 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the correlation China

betweAcad 3/8/2020 20200308 3/25/2020 ChiCTR http://wwwNot Recrui
Analysis of the characteriThe First A 3/8/2020 20200308 3/25/2020 ChiCTR http://wwwNot Recrui
A multicentre, randomized,
Thecofirst a 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui

Luohu(COV
hosp ### 20200228 3/25/2020 ChiCTR http://www.chictr.or
Study for sleep status of medic

Guangzhou ### 20200225 3/25/2020 ChiCTR http://wwwRecruiting
Lung ultrasound in the diagnosi

Peking Univ ### 20200223 3/25/2020 ChiCTR http://wwwNot Recrui

ThefFirst A ### 20200222 3/25/2020 ChiCTR http://www.chictr.or
Application of TCM Nursing

TheScheme
Second3/6/2020 20200306 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study of NK Cells The

in the
First H 3/5/2020 20200305 3/25/2020 ChiCTR http://wwwNot Recrui
Positively Controlled Clinical

Affiliated 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwNot Recrui
Multicenter study for theThe

treatme
Efficacy and safety of Lopinavir

Jingzhou Fi ### 20200224 3/25/2020 ChiCTR http://wwwRecruiting
Single arm study for the efficac

Guangzhou ### 20200216 3/25/2020 ChiCTR http://wwwRecruiting
Study for meditation assists

Cancer
for Inst 3/3/2020 20200303 3/25/2020 ChiCTR http://wwwRecruiting
Efficacy and safety of chloro

Harbin infe 3/1/2020 20200301 3/25/2020 ChiCTR http://www.chictr.or
Study on the effect of human

An observational study ofThe

high
A randomized, double-blin
The Sixth A ### 20200221 3/25/2020 ChiCTR http://www.chictr.or
Nucleic acid analysis of nove

First peopl ### 20200229 3/25/2020 ChiCTR http://wwwNot Recrui
trialSecond ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
Jingzhou Ce ### 20200215 3/25/2020 ChiCTR http://wwwNot Recrui
Jingzhou Ce ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study of Cord Blood

Clinical Study for Umbilical

Guangzhou
Co ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the false positive

Department
ra ### 20200222 3/25/2020 ChiCTR http://www.chictr.or

Shanghai
(C U ### 20200218 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Study for Umbilical

Guangzhou
Cor ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Study of Cord Blood

Guangzhou
M ### 20200214 3/25/2020 ChiCTR http://wwwNot Recrui
A cox regression analysisWuhan

of prognAsia ### 20200214 3/25/2020 ChiCTR http://www.chictr.or
Serum TestingSTORY University ### 20190730 3/25/2020 ClinicalTri https://cl Recruiting
Study for epidemiology, diagnosis

Washed Microbiota TransThe Second ### 20200130 3/25/2020 ClinicalTri https://cl Not recruit
Clinical Study of Arbidol Hydro

Union Hosp2/5/2020 20200205 3/25/2020 ChiCTR http://wwwNot Recrui
Prognostic Characterist Chongqing ### 20200212 3/25/2020 ClinicalTri https://cl Not recruit
A Randomized,Open,Contr
Tongji Hosp2/4/2020 20200204 3/25/2020 ClinicalTri https://cl Recruiting
An Open, Prospective/ReTongji Hosp2/2/2020 20200202 3/25/2020 ClinicalTri https://cl Recruiting
Vitamin C Infusion for t ZhiYong P 2/4/2020 20200204 3/25/2020 ClinicalTri https://cl Recruiting
Home Blood Pr
HBPS MedStar Ge1/9/2020 20200109 3/25/2020 ClinicalTri https://cl Recruiting
An Open, Prospective/ReTongji Hosp2/2/2020 20200202 3/25/2020 ClinicalTri https://cl Recruiting
A Randomized, Open Labe

The First A ### 20200221 3/25/2020 ClinicalTri https://cl Not recruit
An Open, Prospective/RetTongji Hosp2/2/2020 20200202 3/25/2020 ClinicalTri https://cl Recruiting
An Exploratory Clinical Wuhan Unio2/8/2020 20200208 3/25/2020 ClinicalTri https://cl Not recruit
Study for Clinical Epid Wuhan Unio ### 20200213 3/25/2020 ClinicalTri https://cl Recruiting
Critically Ill Patients Chinese Un ### 20200224 3/25/2020 ClinicalTri https://cl Not recruit
Phase I/II Multicenter T Shenzhen G ### 20200217 3/25/2020 ClinicalTri https://cl Recruiting
Adaptive, Randomized, SiChina Acad ### 20200219 3/25/2020 ClinicalTri https://cl Not recruit
Phase I, Open-Label, Do National In ### 20200221 3/25/2020 ClinicalTri https://cl Recruiting
A Phase 3 Randomized StGilead Sci ### 20200228 3/25/2020 ClinicalTri https://cl Recruiting
A Multicenter, Adaptive, National In ### 20200220 3/25/2020 ClinicalTri https://cl Recruiting
Prospective, RandomizedBeijing 302 ### 20200224 3/25/2020 ClinicalTri https://cl Recruiting
Human Umbilical Cord Me

Puren Hosp ### 20200224 3/25/2020 ClinicalTri https://cl Not recruit
Intermediate-Size Patie U.S. Army 3/2/2020 20200302 3/25/2020 ClinicalTri https://cl Not recruit
The Efficacy and Safety Tongji Hosp ### 20200227 3/25/2020 ClinicalTri https://cl Not recruit
Prognostic Factors of Pa Chongqing 3/1/2020 20200301 3/25/2020 ClinicalTri https://cl Not recruit
Safety and Immunity EvalShenzhen G3/5/2020 20200305 3/25/2020 ClinicalTri https://cl Recruiting
Accurate Classification Renmin Hos3/7/2020 20200307 3/25/2020 ClinicalTri https://cl Not recruit
A Phase 3 Randomized Stu

Gilead Sci ### 20200228 3/25/2020 ClinicalTri https://cl Recruiting
Chloroquine PCOPCOV University 3/6/2020 20200306 3/25/2020 ClinicalTri https://cl Not recruit
Randomized Controlled ClAsan Medic ### 20200310 3/25/2020 ClinicalTri https://cl Recruiting
Clinical Stud TT-NPC Henan Prov3/4/2020 20200304 3/25/2020 ClinicalTri https://cl Recruiting
Antiviral Tre HCQ4COV1Lihir Medic 3/5/2020 20200305 3/25/2020 ClinicalTri https://cl Not recruit
A Pilot Study of Sildena Tongji Hosp ### 20200214 3/25/2020 ClinicalTri https://cl Recruiting
Blood Donor RecruitmentGuangzhou 3/8/2020 20200308 3/25/2020 ClinicalTri https://cl Not recruit
Clinical Tria CTOROTSAJiangsu Fa 3/1/2020 20200301 3/25/2020 ClinicalTri https://cl Recruiting

Clinical Study of Novel CAR-T (Sha ### 20200227 3/25/2020 ClinicalTri https://cl Not recruit
Nitric Oxide NoCovid Massachuse3/9/2020 20200309 3/25/2020 ClinicalTri https://cl Not recruit
Getting it Right: Toward Jean Liu 3/8/2020 20200308 3/25/2020 ClinicalTri https://cl Recruiting
An Adaptive, Randomized,
Zhong Wan ### 20200315 3/25/2020 ClinicalTri https://cl Not recruit
The Efficacy and Safety Qilu Hospi 3/9/2020 20200309 3/25/2020 ClinicalTri https://cl Not recruit
Nitric Oxide NOSARSCOMassachuse ### 20200310 3/25/2020 ClinicalTri https://cl Not recruit
Favipiravir Combined WitPeking Univ3/9/2020 20200309 3/25/2020 ClinicalTri https://cl Recruiting
Randomized Controlled Tr
University ### 20200313 3/25/2020 ClinicalTri https://cl Not recruit
Randomized Controlled Tr
University ### 20200313 3/25/2020 ClinicalTri https://cl Not recruit
Nitric Oxide NOpreventMassachuse ### 20200315 3/25/2020 ClinicalTri https://cl Not recruit
Retrospective Study of Wuhan Unio3/4/2020 20200304 3/25/2020 ClinicalTri https://cl Recruiting
Treatment of COVID-19 PStem Cells ### 20200315 3/25/2020 ClinicalTri https://cl Recruiting
A Retrospecti TACOS Tongji Hosp3/8/2020 20200308 3/25/2020 ClinicalTri https://cl Recruiting
The COVISTRES
COVISTRESUniversity ### 20200312 3/25/2020 ClinicalTri https://cl Not recruit
Intravenous ACOVID-AIV NeuroRx, I ### 20200314 3/25/2020 ClinicalTri https://cl Not recruit
Sequential OxSOTSPC Henan Prov ### 20200313 3/25/2020 ClinicalTri https://cl Recruiting
Development and VerificHuashan Ho ### 20200314 3/25/2020 ClinicalTri https://cl Not recruit
A Phase 2 Multiple Dose Pulmotect, ### 20200316 3/25/2020 ClinicalTri https://cl Not recruit
Changes in OrCOVID ME University ### 20200317 3/25/2020 ClinicalTri https://cl Not recruit
An Adaptive Phase 2/3, RRegeneron ### 20200315 3/25/2020 ClinicalTri https://cl Recruiting
A Single-cent PICTHA CanSino Bio ### 20200315 3/25/2020 ClinicalTri https://cl Not recruit
Clinical Char I-COVID Federico II ### 20200318 3/25/2020 ClinicalTri https://cl Recruiting
Exploratory C HOPE Azidus Bras ### 20200318 3/25/2020 ClinicalTri https://cl Not recruit
Clinical Performance of Centro Stud ### 20200314 3/25/2020 ClinicalTri https://cl Not recruit
The Benefits AI-COVID-XProfessor ### 20200317 3/25/2020 ClinicalTri https://cl Recruiting
Adverse EventCovidTox Groupe Hosp ### 20200317 3/25/2020 ClinicalTri https://cl Recruiting
HydroxychloroHYDRA National In ### 20200318 3/25/2020 ClinicalTri https://cl Not recruit
Multi-centre, DisCoVeRy Institut N ### 20200313 3/25/2020 ClinicalTri https://cl Not recruit
A Phase 2 Multiple Dose Pulmotect, ### 20200316 3/25/2020 ClinicalTri https://cl Not recruit
The Observational Study Xiangya Hos ### 20200316 3/25/2020 ClinicalTri https://cl Recruiting
Uppsala IntenUMODCOVIUppsala Un ### 20200313 3/25/2020 ClinicalTri https://cl Recruiting
Multicenter S TOCIVID-1 National Ca ### 20200319 3/25/2020 ClinicalTri https://cl Recruiting
Acute Kidney Injury in P Zhenhua Z ### 20200317 3/25/2020 ClinicalTri https://cl Not recruit
A Randomized,
SAC-COVIDOncoImmun ### 20200319 3/25/2020 ClinicalTri https://cl Not recruit
The correlation between The

Vitamin
People ### 20200323 3/25/2020 ChiCTR http://wwwNot Recrui
Norwegian CorNO COVID-University ### 20200313 3/25/2020 ClinicalTri https://cl Not recruit
Evaluating the clinical imUniversity ### 20200318 3/25/2020 ISRCTN http://isr Recruiting
Platform Randomised trial

University
of INter ### 20200322 3/25/2020 ISRCTN http://isr Recruiting
A medical records based Zhengzhou

study o ### 20200322 3/25/2020 ChiCTR http://wwwRecruiting
Study on the impact on fetus

Unionand
Hosp
n ### 20200322 3/25/2020 ChiCTR http://wwwRecruiting
Prospective exploratory clini

The third x ### 20200322 3/25/2020 ChiCTR http://wwwRecruiting
Application of radiology in
Hwa
theMei
p Ho ### 20200323 3/25/2020 ChiCTR http://wwwRecruiting
Safety and Effectiveness of

Wuhan Jiny ### 20200322 3/25/2020 ChiCTR http://wwwRecruiting
Study for metagenomics The

of patients
Fifth A ### 20200322 3/25/2020 ChiCTR http://wwwRecruiting
The Cohotr of COVID-19 Xiangyang ### 20200322 3/25/2020 ChiCTR http://wwwRecruiting
Clinical Research on Treatment

Guangzhou
of ### 20200322 3/25/2020 ChiCTR http://wwwNot Recrui
Upper Respiratory Tract Virus

RenminD Hos ### 20200320 3/25/2020 ChiCTR http://wwwNot Recrui
Psychological Support forNingbo

Diagnos
Kan ### 20200322 3/25/2020 ChiCTR http://wwwNot Recrui
Effect of Auricular point press

Xiyuan Hos ### 20200320 3/25/2020 ChiCTR http://wwwRecruiting
The Diagnosis and prognosis

Changzheng
pred ### 20200320 3/25/2020 ChiCTR http://wwwRecruiting
Internet based Solution Focu

Beijing No ### 20200320 3/25/2020 ChiCTR http://wwwNot Recrui
Perioperative immune predicti

Hu'nan Can ### 20200321 3/25/2020 ChiCTR http://wwwRecruiting
Detection of SARS-COV-2HwaMei
RNA LevHos ### 20200321 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical Trial of FavipiravirBeijing Cha ### 20200320 3/25/2020 ChiCTR http://wwwRecruiting
Psychological Responses Renmin

of Medi Hos ### 20200320 3/25/2020 ChiCTR http://wwwNot Recrui
association of T lymphocytes
Shenzhen
leve T ### 20200320 3/25/2020 ChiCTR http://wwwRecruiting
The Retrospective Study Changzheng

about ### 20200320 3/25/2020 ChiCTR http://wwwRecruiting
Efficacy and safety of Chin

Guangdong ### 20200320 3/25/2020 ChiCTR http://wwwNot Recrui
A medical records based Hu'nan

study Pro ### 20200318 3/25/2020 ChiCTR http://wwwRecruiting
Clinical application of extra

Beijing Cha ### 20200319 3/25/2020 ChiCTR http://wwwRecruiting
Effects of different VTE preven

Clinical efficacy of TCM syn

Hospital o ### 20200320 3/25/2020 ChiCTR http://wwwNot Recrui
Developing and evaluating

Tongji
of a Hos ### 20200319 3/25/2020 ChiCTR http://wwwNot Recrui
Myocardial injury and arrythmias

The Fifth in
Ht ### 20200319 3/25/2020 ChiCTR http://wwwRecruiting
Study for novel coronavirus

Westpne
China ### 20200319 3/25/2020 ChiCTR http://wwwRecruiting
Study for ''Bai-Du Duan Fang''

Longhua Hos ### 20200318 3/25/2020 ChiCTR http://wwwNot Recrui
Preliminary evaluation ofPLA
theGenera ### 20200318 3/25/2020 ChiCTR http://wwwRecruiting
An open, multi-center, control

The Second ### 20200318 3/25/2020 ChiCTR http://wwwNot Recrui
Combined diagnostic value

Shanghai
of novelK ### 20200318 3/25/2020 ChiCTR http://wwwNot Recrui
Effectiveness of ''Liu-Zi-Jue
Correlation between virologica

Anqing Mun ### 20200318 3/25/2020 ChiCTR http://wwwRecruiting
Venous Thrombosis Risk Shandong

of 2019-nCP ### 20200318 3/25/2020 ChiCTR http://wwwNot Recrui
Hospital of Chengdu Universit

Hospital o ### 20200318 3/25/2020 ChiCTR http://wwwRecruiting
Gu-Shen Ding-Chuan-Wan
The
used
First
i A ### 20200318 3/25/2020 ChiCTR http://wwwRecruiting
An observational study ofXiangya

car Ho ### 20200317 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical investigation andFirst

reseach
Teach
o ### 20200318 3/25/2020 ChiCTR http://wwwRecruiting
The treatment and diagnosis

Affiliated
pl ### 20200317 3/25/2020 ChiCTR http://wwwRecruiting
A Platform for Rapid Immuno-dete

A randomized, double-blind,
Clinical Characteristic andHuiZhou

OutcomMu ### 20200318 3/25/2020 ChiCTR http://wwwNot Recrui
Screening and identification

Theof
Evaluation of the effect oHwaMei Hos ### 20200317 3/25/2020 ChiCTR http://wwwRecruiting
Observation Of Clinical Effica

The First P ### 20200310 3/25/2020 ChiCTR http://www.chictr.or
Study for the effect of 3%Guangzhou

hyd 3/6/2020 20200306 3/25/2020 ChiCTR http://wwwNot Recrui
Optimization and evaluation

Prospective, open-label, contro

Foshan Firs ### 20200317 3/25/2020 ChiCTR http://wwwRecruiting
A single-center, open andJiangsu

do Pro ### 20200317 3/25/2020 ChiCTR http://wwwRecruiting
Evaluation of myocardialWest
injuryChina ### 20200217 3/25/2020 ChiCTR http://wwwNot Recrui
A study for the psychologica
The Fifth A ### 20200215 3/25/2020 ChiCTR http://wwwNot Recrui
Study for the clinical character

Guangzhou 3/5/2020 20200305 3/25/2020 ChiCTR http://wwwNot Recrui
the Efficacy and Safety ofZhongnan

Fa H ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
Clinical guidance of diagnose

The Second
an ### 20200313 3/25/2020 ChiCTR http://wwwNot Recrui
Nasal high-fow preoxygenation

Central Th 2/9/2020 20200209 3/25/2020 ChiCTR http://www.chictr.or
Clinical study of mesenchymal

Unionste
Hosp ### 20200226 3/25/2020 ChiCTR http://wwwNot Recrui
A prospective real world Affiliated

stu ### 20200224 3/25/2020 ChiCTR http://wwwNot Recrui
A randomized, open label,

The First H 2/3/2020 20200203 3/25/2020 ChiCTR http://wwwRecruiting
Hydroxychloroquine treating
Ruijinnov
Hosp ### 20200215 3/25/2020 ChiCTR http://wwwNot Recrui
Multi-centre, adaptive, randomiz

INSERM 3/9/2020 20200309 3/25/2020 EU Clinical https://wwAuthorised
Evaluating efficacy and safety

Tehranof Uni ### 20200316 3/25/2020 IRCT http://en.i Recruiting
Formulation of two natural

Iranp Univer ### 20200317 3/25/2020 IRCT http://en.i Recruiting
Biomarkers for prognosisnone

in critica ### 20200316 3/25/2020 Netherlands
https://tri Recruiting
A randomised double-blinSynairgen ### 20200317 3/25/2020 EU Clinical https://wwAuthorised
Treatment of CoronavirusFondation
SARS-Co ### 20200310 3/25/2020 EU Clinical https://wwAuthorised
Identification of host cellKlinik

res fÃ¼r ### 20200319 3/25/2020 German Clin
http://ww Not Recrui

Tehranof Uni ### 20200319 3/25/2020 IRCT http://en.i Recruiting
The effect of NOSCOVID Qazvin

on pulmon
Uni ### 20200322 3/25/2020 IRCT http://en.i Recruiting
Evaluting the therapeuticShahid

and Beh ### 20200323 3/25/2020 IRCT http://en.i Recruiting

Tehranof Uni
s ### 20200319 3/25/2020 IRCT http://en.i Recruiting
Digestive
c D ### 20200314 3/25/2020 IRCT http://en.i Not Recrui
Response adjustment of emergenc
Study Grou ### 20200320 3/25/2020 TCTR http://wwwNot Recrui

Tehran Uni ### 20200322 3/25/2020 IRCT http://en.i Recruiting
A prospective multi-center
Tokue Yut ### 20200227 3/25/2020 JPRN https://jrc Not Recrui
Critical
Care
A prospective multi-center
Tokue
openYut ### 20200227 3/25/2020 JPRN https://jrc Recruiting
Research
Group
Multicenter, open-label, The
Doi
randYohei 3/2/2020 20200302 3/25/2020 JPRN https://jrc Recruiting
Prince
Charles
ExtraCorporeal Membrane Hospital
Oxygena 3/6/2020 20200306 3/25/2020 JPRN https://up Recruiting
COVID-19 Registry - COVID-19

National
Registry
C ### 20200319 3/25/2020 JPRN https://up Recruiting
Preparedness and Responsiveness

Study Grou ### 20200321 3/25/2020 TCTR http://wwwNot Recrui
other reco Inclusion Inclusion Inclusion Date enrol Target size Study type Study desi Phase Countries
No N/A N/A All 25-Jan-20 500 Interventi Allocation Phase 4
No 18 Both ### Case seriesObservatioSequential RetrospectChina
No Both 2/1/2020 survival g ObservatioFactorial N/A China
No Both 2/6/2020 Case seriesInterventi Single arm N/A China
No 18 75 Both 3/1/2020 experimentInterventi Parallel N/A China
No Both ### Case seriesObservatioSequential N/A China
No 18 Both ### ExperimentInterventi Parallel 0
No 1 100 Both ### Target condDiagnostic Factorial 0 China
No 16 99 Male ### experimentInterventi Non random 0 China
No 0 18 Both ### control gr Interventi Non random 0 China
No Both ### Target condDiagnostic Factorial 0 China
No 15 85 Both ### TCM Group:Interventi Non random 0 China
No Both ### case seriesObservatioSequential N/A China
No 18 90 Both ### ExperimentInterventi Parallel 0 China
No 18 80 Both 2/5/2020 experimentInterventi Parallel 0 China
No Both ### experimentInterventi Parallel 4 China
No 1 Year 90 Years All 1-Jan-20 50 Observational N/A China
No 18 Years 80 Years All 28-Jan-20 125 Interventi Allocation Phase 4 China
No N/A N/A All 20-Jan-20 12000 Observational Phase 4 China
No N/A N/A All 3-Feb-20 30000 Observational N/A China
No 18 80 Both ### Case seriesObservatioSequential N/A China

No Both ### case seriesObservatioSequential 0 China
No 18 70 Both ### General paInterventi Parallel 4 China
No 14 Years 80 Years All 22-Jan-20 150 Interventi Allocation N/A China
No 18 Years 75 Years All 7-Feb-20 380 Interventi Allocation Phase 4
No 18 Years N/A All ### 80 Interventi Allocation Phase 2/Phase 3
No 18 Years 75 Years All 7-Feb-20 160 Interventi Allocation N/A
No Both 2/7/2020 ExperimentObservatioSequential 0 China
No 18 Both 2/9/2020 Case seriesInterventi Single arm 0 China
No 1 100 Both 3/1/2020 Target condDiagnostic Sequential 0 China
No 18 Both ### control gr Interventi Parallel 0 China
No 18 75 Both ### Target condDiagnostic Sequential 0 China
No 18 80 Both ### experimentInterventi Parallel 4 China
No 18 75 Both 3/1/2020 experimentInterventi Parallel N/A China
No Both ### ConventionInterventi Parallel N/A China
No 0 100 Both ### Case serie ObservatioSequential 0 China
No Both ### Case seriesObservatioFactorial N/A China
No Both 2/6/2020 control gr Interventi Non random 0 China
No Both 2/6/2020 Treatment Interventi Single arm 0 China
No 18 75 Both 2/1/2020 ExperimentInterventi Parallel 0 China
No 18 90 Both ### Normal groBasic Scie Factorial 0 China

No Both 2/8/2020 Case seriesObservatioSequential N/A China
No 14 80 Both 2/4/2020 (ordinary) Interventi Parallel 0 China
No 14 80 Both 2/4/2020 treament gInterventi Parallel 0 China
No Both ### Target condDiagnostic Sequential 0 China
No 18 75 Both ### Chinese tr Interventi Parallel N/A China
No 0 100 Both 2/7/2020 ExperimentInterventi Parallel 0
No 18 75 Both 2/1/2020 Case seriesObservatioSequential N/A China
No 18 65 Both 2/1/2020 Control gr Interventi Parallel 0 China
No 18 Both 2/5/2020 control gr Interventi Parallel 0 China
No 18 70 Both 2/3/2020 experimenta

Interventi Parallel 0 China
No 18 Both ### Thymosin tInterventi Parallel N/A China
No 18 Both ### ExperimentInterventi Parallel 0 China
No 18 Both ### Case seriesObservatioSequential 4 China
No 18 80 Both 2/3/2020 ExperimentInterventi Non random 4 China
No 18 Both 2/4/2020 experimentInterventi Parallel 0 China
No 18 80 Both ### Control gr Interventi Parallel N/A China
No 18 80 Both 3/1/2020 Control gr Interventi Parallel N/A China
No Both 2/1/2020 Case seriesInterventi Sequential 4 China
No Both ### A:15;B:15; Interventi Parallel 0 China
No 3 85 Both ### ObservatioPreventionNon random

N/A China
No 18 90 Both ### ExperimentInterventi Non random 4 China
No Both 2/4/2020 control gr Interventi Parallel 4 China
No 18 85 Both ### control gr Interventi Parallel 4 China
No 18 75 Both ### experimentInterventi Parallel N/A China
No Both ### Case seriesPrognosis Cohort stu RetrospectChina
No Both 2/1/2020 Group 1:50Interventi Non random 0 China
No 18 Both 2/3/2020 ExperimentInterventi Parallel 0 China
No Both 2/3/2020 Case seriesObservatioSequential 0 China
No Both ### Epilepsy g ObservatioFactorial N/A China
No 18 Both ### Control gr Interventi Parallel 0 China
No Both 2/1/2020 Suspected ObservatioNon random

N/A China
No Both ### non-severeObservatioFactorial N/A China
No 18 85 Both ### ExperimentInterventi Parallel N/A China
No Both ### ExperimentInterventi Parallel 0 China
No 18 75 Both 2/1/2020 Two groupsInterventi Dose compN/A China
No Both ### Vitamin D ObservatioFactorial 0 China

No 14 ?? Both ### doctors gr Interventi Factorial 0 China
No Both 2/7/2020 ExperimentObservatioNon random 0 China
No 16 75 Both ### Group A:30Interventi Non random 0 China
No 18 65 Both 3/1/2020 1:30;2:30; Interventi Non random

N/A China
No 18 75 Both ### Psychologi Interventi Parallel 0 China
No 18 Both 2/5/2020 control gr Interventi Parallel 0 China
No 18 65 Both ### DRV/c grouInterventi Parallel N/A China
No N/A N/A All 4-Feb-20 300 Observational N/A France
No 18 Years N/A All ### 120 Interventi Allocation Phase 2
No 18 65 Both ### ExperimentInterventi Parallel New Treatm

China
No Both ### ExperimentPreventionCase-ContrN/A China
No 18 80 Both 2/1/2020 experimentInterventi Non random

N/A China
No 18 80 Both ### mild-moderInterventi Non random 4 China
No 18 Both ### Case seriesInterventi Single arm N/A China

No Both 2/3/2020 Case seriesObservatioSingle arm N/A China
No 18 60 Both 2/1/2020 CommunityInterventi Parallel 0 China
No 18 Both 2/6/2020 Low dose gInterventi Parallel 4 Wuhan
No 18 Both ### Group A:20Interventi Non random 0 China
No 16 75 Both ### Control gr Interventi Parallel 0
No Both ### single arm Interventi Single arm 0 China
No 18 75 Both 2/4/2020 A:10;B:10; Interventi Parallel 0 China
No 16 Both ### Case seriesObservatioSequential N/A China
No 16 50 Female 3/1/2020 AdolescentObservatioFactorial N/A China
No 18 85 Both 2/7/2020 ExperimentInterventi Parallel N/A China
No 1 90 Both ### Case seriesObservatioSequential 0 China
No 18 Years N/A All 26-Jan-20 80 Interventi Allocation Phase 2/PhChina
No 18 80 Both 2/7/2020 Case seriesInterventi Single arm 0 China
No Both ### Case serie ObservatioSequential RetrospectChina
No Both 2/2/2020 control gr Interventi Parallel 0 China

No 18 75 Both ### Case seriesInterventi Single arm 0 China
No 18 80 Both 2/4/2020 1:30;2:30; Interventi Parallel 4 China
No 18 80 Both ### control groInterventi Factorial 0 China
No 18 75 Both ### Group 1:20Interventi Non random 4 China
No 18 Years 75 Years All 6-Feb-20 10 Interventi Interventi Phase 2 China
No 18 60 Both ### Case seriesTreatment Sequential 0 China
No 18 70 Both ### CombinatioInterventi Parallel 4 China
No 18 Both ### Case seriesObservatioSingle arm N/A China
No 18 Both ### ExperimentInterventi Parallel N/A China
No 50 100 Both ### severe NCPInterventi Factorial 0 China
No Both ### Severe gro ObservatioFactorial 0 China
No 15 35 Both ### Exercise p Interventi Parallel N/A China
No 18 Both ### Low-dose gInterventi Parallel 2 China
No 18 75 Both ### Ganovo / r Interventi Non random 4 China
No Both ### ExperimentInterventi Parallel N/A China
No Both ### case seriesObservatioSequential N/A China

No 16 75 Male ### ExperimentInterventi Parallel 2 China
No 15 60 Both ### Case seriesObservatioSingle arm 0 China
No Male ### pneumoniaObservatioFactorial N/A China
No 18 80 Both ### Control gr Interventi Parallel 0 China
No 18 80 Both ### Interventi Interventi Parallel New Treatm

Chinese
No Both ### Severe gro ObservatioFactorial 0 China
No Both ### Control gr Interventi Non random 0 China
No Female ### Case seriesBasic Scie Sequential 0 China
No 0 90 Both ### HumanisticInterventi Non random 0 China
No Both ### ExperimentInterventi Parallel N/A China
No 18 Both ### experimentInterventi Parallel 4 China
No 16 99 Both ### hydroxychlInterventi Parallel 4 China
No Both ### Light grou ObservatioFactorial 0 China
No Both ### general an ObservatioFactorial RetrospectChina
No 0 1 Both ### COVID-19 pObservatioFactorial N/A China
No 18 85 Both ### Target condDiagnostic Factorial RetrospectChina

No Both ### common gro
ObservatioFactorial N/A China
No 18 100 Both ### Mild GroupInterventi Factorial 0 China
No 18 75 Both ### ChloroquinInterventi Parallel 4 China
No 18 75 Both ### HydroxychlInterventi Parallel 0 China
No 18 60 Both ### ExperimentInterventi Non random

N/A China
No Both ### experimentInterventi Parallel 1-Feb China
No 18 Female ### Target condDiagnostic Sequential 0 China
No Both ### Case seriesObservatioSequential RetrospectChina
No 18 70 Both 2/6/2020 Case seriesInterventi Sequential N/A China
No 18 60 Both ### A1:80;A2:8Interventi Parallel 0 China
No 18 90 Both ### Training:1 ObservatioFactorial N/A China
No 16 30 Both ### college st ObservatioSequential N/A China
No 18 Years N/A All 6-Feb-20 453 Interventi Allocation Phase 3 China
No Both ### Group 1:12Interventi Parallel N/A China
No 22 55 Both ### Case serie ObservatioSequential N/A China

No 18 Years N/A All ### 308 Interventi Allocation Phase 3 China
No N/A N/A All 1-Feb-20 300000 Observational N/A China
No 18 Years N/A All ### 400 Interventi Allocation N/A China
No N/A 18 Years All ### 500 Observational Phase 1 China
No 18 Years 65 Years All ### 48 Interventi Allocation N/A China
No 18 Years 90 Years All ### 450 Observational N/A China
No Both 3/1/2020 Control gr Interventi Parallel N/A China
No Both ### Control gr Interventi Parallel 4 China
No N/A 28 Days All 1-Feb-20 100 Observational N/A China
No 18 Years 75 Years All 3-Feb-20 20 Interventi Interventi Phase 1/PhChina
No 18 Years 70 Years All ### 348 Interventi Allocation N/A
No 18 Years 65 Years All ### 136 Interventi Allocation Phase 2 China
No 20 45 Both 3/2/2020 Case serie Interventi Parallel 0 China
No 18 Years N/A All Feb-20 100 Observational N/A
No 18 Years 80 Years All Feb-20 20 Interventi Interventi Phase 2/PhChina
No Both 1/1/2020 Target condDiagnostic Sequential RetrospectChina
No 0 18 Both ### Monitor caObservatioSequential N/A China
No Both 3/1/2020 one group:Interventi Single arm 1 China

No 18 80 Male 3/1/2020 Group 1:40Interventi Parallel N/A China
No 18 Both ### Exposure gObservatioNon random 0 China
No Both 3/1/2020 Mild groupObservatioFactorial RetrospectChina
No 0 0 Both 3/1/2020 Case serie Interventi Sequential 0 China
No 18 65 Both 3/1/2020 Case seriesObservatioSingle arm 0 China
No 0 120 Both 2/1/2020 Case seriesEpidemilogSequential N/A China
No 18 90 Both 2/1/2020 Light and ObservatioFactorial 0 China
No 18 Both 3/2/2020 ExperimentInterventi Sequential 4 China
No 20 90 Male 3/5/2020 Case seriesInterventi Non random 0
No 1 15 Both ### Case seriesInterventi Single arm 0
No 18 90 Both 3/9/2020 Case seriesObservatioSingle arm 0 China
No 0 100 Both ### Target condDiagnostic Factorial 0 China
No 18 Both 3/4/2020 Pirfenidon Interventi Parallel 0 China
No 18 79 Both 3/1/2020 The experi Interventi Parallel N/A China
No 18 Both 1/1/2020 Case seriesObservatioSequential 0 China
No 18 75 Both ### experimentInterventi Parallel N/A China
No Both ### Case seriesEpidemilogSequential N/A China

No Both 3/1/2020 Case seriesObservatioSequential RetrospectChina
No 18 70 Both 2/1/2020 Group 2:10Interventi Sequential 0 China
No Both ### Interventi ObservatioSequential N/A China
No 18 75 Both ### Case seriesInterventi Non random 1 China
No Both ### case seriesObservatioSingle arm RetrospectChina
No Both ### Two groupsInterventi Non random 0 China
No 16 92 Both 3/1/2020 Case seriesObservatioSequential RetrospectChina
No 18 75 Both 3/1/2020 Routine tr Interventi Parallel 4 China
No Both ### Target condDiagnostic Cross-secti 1 China
No Both 3/1/2020 Exocrine g Interventi Parallel 0 China
No 60 Both ### the elderly ObservatioSequential N/A China
No Both ### High infla Interventi Parallel 0 China
No 18 Both ### Burnout poObservatioSequential N/A China
No 8 91 Both ### Case seriesInterventi Sequential New Treatm

China
No 0 79 Both ### Case seriesObservatioSequential RetrospectChina

No 18 70 Both ### ExperimentTreatment Single arm 0 China
No 18 Both ### ExperimentInterventi Single arm 4 China
No 18 80 Both ### Low-dose gInterventi Parallel 4 China
No Both ### Case seriesInterventi Single arm 2 china
No Both ### ExperimentInterventi Non random 4 China
No 18 75 Both ### Kesuting s Interventi Parallel 4 China
No 18 100 Both ### General poHealth ser Sequential N/A China
No Both 3/1/2020 Interventi Parallel 0
No 18 Both ### hydroxychlInterventi Parallel 4 China

No 18 75 Both ### hydroxychlInterventi Parallel 4 China
No 18 65 Both ### arm A:36;aInterventi Parallel N/A China
No 18 Years N/A All ### 70 Interventi Allocation Phase 2 Hong Kong
No 18 Years 70 Years All 27-Jan-20 20 Interventi Allocation Phase 1 China
No 18 Years 75 Years All ### 30 Interventi Interventi Phase 1
No 18 Years 75 Years All ### 520 Interventi Allocation Phase 4
No 18 90 Both 3/8/2020 Case seriesObservatioSequential 0 China
No 18 90 Both 3/8/2020 case seriesObservatioSequential 0 China
No 18 - Both ### Target condDiagnostic Sequential 0 China
No 18 100 Both ### Case seriesObservatioSingle arm RetrospectChina
No 18 Both 3/7/2020 Case seriesObservatioSequential RetrospectChina
No Both 3/9/2020 Patients w ObservatioFactorial RetrospectChina
No 18 90 Both 3/8/2020 CRRT groupInterventi Parallel 0 China
No N/A N/A All Feb-20 230 Interventi Interventi N/A China

No N/A N/A All 31-Jan-20 39 Observational N/A China
No 18 Both ### ExperimentInterventi Non random 0 China
No 18 Both 3/4/2020 Azvudine PInterventi Single arm 0 China
No Both 3/4/2020 Control gr ObservatioNon random

RetrospectChina
No 18 75 Both 2/1/2020 Case seriesInterventi Single arm 0
No Both 2/1/2020 ExperimentInterventi Parallel 0 China
No 14 90 Both 3/3/2020 Group 2:50ObservatioFactorial RetrospectChina
No 18 75 Both ### ExperimentInterventi Non random

N/A China
No 16 30 Both 3/6/2020 Medical st ObservatioSequential N/A China
No 18 Both 3/1/2020 Early corti Interventi Parallel 4 China
No Both 3/1/2020 Control gr Interventi Parallel N/A China
No 18 75 Both 3/2/2020 Lipoic aci Interventi Parallel 4 China
No Both 3/7/2020 ExperimentInterventi Parallel N/A China
No 0 18 Both ### monitor caObservatioSequential N/A China
No Both 3/3/2020 Patients i ObservatioCross-secti 0 China
No 18 70 Both 2/1/2020 COVID-2019EpidemilogSequential 0 China
No 14 90 Both ### Case serie ObservatioSequential RetrospectChina
No 18 100 Both 3/1/2020 Novel coroObservatioSequential RetrospectChina

No Both ### PRE-GROUPObservatioNon random
N/A China
No Both 3/2/2020 ACEIs/ARBsObservatioSequential RetrospectChina
No Both 2/2/2020 treatment Interventi Parallel N/A China
No Both 3/6/2020 Case serie ObservatioSequential N/A China
No 18 90 Both 3/2/2020 Group 2:35Interventi Parallel N/A China
No 18 65 Both 3/4/2020 cross-secti ObservatioSequential N/A China
No 18 110 Both 3/3/2020 Interferon Interventi Parallel 4 China
No Both 3/3/2020 Case seriesEpidemilogSequential Retrospective study
No 18 70 Both ### Case seriesInterventi Single arm N/A China
No 18 Both ### group A:20Interventi Parallel 0 China
No Both 2/1/2020 Case serie EpidemilogSequential RetrospectChina
No Both ### ExperimentInterventi Factorial N/A China
No Both ### Mild COVIDObservatioSequential 0 China
No 18 75 Both 2/3/2020 Treatment Interventi Parallel 0 China

No 18 80 Both 3/6/2020 Case seriesObservatioSingle arm N/A China
No 18 99 Both ### patient gr ObservatioFactorial RetrospectChina
No Both 2/3/2020 ExperimentInterventi Parallel N/A China
No Both ### ExperimentInterventi Cluster ra N/A China
No 18 Both 2/1/2020 Routine tr Interventi Parallel 4 China
No 18 Both ### interventi Interventi Parallel N/A China
No 18 Both 2/1/2020 Routine tr Interventi Parallel 4 China
No 18 Years N/A All Mar-20 Expanded Access Phase 2
No 18 - Both ### ExperimentInterventi Parallel 0 China
No N/A N/A All 30-Jan-20 30 Interventi Allocation Phase 3 China
No 18 75 Both 2/6/2020 Case seriesInterventi Single arm 0 China
No Male ### Case serie ObservatioSequential 1 China
No 18 65 Both 3/1/2020 Group 1:90Interventi Parallel 4 China
No 18 70 Both ### ObservatioObservatioSingle arm N/A China
No Both ### Case serie ObservatioSequential RetrospectChina
No 0 99 Both ### Ordinary C ObservatioSequential RetrospectChina
No 18 85 Both ### Case seriesHealth ser Sequential 0
No 18 Years 90 Years All 7-Mar-20 120 Observational N/A
No 18 80 Both ### PopulationObservatioSequential N/A China
No 18 85 Both 2/1/2020 MSC groupObservatioSingle arm 0 China
No Both 2/1/2020 Case seriesInterventi Non random

N/A China
No 18 85 Male ### Case seriesObservatioSequential 0 China
No 18 100 Both ### Case seriesObservatioCohort stu N/A China
No Both 3/1/2020 Group 1:70ObservatioFactorial N/A Chian
No N/A N/A All 1-Feb-20 15 Observational Phase 2/PhChina
No 18 Years N/A All 1-Mar-20 328 Interventi Allocation Early Phase 1
No 18 Years N/A All 1-Mar-20 104 Interventi Allocation Phase 2
No 18 Years 75 Years All 1-Jan-20 400 Observational Phase 2/PhChina
No 18 Years N/A All 1-Apr-20 576 Interventi Allocation N/A
No 18 Both ### ExperimentInterventi Cross-secti 1 China
No Both ### The triple ObservatioCohort stu N/A China
No Male 2/1/2020 Case seriesInterventi Sequential 1
No 18 ?? Both ### ObservatioObservatioFactorial N/A China
No 18 Both 2/1/2020 Case seriesInterventi Sequential 0
No 10 Years 19 Years All 15-Oct-20 3428 Observational N/A
No Both ### Control gr Interventi Parallel N/A China

No 18 Both ### ExperimentInterventi Non random 0 China
No 12 85 Both 3/1/2020 Case seriesScreening Sequential 0 China
No 12 Both ### Case seriesObservatioFactorial RetrospectChina
No 18 80 Both ### Target condDiagnostic Sequential N/A China
No 18 80 Both 2/1/2020 Group 2:15Interventi Non random 4 China
No Both ### Group 1:20Interventi Parallel 0
No 16 75 Both ### High dose Interventi Single arm New Treatm

China
No Male 2/1/2020 Case seriesObservatioSequential RetrospectChina
No 18 75 Both 2/1/2020 experimentObservatioSequential 1 China
No 18 75 Both 2/1/2020 ExocarpiumInterventi Parallel 4 China
No Both ### control gr Interventi Parallel 0 China
No 14 90 Both ### NIV group: ObservatioFactorial RetrospectChina
No 1 100 Male 3/1/2020 Case seriesObservatioSequential N/A China
No 7 70 Both ### Case seriesInterventi Sequential 0 China

No Both ### Target condDiagnostic Sequential RetrospectChina
No Both ### Light grou ObservatioFactorial 0 China
No 18 Both ### severe pat ObservatioSequential Retrospective study
No 20 80 Male ### Case seriesObservatioSequential 0 China
No Male ### Target condDiagnostic Sequential 0 China
No Both ### Case serie ObservatioCase study RetrospectChina
No 65 100 Both ### discharge ObservatioCase study 1 China
No 14 90 Both 2/1/2020 case seriesObservatioSequential RetrospectChina
No 18 70 Both ### Target condDiagnostic Sequential RetrospectChina
No 14 90 Both 2/1/2020 transnasal ObservatioSequential 0 China
No 23 94 Both ### non-cancerObservatioFactorial RetrospectChina
No Both ### Case seriesObservatioSequential Retrospective study

No Both ### Case seriesObservatioSequential Retrospective study
No Both 2/1/2020 Case seriesEpidemilogSequential N/A China
No 18 70 Both ### Case seriesInterventi Sequential N/A China
No Both ### Control gr ObservatioNon random 0 China
No 2 89 Both 2/1/2020 Case seriesObservatioCase-ContrN/A
No 18 80 Both ### Case seriesInterventi Cohort stu N/A China
No 18 Both 3/7/2020 4 groups:2 ObservatioFactorial RetrospectChina
No 1 99 Both ### Case seriesEpidemilogSingle arm RetrospectChina
No 18 74 Both ### two groupsObservatioCase-ContrRetrospectChina
No 18 Both 3/9/2020 Case seriesObservatioSequential N/A China
No 18 65 Both 3/1/2020 Group 2:60Interventi Parallel 0 China
No 14 90 Both 2/1/2020 ECMO group

Interventi Non random
RetrospectChina
No 25 65 Both 3/1/2020 common typ

Interventi Parallel 1-Feb China

No 14 90 Both 2/1/2020 case seriesObservatioCase study RetrospectChina
No 18 - Both ### eperimentaInterventi Parallel 0 China
No 18 96 Both ### Case serie ObservatioNon random

RetrospectChina
No 18 80 Both ### Two groupsBasic Scie Factorial N/A China
No 14 90 Both 4/1/2020 Exposed grObservatioFactorial RetrospectChina
No 22 55 Male 3/5/2020 in hospita ObservatioSequential N/A China
No Both 3/1/2020 Integrated ObservatioCohort stu RetrospectChina
No 18 Both 3/9/2020 experimentInterventi Parallel 0 China
No 0 18 Both 2/1/2020 Infection wBasic Scie Factorial 0 China
No 18 75 Both 2/4/2020 Control gr Interventi Parallel 4 China?
No 18 Both 3/3/2020 tumor pati ObservatioSequential N/A China
No 0 18 Both ### case seriesObservatioSequential N/A China
No 60 110 Both 3/9/2020 Target condDiagnostic Sequential RetrospectChina
No 2 65 Both ### Group A:60Interventi Parallel 0 China
No 1 80 Both 3/7/2020 1:132;2:13 EpidemilogSequential RetrospectChina
No 18 65 Both 3/5/2020 Control gr Interventi Parallel 0 China

No 18 ND Both 3/9/2020 Chinese meObservatioFactorial RetrospectChina
No 18 ND Both 3/9/2020 Case seriesObservatioSequential RetrospectChina
No Both 3/1/2020 treatment Interventi Parallel 1 China
No 18 60 Both ### Case seriesHealth ser Sequential 0
No 18 Both ### Target condDiagnostic Sequential 0 China
No 18 Male 3/6/2020 Group 1:30ObservatioNon random

N/A China
No 18 75 Both ### Positive d Interventi Parallel 0 China
No 18 70 Both ### Routine tr Prognosis Parallel 4 China
No 18 Both ### Case seriesInterventi Single arm 1-Feb China
No 14 70 Both 3/3/2020 1:100;2:10 Interventi Parallel 0 China
No Both 3/1/2020 ExperimentInterventi Parallel 0
No 18 65 Both ### PhosphoricInterventi Parallel 4 China
No 18 85 Both ### Target condDiagnostic Sequential N/A China

No 18 Both ### High dose Interventi Parallel 0
No 12 Both ### Target condDiagnostic Factorial 0 China
No N/A 24 Years All 15-Oct-19 2300 Observational Phase 3 United Ki
No 14 Years 70 Years All 5-Feb-20 0 Interventi Allocation N/A China
No 18 65 Both 2/7/2020 Two cohortObservatioFactorial 4 China
No 18 Years 100 Years All 25-Jan-20 0 Observational Phase 2 China
No 18 Years 55 Years All 1-Feb-20 60 Interventi Allocation Phase 3 China
No 18 Years N/A All ### 140 Interventi Allocation Phase 2 China
No 18 Years N/A All ### 32 Interventi Allocation N/A United Sta
No 18 Years 80 Years All Feb-20 0 Interventi Allocation N/A China
No 18 Years N/A All ### 10 Interventi Allocation N/A China

No 18 Years N/A All ### 8 Observational N/A Hong Kong
No 6 Months 80 Years All ### 100 Interventi Interventi Phase 1/PhChina
No 18 Years N/A All ### 300 Interventi Allocation Phase 2/PhChina
No 18 Years 55 Years All 3-Mar-20 45 Interventi Allocation Phase 1 United Sta
Yes 18 Years N/A All ### 600 Interventi Allocation Phase 3 United Sta
No 18 Years 99 Years All ### 394 Interventi Allocation Phase 2 United Sta
No 18 Years 70 Years All 5-Mar-20 60 Interventi Allocation Phase 1/PhChina
No N/A N/A All 2-Mar-20 Expanded Access N/A
No 18 Years 75 Years All 1-Apr-20 550 Interventi Allocation Phase 2/Phase 3
No 18 Years N/A All 1-Mar-20 201 Observational N/A China
No 6 Months 80 Years All ### 100 Interventi Interventi Phase 1 China
No N/A N/A All ### 669 Observational N/A China
Yes 18 Years N/A All 6-Mar-20 400 Interventi Allocation Phase 3 United Sta
No 16 Years N/A All May-20 10000 Interventi Allocation: N/A
No 16 Years 99 Years All ### 150 Interventi Allocation Phase 2 Korea, Rep
No 18 Years 75 Years All 5-Mar-20 60 Interventi Allocation Phase 4 China
No 18 Years N/A All 9-Feb-20 10 Interventi Interventi Phase 3 China
No 18 Years 75 Years All 2-Mar-20 340 Observational Phase 4 China

No 18 Years 75 Years All 5-Mar-20 24 Interventi Interventi Early Phase 1
No 21 Years N/A All 8-Mar-20 5000 Observational N/A Singapore
No 18 Years N/A All ### 116 Interventi Allocation Phase 2/PhChina
No 18 Years 65 Years All 8-Mar-20 150 Interventi Allocation N/A China
No 18 Years N/A All ### 478 Interventi Allocation Phase 2 United Sta
No 18 Years N/A All ### 200 Interventi Allocation Phase 2 United Sta
No 18 Years N/A All 1-Jan-20 500 Observational N/A China
No 18 Years N/A All ### 5 Interventi Interventi Phase 1 Jordan
No 18 Years 80 Years All ### 120 Observational Phase 4 China
No N/A N/A All ### 50000 Observational [PatientPhase 2 France
No 18 Years 100 Years All Apr-20 20 Interventi Allocation Phase 2 United Stat
No 18 Years 75 Years All 1-Feb-20 30 Observational N/A China
No 18 Years N/A All Apr-20 200 Interventi Allocation Phase 2
No 18 Years N/A All ### 200 Observational Phase 3
No 18 Years N/A All ### 400 Interventi Allocation Phase 2/PhUnited Sta
No 18 Years 50 Years Female 1-Jan-20 20 Observational [PatientN/A Italy

No 18 Years N/A All Apr-20 6 Interventi Interventi Phase 1
No 18 Years N/A All Mar-20 200 Interventi Interventi N/A Italy
No N/A N/A All ### 200 Observational N/A Romania
No N/A N/A All ### 1000 Observational Phase 1 France
No 18 Years N/A All Mar-20 3200 Interventi Allocation Phase 3
No 18 Years N/A All Apr-20 100 Interventi Allocation Phase 2 United Sta
No 18 Years N/A All ### 80 Observational [PatientN/A China
No 18 Years N/A All ### 100 Observational Phase 4 Sweden
No N/A N/A All ### 330 Interventi Interventi Phase 2 Italy
No 18 Years N/A All ### 287 Observational N/A China
No 18 Years N/A All May-20 230 Interventi Allocation Phase 3 United Sta
No 0.1 85 Male ### Case seriesObservatioSequential N/A China
No Both ### 500 Interventi Prospectiv Not Applic United Kingdom
No Both ### 3000 Interventi Open prospPhase III United Ki
No 18 80 Both 5/1/2020 Case seriesObservatioSequential 0 China
No 20 50 Female 2/1/2020 Case seriesObservatioSequential 0 China
No Both ### Pirfenidon Interventi Parallel 0 China
No Both 4/1/2020 Case seriesHealth ser Sequential N/A China
No 18 80 Both ### Case seriesInterventi Sequential 0 China
No 0 90 Both 2/5/2020 Diagnosed ObservatioSequential N/A China

No 0 100 Both 2/9/2020 COVID-19 ObservatioCohort stu RetrospectChina
No 18 80 Both ### experimentInterventi Non random

N/A China
No 18 65 Both ### Group 1:30Interventi Parallel N/A China
No Both ### Target condDiagnostic Sequential Retrospective study
No 11 18 Both ### SFBT groupInterventi Parallel N/A China
No Both ### Group 2:16Interventi Historical N/A China
No Both ### SARS-COV-2ObservatioFactorial RetrospectChina
No 18 75 Male 3/5/2020 ExperimentInterventi Parallel 2-Mar China
No 18 65 Both 3/4/2020 cross-secti ObservatioSequential N/A China
No Both ### Critical gr ObservatioFactorial RetrospectChina
No Both 1/1/2020 Case serie ObservatioSequential Retrospective study
No 38 70 Male ### Case seriesObservatioCohort stu N/A China
No 18 80 Both ### 1:80;2:40; Interventi Non random 4 China
No Both 3/1/2020 Case seriesObservatioSingle arm N/A China
No Both ### the patien Basic Scie Sequential 0 China
No 18 80 Both 2/1/2020 ExperimentInterventi Non random

N/A China
No 14 Both ### Case seriesInterventi Non random 0 China
No 18 75 Both ### Group 1:36Interventi Parallel 0 China
No 16 90 Both 2/1/2020 COVID-19 pObservatioSequential RetrospectChina
No Both ### Case seriesObservatioSequential 0 China
No 18 75 Both ### CM group: Treatment Quasi-randN/A China
No 18 - Both ### observatio ObservatioSingle arm N/A China
No 18 ?? Both ### confirmed ObservatioFactorial 0 China
No 0 ?? Both ### Suspected Interventi Parallel 0 China
No Both ### COVID-19 pObservatioSequential RetrospectChina
No Both ### TricholomaInterventi Parallel N/A China
No 7 90 Both ### ExperimentInterventi Cross-over 4 China
No 18 85 Both 3/6/2020 control gr Interventi Case-Contr 0 China
No Both ### Case seriesObservatioSequential 0 China
No 18 65 Both ### A:15;B:15; Interventi Parallel N/A China
No 18 60 Both ### 1:36;2:36;3PreventionNon random 1 China
No Both 3/1/2020 Target condDiagnostic Sequential 0 China

Controlle
d: yes
No Both ### Randomis
tumor pati ObservatioFactorial 0 China
ed: yes
Open: yes
No 18 85 Both 3/6/2020 Single
Case seriesObservatioSequential 0 China
blind: no
Double
No 18 100 Both ### ExperimentInterventi blind:
Parallelno 0 China
Parallel
group:
No 1 99 Both ### yes
EpidemilogSequential RetrospectChina
Cross Human
Controlle
over: no pharmac
No 18 80 Both ### experimentInterventi d: yes no ology
Other:
Parallel N/A China
Randomis
If (Phase I):
ed: yes
controlle no
No 18 100 Both ### 1 the criti Interventi Open:
d,
Parallel no Therapeu
specify N/A China
Single
comparat tic
blind:
or, Other no explorato
No 18 ?? Both ### Double
Medicinia
ExperimentObservatioNon random ry
N/A (Phase China
blind:
Randomiz
l Product:yes II): no
Controlle
Parallel
ed:
yes No, Therapeu
No Both 2/6/2020 Mild Type Interventi d: no no tic
group:
Placebo:
Parallel 4 China
Randomis
Cross
no Human
confirmat
ed:
over: nono
Masking:
Other: no pharmac
ory -
No 18 70 Both ### InterventioInterventi Randomiz
Open:
Parallelno
Other:
None,
Number no ology
(Phase 4 China
ation:
Single
If
of Not Human
(Phase
III): yes I):
randomiz
blind:
controlle
treatmen no pharmac
no
Therapeu
No 18 Both ### ExperimentInterventi Randomiz
ed,
Double
d,
Control:
tParallel
arms in ology
specify Therapeu
tic use 4 China
ation:
Blinding:
blind:
comparat
Not no (Phase
the trial: tic I):
Randomiz
Double
Parallel
4 Other no
or,
applicabl explorato
IV): no
No Female3/9/2020 3300 Interventioed,blinded,
group:
Medicinia
e, no Therapeu
ry (Phase France
Blinding:
Placebo:
Cross
l Product: ticII): yes
Not
over: used,
no Group:no explorato
Therapeu
No 18 years 65 years Both ### blinded,
Assignme
Other:
Placebo:
undefine
30 interventioRandomizati no ry
tic (Phase
2-Mar Iran (Islam
Placebo:
nt:
If
yes
d, II): no
confirmat
Not used,
Parallel,
controlle
Other: no Therapeu
ory -
No 18 years 65 years Both ### Assignme
Purpose:
d, specify
Type: tic
Number
150 interventioRandomizat (Phase2-Mar Iran (Islam
nt:
Treatmen
comparat
of
Single confirmat
III): no
Parallel,
t,
or, Blinding
Other ory
treatmen
arm -
Therapeu
No ### 50 Observatio Purpose:
descriptio
Medicinia
t arms in (Phase
tic use The Nether
Treatmen
n:
ltheIntrial:
this III):
Product: (Phaseyes
t,
study
no
2 Therapeu
IV): no
No Female ### 400 InterventioRandomiz
patients,
Placebo: tic use United Ki
ation
nurse
no , (Phase
descriptio
superviso
Other: no IV): no
No Female3/5/2020 25 Intervention: r and France
Randomiz
researche
ation
r don'twill
No 18 Years no maximuBoth, male ### 60 observatio be knowdone N/A
Allocation Germany
according
which
to the of
group
No 18 years 75 years Both ### blocks
patients
30 interventioRandomizat 2-Mar Iran (Islam
randomiz
will use
ation
the
No 2 years no limit Both ### 125 interventiomethod.
medici 2 Iran (Islam
Regarding
to the
No 18 years no limit Both 3/3/2020 sample
20 interventioRandomizat 3 Iran (Islam
size, 5
patients
No 18 years 75 years Both ### 50 interventiowil 2-Mar Iran (Islam
No 18 years no limit Both ### 70 interventioRandomizat 3 Iran (Islam

No 18 Years 95 Years Both ### 5000 ObservatioN/A N/A France;Fra
No no limit no limit Both ### 50 interventioRandomizat 2-Mar Iran (Islam
No >= 20age oNot applic Both ### 50 Interventi single arm 2 Japan
No >= 20age oNot applic Both ### 50 Interventi single arm 2 Japan
No >= 16age oNot applic Both 3/2/2020 86 Interventi randomized 2 Japan
No 1years-old 100years-oMale and 2/1/2020 500 ObservatioNot select Not applic Japan,Asia
No Not applic Not applic Male and ### 9999 ObservatioNot select Not applic Japan
No 30 Years 70 Years Both ### 650 ObservatioN/A N/A France

 Inclusion Criteria:
 
 Patients diagnosed with RT-PCR for 2019 Nove
 
 
Contact Fi Contact L Contact AdContact EmContact Te Contact AffInclusion Exclusion
CExclusionCriteria:
CCondition Interventi
 
 Patients infected with other viruses
Pinhua Pan, Medical pinhuapa +86 13574810968 2019 NovelDrug: Conv
Inclusion criteria: 1. Aged >=18 years;
 2. Diagnosed of 2019-nCoV infection with "guidelin
Yan, Zhao 169 Donghudoctoryan +86 13995 Emergency 3. Failed Exclusion
by cNovel CoroCase serie
Exclusion criteria: 1. Female patients during p
Yan Zhao 169 Donghudoctoryan +86 13995 EmergencyInclusion c 2. Patients
Exclusion with known allergy
2019-nCoVsurvival g to chloroq
 3. Patients with haematological diseases
Inclusion criteria:
 4. Patients
Patients aged
with chronic
18 or older,
liverand
or kidney
meet th
d
Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos
 Criteria 5.
for diagnosis
Patients
Novel
(meet
with
CoroCase
arrh
all theserie
following crite
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.diagnostic
Patients with
criteria
respiratory
forconfi
LU Zhenhui 725 Wanpintcmdoctor +86 13817 Longhua Hos
 2. The 2.
acute stage
Pregnant,
Novel
is complicated
preparing
Coroexperiment
by
or sepsis,
lac respirat
Inclusion criteria:
Exclusion
1. Suspected,
criteria: 1. Unable
mild, normal
to receive
and severe
traditi
Wang Tan 1478 GongnWangtan2 +86 13756 Affiliated 2. The 2.
expert Cases
team novel
of
where
consultation
coro complete
Case serie
indiagnosis
our hospital
andwt
Exclusion criteria: 1. Extremely ill patients wi
Inclusion criteria:
 2. 1.
Pregnant
Patientsorwith
lactating
confirmed
women;new corona
Chao Xu 1 Fourth N 16497276 +86 15018720816 2. Voluntarily
 3. Insign
the
novel
written
opinion
coroinformed
of
Experiment
the investigator,
consent. pre
Inclusion criteria: Pneumonia cases with suspected SARS
Weiren Huang 3002 Sungapony8980 +86 13923 Shenzhen SInclusion criteria:
 A comprehensive 1. Laboratory
Exclusion cNovel
analysis confirmed
CoroGold
was diagnosis
conducted
Stand basedofonC
 2. Aged > 18 years;
 3. Written
Exclusion
informed
criteria:
consent
1. Hypersensitive
given by the patient
to immuno
Xiaowei Xu 79 Qingchuxxw69@12+86 13605 The First A 4. Clinical
 2.
deterioration
HaveNovel
immunoglobulin
Coroexperiment
despite conventional
A deficiency.
treatm
Zhai Xiaowen 399 Wanyua

zhaixiaow +86 64931 Children's Inclusion c Exclusion cNovel Corocontrol gr
Xiangming Fang 299 Qingyan

xiangming +86 13861 Wuxi PeoplInclusion c Exclusion cNovel CoroGold Stand
Exclusion criteria: 1. Pregnant or lactating wo
 2. Combined with cardiovascular, liver, k
Wei Zhang Pulmonary zhangw119+86 13601 Shuguang HInclusion c 3. ThoseNovel
withCoroTCM
observational
Group:factors af
Exclusion
Inclusion criteria: (1) criteria:
Patients1. Patients with
diagnosed with cognitive
2019-nCoV d
Wu Wenjuan 2.
1 Yintan R 88071718 +86 13397 Wuhan Jiny (2) Patients Pregnant
Exclusion
admitted
cNovel toor lactating
Corocase
the women;
ICU during
series the study pe
Inclusion criteria:
 3. 1.
Patients
General/severe/critical
with active tuberculosis,
patientspulm
wh
Inclusion criteria:
 2. Patients
 4. 1.
whoseHospitalized
Patients
viralwith
nucleicpatients
tumor;
acid haswith novelnega
turned cor
Li Jiansheng 156 Jinshu li_js8@16 +86 371-6 He'nan Uni 2.
 3. Meet
Patientsanywho
 5.one of
Patients
are the
Novel wicriteria
characterized forby
CoroExperimentsevere type: sym
respiratory
 1) Respiratory
Exclusiondistress:
criteria:RP 1. >=
Pregancy
30/min;or lactating wo
 2) At rest,
 2.
thePeople
oxygenwith saturation
allergies <=or93%;
allergies to co
Tingrong Huang, Bang6 Guangchafangbji@1 +86 0714- Huangshi H < Inclusion Criteria:
 3. Patients
severe withnovexperiment
serious basic diseases su
 
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Severe
confirmed
pneumonia
new corona
requ
 
 2. Above- 2.
1.18
Suspected
years oldcases
Estimated (formerly
(inclusive);
Time of Death observed case4
is less than
Xiaoyin Huang Nanbaixianzjwzhxy@1+86 13819 The First A 
 3. Voluntarily
 3. There
signNovel
written
is clear
Coroexperiment
informed
evidenceconsent.
of bacterial inf
 Meet the following 2 at the same time:
;; Yao Xie, Doctor;Yao Xi;xieyao00 ;8610-843 Department Epidemiological New history
CoronDiagnostic
There was a history of
 - can use mobil
Patients
In sputum,visitingphone
throat or computer
emergency
swab, department.
lower respiratory tr
 the nucleic acid of the novel coronavirus wa
; Yueping Li, MD, Mastelipipi007@020- 36052117; - volunteer
Exclusion to take part in the
Criteria:
CoronaviruDrug: investigation
Lopin
 
 Exclusion
- Criteria:
Panpan Hao, MD panda.how86-18560086593 Cardiovascular Death;
 - can not use phone or computer
 
; Yuhong Dai;Yuhong D eier_dai@ +86 13476229575;+8 Virus; Pneumonia
Exclusion criteria: 1. Rest or unattended staff
 2. Staff with respiratory symptoms;
Yongshi Jia 158 Shangtjiayongsh +86 13605 Zhejiang PrInclusion c 3. Staffnovel
who coro
needCasethe necessary
series isolation
Inclusion criteria: 1. Patients diagnosed with COVID-19;
 2. Underwent
Exclusion chest
criteria:
CT scan
1. CTduring
imagethequality
treatment
does no a
Bin Song 37 Guoxue songlab_r 86 28 854 West China 3. Able 2.to complete
Pregnant
Novel
theand
Corocase
study.
lactating
series
women.
Inclusion criteria:
Exclusion1. Aged
criteria:
>=181. to
Pregnant
70 years;or lactating wo
 2. Diagnosed
 2. Those
2019-nCoV
who areinfected
allergic
patients
to the by
drug
viral
ingn
Qin Ning, Meifang Ha 1095 Jiefa 31531955 +86 27 83 Tongji Hos 
Inclusion Inclusion
criteria:
Exclusion
 3. Understand Criteria:
 3. (Allancriteria:
the
Severe
Novelfollowing
(Subjectscriteria
cardiovascular
CoroGeneral cannot
paare enter
metsuch
diseases, befo
thea
 
 1. Aged 1.
>= 18Patients
years; with a history of allergy to ch
 Inclusion
 2. Meet - 2.
ConfirmedCriteria:
2019-nCoV
all thePatients
followingwith infection
criteria
hematological
(refer tocase in term
confirmed
diseases;
Xia Jinyu 52 Meihua xiajinyu@m+86 13823 The Fifth A 
 (1) Epidemiological
 3. Patients
2019
histNovelexperiment
 1.
- 80Sign the =informed
years consent form;
age = 14years;
;; Xiao-he Xiao, PD.;Rui- ;wrl7905@;+86 10 6 302 Militar 2. Age =18
- Within 72years,
hoursregardless
PneumoniaafterDrug: of
the onsetgender;
Conve of abnorma
 - Adult aged >=18years old;
 3. Subjects with pneumonia diagnosed as 201
 
 Inclusion Criteria: tract samples;
lower respiratory
 
Taisheng Li litsh@263. 010-69155086 - 1. Aged between 18 and 75Intr
2019-nCoVDrug: years, extremes
 
 - 2. Laboratory (RT-PCR) and clinical symptom
; Yunqing Qiu, Master; ;xxw69@1 ;+86 1360 First Affil according 2019-nCoVDrug: ASC0
Exclusion criteria: ?Allergic constitution, ie, a
Zhang Zhongde 111 Dade Rdoctorzzd +86 13903 GuangdongInclusion c Exclusion criteria:
 ?Patients
novel
who 1)do
coro Known or suspected
Experiment
not agree to b
with taking
 2) Confirmed hepatitis B, C, AIDS and oth
Inclusion criteria:
 3) 1)
Acute
Agedrespiratory
>=18 years, distress
gendersyndrome
unlimited,(
Hu bo, Li wei 1277 Jiefa hubo@mail+86 13707 Union Hosp 2) Patients
 4)
with
According
new
novel
coronavirus
coro
to theCase
judgment
infection
serie ofwere
the rese
con
Inclusion criteria: Suspected cases of pneumonitis with t
Deng Guofang Exclusion analysis
29 Bulan R jxxk1035@+86 13530 Pulmonary Comprehensive criteria: 1.
novel coro Known
based
Gold to receive
onStand
the foll hormo
Inclusion criteria:
 2. 1.
Hormone
Adults (defined
therapy as
is needed
age >= 18dueyears);
to co
 2. Patients
 3.with
Patients
new type
withofdiabetes
coronavirus
are receiving
infectionoc
Ronghui Du 28 Baofengbluesearh +86 15337 Wuhan PulInclusion
 3. Thecriteria:
Exclusion
 4. Confirmed
criteria:
time interval
Known
novel or
1. suspected
between
co coroPatients
control
symptomwithout
grcase ofany
onset COVID
andclin
ra
 1. Aged 2.
<= 75Those
years;with severe nasal diseases affec
 2. Patients
 3.with
Inability
newlyto diagnosed
understandandorsuspected
follow resea
co
Xu Shuyun 1095 Jiefa sxu@hust. +86 13517 Tongji Hos Inclusion
 3 criteria:
Exclusion
 4. 1. patients
criteria:
Invasive with
1. Pregancy
novelStanda
NovelveCoroGold coronavirus
or lactatingpne
wo
 2. Fever,
 2.
respiratory
People tract
with allergies
and otherorsymptoms,
allergies tothe
tra
 3. Aged 3.
18 to Severe
80 years;
Primary disease such as uncon
Tingrong Huang, Bangj6 Guangchafangbji@1 +86 0714- Huangshi H 4. Signed 4.
informed
Obstructive
Novel
consCoroexperiment
pneumonia ca
Exclusion
Inclusion criteria: criteria:
1. Meet the1.diagnostic
Female
Patientspatients
with
criteria during
for suspp
respiratory
LU Zhenhui 725 Wanpintcmdoctor +86 13817 Longhua Hos
 2. Meet 2. Patients
the TCM
Pregnant,
Novel with
diagnostic known
preparing allergy
Coroexperiment
criteria
or lac to chloroq
 3. Patients with haematological diseases
Inclusion criteria:
 4. Patients
Patients aged
with chronic
18 or older,
liverand
or kidney
meet th
d
Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos
 Criteria 5.
for diagnosis
Patients
Novel(meet
with
CoroConvention
arrh
all the following crite
Yao, Rong 37 Guoxue 10370705 +86 18980 West ChinaInclusion c Exclusion cCOVID-19 Case series
Inclusion criteria:
Exclusion
1. Influenza
criteria: 1.patients
Patientsdiagnosed
who refusein our
to s
Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan HInclusion criteria:
 2. From 2. (1)
December Comply
Clinical
Novel
1,data
2019with
CoroCase the diagnostic
istoseriously
February
series
missingcriteria
13, 2020,
or un
pa
 (2) TheExclusion
classification
criteria:
was(1)
judged
Patients
as common
whose estimat
type;
 (3) Body (2)
temperature
Tracheal>intubation
37.3 degree and
C; mechanical v
LIU QINGQUAN 23 Art Gall Liuqingqu +86 010-5 Beijing hos (3) Othernovel
problems
coro controlthat doctor's
gr judgme
Chengping Wen 548 Binwenwengcp@1+86 571 8 Zhejiang C Inclusion c Exclusion cnovel coro Treatment
Inclusion criteria: 1. Subjects have signed informed cons
 2. AgedExclusion
>= 18 and criteria:
<= 75 1.
years.
Patients who have recei
Ronghua Jin 8 Xitoutou,dinghuigu +86 13811 Beijing You 3. Met 2.
th Patients
NovelwhoCoroExperiment
have used antibacterial
Huaqi Wang 1 Jianshe wanghuaq +86 15890 The First A Inclusion c Exclusion cNovel CoroExperiment
Inclusion criteria: 1. Patients with novel coronavirus infe
Fang Xueling 79 Qingchu13588867 +86 13588 The First A Exclusion cnovel coro Normal gro
Inclusion criteria: 1. Suspected case:
Lu Hongzhou 2901 CaolaLuhongzho+86 18930 Shanghai Pu PatientsExclusion
in observation
cnovel coro
period
Case
of traditional
serie Chines
Exclusion criteria: (1) The critically ill patients
Wen Chengping 548 Binwenwengcp@1+86 13906 Zhejiang C Inclusion c (2) It isnovel
not suitable
coro (ordinary)
for patients who tak
Exclusion criteria: (1) Patients are not suitabl
 (2) Patients have other serious organ dis
Chengping Wen 548 Binwenwengcp@1+86 13601 Zhejiang C Inclusion c (3) Patients
novelallergy
coro treament
or have contraindicati
g
Cao Jun criteria:CoroGold

117 Meiyuacaojuncn@+86 0510- Jiangsu Ins Inclusion Exclusion cNovel 1) pneumonia Standpatients wit
Inclusion criteria:
 2) 1)
daily
common
treatmenttypeof pneumonia
asthma, any patients
other
 2) agedExclusion
 3) 75 criteria:
18 to patients
years with (1)confirmed
old; Those whohistorycannotoftake
dia
Wu Guolin (2)
79 Qingchuwuguolin2 +86 13136 The First A 3) voluntary mentally
 4)signing
thoseNovel ill
allergi subjects
of written
CoroChinese who
tr are
informed not easy
consent.
 (3) those who are pregnant or breast-fee
Inclusion criteria:
 (4)1.those
Age iswho
notuselimited;
other Chinese medicin
Yongxiang Yi 1 Kangfu Roian0126@1+86 13338 Nanjing Se 2. Clinical
 (5)
diagnosis
those
Novel
is inCoroExperiment
accordance with the "Notic
Inclusion criteria:
Exclusion
1. Aged>
criteria:
181.years
Staffold;
and pharmacists in
 2. Working
 2.time
Regulatory
in the front
students,
line ofinterns,
novel coronavir
re-emplo
Zhan Jie 111 Dade Rzhanjie34 +86 15818 Guangdong 3. The 3.
working Those
department
Emotional
who refused isCase
thetoseries
hot
participate
spot for the s
Inclusion criteria: 1. Suspected and confirmed cases of p
18-65 years
criteria:
old; 1. Clear evidences?of bacte
Tong Xiaolin 856 Luoyu 25241708 +86 18908 Hubei Prov 3. Signing 2.
theSerious
general
novelprimary
informed
coro Control
diseases
consent
gr judged
form. by re
Inclusion criteria: 1. patients diagnosed as Pneumonia c
Pei Bin 15 Jiefang xyxzyxzh@+86 18995 Xiangyang 1 2. virus
Inclusion turned negative
c Exclusion aftercontrol
cnovel coro treatment;
gr
 3. agedExclusion
18-70 years
criteria:
old; 1. Patients with serious illn
Inclusion criteria:
 4. patients
 2. 1.
with patients
Pregnant ordiagnosed
clear consciousness as Pneumonia c
lactating women;
Min Huang 11 Lingjiao 10258233 +86 13307 1. Xinhua a 2.
 5. virus
Signingturned
 3. negative
thePatients
informed
novelwho after
coro
con treatment;
have
experiment
mental confusion,
 3. Patients
Exclusion
diagnosed
criteria:
with
1. pulmonary
Patients withfibrosis;
serious illn
 4. aged 2.
18-70Pregnant
years old;or lactating women;
Jixian Zhang 11 Lingjiao jxzhang16 +86 13377 1. Xinhua a 5. patients
 3.
with
Patients
cle
novelwho
corohave
experiment
mental confusion,
Inclusion criteria:
Exclusion
(1) criteria:
Those who (1) Immunodeficiency
meet the diagnosisdise of n
 (2) ThoseExclusion
 (2) criteria:
who Preparing
have 1.diagnosed
Aged <18
beenpregnant, years;
pregnant
with TCMandaslac
ep
 2.
 (3)Pregnant
Hongzhou Lu, Xiaoron2901 Caolaluhongzho +86 18930 Shanghai Pu (3) Inpatients aged
Patients
Novel or
18 to
withlactating
CoroExperiment
75 women;
allergies
years, regardle
(referring to al
 3. Allergic to the test drug;
Inclusion criteria:
 4. 1.
The2019
underlying
adult patients
diseasewith
is very
new-type
seriousc
Xia Jiaan 1 Yintan R 31318629 +86 13871 Wuhan Jiny 2. The 5.
absolu CO Novel CoroThymosin t
Inclusion criteria: 1.
(1)Aged
Exclusion aged>=
criteria: 18
(1)years;
>=18 years
known old;or suspected all
Pei Guangzhong 222 Zhengd50381850 +86 13839 People's H 2.
 (2)Laboratory
real-time (RT-PCR)
 (2)fluorescence
patients confirmed
Novelwith ofinfection
CoroExperiment
rt-pcr
malabsorption
respiratory withor20
syndrom bl
 3. Pneumonia confirmed with chest CT;
 4. <= 8Exclusion
days sincecriteria:
illness 1. pregnant
onset
Pregnant woman
and hospitalization
and patien
nursing wo
w
Chao Cao 2.
59 Liuting caocdocto +86 574-8 Ningbo Firs 5. Willing to Documented
Patients
Novelwith allergic
CoroCase history
severeseries
liver to chloro
disease and
Inclusion criteria:
 3. 1.
Documented
Aged >=18 yearshistoryold;
of hematological
 2. Patients
 4.
hasDocumented
been diagnosed history
withof2019-nCoV
chronic liverpne a
Jiang Shanping 102 Yanjia shanpingj +86 13922 Sun Yat se * WHO. Exclusion
 5.
Clinical criteria:
Documented
management 1) history
novel coro Any ofsituation
Experiment
severe
of c acutethat make
respir
 2) patients who have used Kaletra or rem
Inclusion criteria:
 3) 1.noAdult
clinical
agedor chest
>= 18 imaging
years old; manifesta
Jianping Zhao 1095 Jiefa zhaojp@tjh+86 13507 Tongji Hos 2. Patients
 4)
withIn the
unexplained
novel
statecoro
of no
experiment
viral
oxygen
pneumonia
at rest,that
the hp
Inclusion criteria:
Exclusion
(1) criteria:
Comply (1)withImpaired
the standards
consciousness
of diagn
 (2) Aged (2)
18-80Those
years.with severe organ dysfunction
Lixin Wang 507 Zhengm Exclusion
wlx1126@h+86 18917 Shanghai P (3) Those
 (3) criteria:
who Pregnant
voluntarily 1.participated
People with
Novel CoroControl
women. gr inallergies
this researand
Inclusion criteria:
 2. 1.
Combined
Meet thewith diagnostic
other malignant
criteria oftumothe "
 2. Pneumonia
 3. Patients
Severitywith
Indexhematological
(PSI) grade isdiseases,
I ~ II;
Yaosheng Zhang, Jia 5 Hai-Yun-Czysjsgzs@ +86 18134 Dongzhimen 3. Aged 4.
18- Combined Novel CoroControl
with severe cardiovascular
gr
Exclusion criteria: 1. Patients with severe nov
 2. Patients with severe basic diseases;
Zhongqi Yang, Minyo 16 Jichang yang_zhon+86 13688 The First A Inclusion criteria:
Exclusion
 3. 1. 2019-nCoV
criteria:
Patients
novelwho 1. Those
coroinfected
have with
Casemental patients
serie allergies;
treate
confusion,
 2. nCoV 2.
nucleic
Patients
acid positive;
with a history of severe cardi
 3. Aged 3.
>=18 History
years; of hip or knee trauma or surge
Dewei Zhao 6 Jiefang S zhaodewe +86 0411- Affiliated 4. novel coro A:Critical
Inclusion criteria:
Exclusion
1. Non
criteria:
suspected
1. Suspected
cases and cases nonandconfir
con
 2. Participate
 2. Patients
in novel with
coronavirus
severe heart,
front-linebrain,
preven
liver
Qiu Jun 159 Tiansh97300753 +86 13881 Deyang int 3. Novel 3.
coronavirus
People Novelwho
pneumonia
CoroObservatio
could notis recommended
complete the stb
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=181. years,
Pregnant
unlimited
or lactating
for men
wo
 2. A novel
 2.
coronavirus
The patients
infection
had mental
confirmed
disorder,
by patho
dru
Ying Kejing 3 Qingchunyingsrrsh +86 13588 Sir Run Ru 3. According
 3. to
Potential
novel
Novelcoronavirus
violation
CoroExperiment
ofinfection
test compli
pneumo
Inclusion criteria: 1. Patients with pneumonia infected b
Li Jiansheng 156 Jinshu li_js8@16 +86 371 6 The First A 2. To sign
Exclusion
informedcnovel
consent.
coro Case serie
Inclusion criteria: 1) Pneumonia patients diagnosed as n
 2) The Exclusion criteria: 1.
type of pneumonia Patients
1)was
patients who
judged as are
were particip
severe
judged and
no
LIU QINGQUAN, MIAO23 Back StrZJHTCM@F+86 13902 Beijing Hos 3) Informed 2. Pregnant
 2)consent.
patients or
novelwere lactating
coro not
controlwomen;
suitable
gr to use Chin
Inclusion criteria:
 3. 1.
ALTThe
/ AST>
patients
5 ULN,
whoneutrophils
were diagnosed
<0.5, pl
w
 2. Aged 4.
18 to Definite
85 years;diagnosis of rheumatic immu
Xiaoling Xu 17 Lujiang xxlahh08@+86 18963 The First A 3. IL-6 (2)(1)
Patients
Complywho withhave
the been
diagnostic
morecriteria
than 7
Huang Luqi; Li Zhiqian16 Nanxiaohuangluqi +86 010-6 China Acad (2) Agree 75 years.
Inclusion criteria:
 2. 1.
After
Patients
CPR. who meet the requirement
Wu Wenjuan 1 Yintan R 13468014 +86 13397 Wuhan Jiny 2. ECMO-treated
 3. Accompanied
patients
Novel CoroCase
with
by other
serie
serious organ d
Lv Dongqing 1 Tongyanglvdq@enz +86 13867 Enze HospiInclusion c Exclusion criteria: 1. Patients

novel coro complicated wi
Experiment
 2. pregnant and lactating women;
Inclusion criteria:
 3. 1.
Patients
patients
complicated
with 2019-nCoV
with severe
pneumoni
cogn
Li Jiansheng, Li Suyun 19 Renmin lisuyun20 +86 371 6 The First H 2. Sign 4.
informed
Clinica
consent.
novel coro Group 1:TC
Inclusion criteria: 1) Aged >= 18 years;
 2) Meet Exclusion
the diagnostic
criteria:criteria
1) Severe
of severe
basic diseases
pneumonia
th
Tengxiao Liang, Tong 5 Haiyuncashanghong+86 010 8 Dongzhimen 3) The 2)
informedObstruct
consent
novel coro
form.
Experiment
Kang Yan 37 Guoxue Kangyan@s+86 18980 DepartmentInclusion c Exclusion cnovel coro Case series
Exclusion criteria: 1. Chronic lung diseases re
Inclusion criteria:
 2. 1. Aged
Long-term18-75
18 years oldyears
application
<= agemale
<= or years
of 60 female;
glucocortico
old
Zhan Zhang 99 Zhangzhdoctorzha +86 18062 Renmin Hos 2. BodyExclusion
weight
Pharyngeal
 3. 40-100
criteria:
Based
swabs,
novel kg1.and
Infected
onalveolar
the
coro BMI >=with
researcher's
experiment
lavage 18kg/m2;
other
fluid, virusp
judgment,
or sputu
 3. Been 2.
Confirmed
Used non-steroidal
with commomanti-inflammatory
2019-nCoV pneu
 4. With 3.
fever,Have
respiratory
severe tract
liver and
disease;
other symptom
Jun Lin 169 Donghuwdznyy@1+86 13971 Zhongnan H 4. ThoseNovel
whoCoroexperimenta
are known to be allergic to
Exclusion criteria: 1. Patients who are unable
Chen Lei 37 Guoxuexleilei_25 +86 18980 West ChinaInclusion c Exclusion criteria:
 2. Patients
Epilepsy,
and1.healthy
History of gtumor;
Epilepsy
people who are n
Inclusion criteria:
 2. 1.
Vascular
Aged 18-60
embolism yearsand
old;pulmonary hy
 2. Patients
 3.
with
Suspected
clinical symptoms,
or establishedsigns,history
auxiliary
of ald
Xue Zhigang 102 South xuezg@tong +86 15000 Hu'nan Yua 3. Voluntarily
 4. Female
signNovel
thepatients
informed
CoroExperiment
of consent
child-bearing
t age w
Inclusion criteria:
Exclusion
Inclusion
criteria:
of1.case
Thecriteria
patient(pneumonia
has other imd
 1. Common
 2.type
Accompanied
patient: with by fever,
chronicrespiratory
diseases, suc
tra
Yanling Zhao 100 West Fo Exclusion
zhaoyl285 +86 13681 The 5th Me 2. Severe
 3.
pat have criteria: 1. Patients with
Novel CoroControl gr severe prim
Inclusion criteria:
 2. 1.
pregnant
Patientsordiagnosed
lactating women;
with suspected
 2. Be between
 3. Patients
18-85 years
with mental
of age; illness;
Mao Wei 54 Youdianmaoweilw +86 0571- The First A 3. Informed
 4.consent
Thosenovel
who
andcoro
are
signedSuspected
participating
informed in consent.
other c
Inclusion criteria: SARI
 1. An ARI with history of fever or measured temper
Min Xie 1095 Jiefa xie_m@12 +86 18602 Tongji Hos 2. Surveillan
Exclusion cNovel Coronon-severe
Nianzhi Zhang 117 Meisha13505615 +86 13505 The First A Inclusion c Exclusion cNovel CoroExperiment
Inclusion criteria: Subjects participating in this clinical st
Nanshan Zhong, Zegu 151 Yanjin zheng862 +86 18928 The First A Inclusion criteria:
 1. General- (1) cNovel
Exclusion
severeAllhospitalized
patients were
CoroExperimentdiagnosed
patients who with
meeta
 (2) Clear
Exclusion
mind, cooperation
criteria: (1) with
and communication;
severe liver or kidn
 (3) Men Exclusion
 (2)
and women criteria:
Pregnant
aged 1)18
and ARDS
andcaused
lactating by other v
80 years;
women;
Yuan Yongming 2)
Room 18A 064699629 +86 18664 Shenzhen n (4) informed ARDS
 (3)consent caused
Persons
Novelhas
who by
areother
CoroExperiment
been signednon-viral
participating
and is ininfecti
willing
othe
Inclusion criteria:
 3) Patients
WHO grade are eligible
III or IV for
pulmonary
admissionhypert
if th
 1) Aged 4)
18-75Patients
years; with malignant tumors of the
Zhang Wei 17 Yongwaizhangweil +86 13707 The First A 2) The Exclusion criteria:
<patient meets
Novel 1.ARDS
Patients
theCoroTwo without
diagnostic
groups any clin
standard
 2. Supplementation with vitamin D or ca
Inclusion criteria:
 3. 1.
Patients
Aged >= with
18 severe
years. failure with chro
Jun Guo 37 Guoxue guojun@wc+86 15388 West China 2. Patients 4.
whoMalignant
meet
novelthe
coro
tumors;
diagnostic
Vitamin criteria
D of susp
Inclusion criteria: 1) Medical staff involved in the diagno
 2) 2019-nCoV infection suspected or confirmed cas
 3) Voluntarily participate in this research project an
Wen Shenglin, Xia Jin 52 Meihua wenshl@ma
+86 13312 Department 4) A Exclusion cnovel coro doctors gr
Inclusion criteria:
Exclusion
1. Sign
criteria:
the informed
1. Critical consent
type: If one
form;
of th
Chengfeng Qiu 144 Jinxi qiuchengf +86 14786 The First P 2. Aged
Inclusion c (1)
>=18 years;
ExclusionRespiratory failure occurs
cNovel CoroCase serie and mecha
 3. Subjects
 (2)
diagnosed
Shock occurred;
as 2019-nCoV pneumonia;
 (1) Detection
 (3)ofPatients
2019-nCoV
with nucleic
other organ
acid positive
failure nee
by
Qu Jieming 197 Secondjmqu0906 +86 21 64 Ruijin Hosp (2) The 2
virus genenovel
s coro Experiment
Zhang Zhongde 111 Dade Rdoctorzzd +86 13903 GuangdongInclusion c Exclusion cnovel coro Experiment
Inclusion criteria: 1. Patients with novel coronavirus infe
Cai Hongliu 79 Qingchucaiicu@16 +86 13505 The First A Exclusion cnovel coro Gold Stand
Inclusion criteria:
Exclusion
1. Conforming
criteria: 1. Severe
to the or
diagnostic
criticallycriteri
sever
 2. Aged 2.
between
Clear18evidence
and 65 years
of bacterial
old; infection;
Xiaolin Tong 856 Luoyu Xiaolinto +86 13910 Hubei Prov 3. Signing 3.
thePatients
generalized
Novelwith
CoroExperiment
informed
severe primary
consent diseases
form.
Inclusion criteria:
Exclusion
1. 16
criteria:
to 75 years
1. Anyofsituation
age, male which
or fema
the
 2. Respiratory
 2. Patient
or blood refuses
samplesto receive
tested positive
invasivefor
tra
Liu Yingxia 29 Bulan R yingxialiu +86 755 6 The Third 3. Within
 3.
7 days
Pregnant
of
novel
onset:
or
coro
lactating
Onset
Group
is defined
women:childbea
A:al as body
Tian Feng 382 Wuyi Rotflook@16 +86 13934 The SecondInclusion c Exclusion cMental hea1:Simplify
Exclusion criteria: 1. In the six months before
Inclusion criteria:
 2. 1.
Patients
Age between
with psychotic
18 and 75
symptoms;
years old (in
Xu Yong 85 Jiefang xuyongsmu+86 18234 The First H 2. The patient undernovel
isolation
coro Psychologi
observation is diagno
Exclusion criteria: 1. Have any known disease
Pei Bei 15 Jiefang xyxzyxzh@+86 18995 Xiangyang FInclusion c 2. Other
novel
circucoro control gr
Zhang Zhan 238 Jiefan doctorzha +86 18962 Renmin HosInclusion c Exclusion cnovel coro experiment
Exclusion criteria: 1. Allergic constitution, kno
Exclusion
Inclusion criteria:
 2. 1.Bodycriteria:
18 to
weight 1.<40
75 yearsAllergic
of history
kg;age, maleto orstudy
fema
Qiu Yunqing 79 Qingchuqiuyq@zju +86 13588 The First H 
Inclusion Inclusion
criteria:
 2. Tested 2.
 3. Criteria:
1.
ALT/AST
Aged
positive for 18-65
Considered
novel >5
novel UNL
coro
as years;
or Child-Pugh
coronavirus
severe
Experimenta
disease: Class
infection
has C
anaft
 
 2. been 3.
Confirmed
Severely withill2019-nCoV
patients with pneumonia,
life expectan ho
 
 3. Sign- 4.
High/moderate
the ICF; risk contact
Contraindication of DRV with
or athymosin;
laborator
Wang Xinghuan/Ke He169 Donghuwangxingh+86 18971 Zhongnan H 4. noInclusion
more
 5. Criteria:
than
Pregnancy
10
novel
dayscorotesting
fromDRV/cthepositive
occurrence
grou for child-b
of rel
 - Undergoing standard sanitary surveillance b
 1. Adult SARI patients with 2019-ncov infectio
;; Xavier Duval, MD;Xav ;xavier.du ;01 40 25 Institut N - Written informed
CoronaviruBiological
c
 2. Absolute value of lymphocytes < 0. 6x 109/
 
 3. Severe respiratory
2019 nCoV, failure
Drug:within
PD-1 48 hours a
Inclusion criteria:
Exclusion1) The
criteria:
confirmed
1) Anypatient
situation(orwhere
legal gua
the
 2) aged 2)
18 to Allergic
65 years; constitution, allergic to plasm
Le Aiping 17 Yongwaileaiping@ +86 13707 The First A 3) Real-time
 3)fluorescent
BeingNovel
too oldCoroExperiment
RT-PCR
with of severe
respiratory
underlyingspecd
Inclusion criteria: Healthy children between the ages of
 (1) Main Exclusion
features:criteria:
moderate 1. Clinical
body shape,
suspected ruddyor com
con
Su Wen 215 Zhongs78440452 +86 13659 Wuhan Hosp (2) Common
 2. manifestations:
Thosenovel
whocoro have Experiment
Symmetric
received other body traditi
shape
Exclusion criteria: 1. ARDS was developed aft
Inclusion criteria:
 2. 1.suffering
diagnosis fromof 2019-new
HBV, HIV, pancreatitis,
coronavirus
Jiang Hua 32 Second cdjianghu +86 028 8 Sichuan Ac 2. adultExclusion
 3.
patients criteria:
severe
aged
novel heart,1. Pregnant
18-80
coro liver,
experimenta
years woman
kidney
old. patien
and resp
Inclusion criteria:
 2. 1.Documented
Aged >=18 years allergic old;
history to any of
 2. Patients
 3.hasDocumented
been diagnosed history with
of2019-nCoV
hematological pne
Hong Shan 52 Meihua shanhong@+86 0756 The Fifth A 4. Documented
novel corohistory mild-moder
of chronic liver a
Exclusion criteria: 1. Pregnant or lactating wo
Inclusion criteria:
 2. 1.There
Diagnosed
are comorbidities
as novel coronavirus
that affectpne th
Lanjuan Li /Xiaowei X 79 Qingchuljli@zju.ed +86 0571- The First A Inclusion criteria:
 1) Basis 3. 1. Confirmed
of diagnostic
The Novel
investigator and"Notice
criteria: suspected
Coroexperiment
believes onthatcases
Printing ofan
the patip
 2. Meet Exclusion
the diagnostic
criteria:criteria
1. Pregnancy
for community
or lactating
- acqw
 3. Clinical
 2.
classification
People with is "heavy"
allergiesor or"critical";
allergies to Sh
Ma Penglin 49 North Humapenglin +86 13810 Peking UnivInclusion
 4. Agedcriteria:
18 to(1)
 3. 75 Aged
Severe
years
Novel >=18
basic years old
CoroExperiment
diseases inpatient;
that affect survi
 (2) novelExclusion
coronavirus
criteria:
nucleic
(1) Itacid
is known
positiveor suspecte
was dete
 (3) The (2)
clinicalLight
typesorweresevere common
patients;type or severe
Cheng Zhenshun 169 Donghuchzs1990@+86 02767 Zhongnan H (4) Informed (3)consent
Patients
Novel has
with
CoroCase
b dysabsorption
serie syndrom
Xia Wenguang, An Cha11 Lingjiao DOCXWG@+86 13902 Hubei inte Inclusion c Exclusion cnovel
criteria:coro
1. Pregnancy
Case seriesor lactation;
Inclusion criteria:
 2. 1.
Previous
aged 18serious
to 60 years
chronic basic disease
 2. to be 3.
confirmed
Previous
withallergy
a exposure
to traditional
history of
Chinese
diagn
Wei Li 215 Zhongswhsdyyykj +86 13163 Wuhan 1st 3. with 4.
fever, Newly
positive
novel
diagnosed
results
coro Community
of2019-nCOV
blood routine
pneumo
exam
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Severe
confirmed
pneumonia
new corona
requ
 2. Above 2.
18 years
Estimated
old (inclusive);
Time of Death is less than 4
Wang Daowen, Zhao J1095 Jiefa dwwang@tj+86 13971 Department 3. Voluntarily
 3. There
signnovel
written
is clear
coroinformed
evidence
Low dose consent.
ofgbacterial inf
Inclusion criteria: 1. Aged 18-75 years old;
Qiu Yunqing 79 Qingchuqiuyq@zju +86 13588 The First A 2. Patients
Exclusion
with novel
cnovelcoronavirus
coro Experiment
infection pneum
criteria:coro
ZHANG ZHONGDE, ZH10 Poyang LZJHTCM@F+86 13902 Tianjin Uni Inclusion Exclusion cnovel 1) Patients with particularl
Case series
 2) Patients whose initial onset time exce
Inclusion criteria:
 3) 1)
Patients
Complywithwithsevere
the diagnostic
primary respirato
criteria
Huang Luqi 16 Nanxiaohuangluqi +86 010-6 China Acad 2) Agree 4)
to participate
It is novel
difficult
in
coro
tto Group
administe
A:tr
You Shang 1277 Jiefa you_shan +86 15972 Union HospInclusion c Exclusion cNovel CoroCase serie
Inclusion criteria:
Exclusion
1. 16
criteria:
to 75 years
1. Anyofsituation
age, male
which
or fema
the
 2. Respiratory
 2. Patient
or blood refuses
samples
to receive
tested positive
invasivefor
tra
Liu Yingxia 29 Bulan R yingxialiu +86 755 6 Shenzhen t 3. A novel
 3.
coronavirus
Pregnant
novelnucleic
or
coro
lactating
Control
acid was
women:childbea
gr detected in
Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital o Inclusion Exclusion cnovel coro single arm
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. Hypersensitive
75 years male or tofemale
study
 2. Tested 2.
positive
Bodyforweight
novel<40coronavirus
kg; infection aft
Yunqing Qiu 79 Qingchuqiuyq@zju +86 13588 The First A reaction 3.
(RT-PCR)-based
Considered
novel corodiagnostic
as severe
A:Baloxavi
disease:
a has an
Inclusion criteria: 1. COVID-19 diagnosed based on the i
 2. Excess specimens for clinical testing (sputum, na
Hong Zhao 8 Xi-Shi-Ku zhaohong_+86 13810 Peking Univ 3. SignExclusion
the informedcNovelconsent
CoroCasef series
Inclusion criteria:
Exclusion
1. aged
criteria:
between
1. pregnancy
16 and 50or lactation;
years;
 2. no history
 2. ofhistory
gynecological
of psychiatric
diseases
disorders(seriou
before;
Hua Lu 37 Shi-Er-Q19242380 +86 18980 Chengdu Un Inclusion criteria:
 3. willing 3. 1.
to join patients
takethis
Novel diagnosed
sedatives
research
CoroAdolescent
inand as Pneumonia
the sign
pastan informedc
week.
18-70 yearscriteria:
Inclusion criteria:
 3. patients
 2. 1.
with patients
Pregnant ordiagnosed
clear consciousness; as Pneumonia c
lactating women;
Wenguang Xia 11 Lingjiao docxwg@1+86 13377 1. Xinhua a 2.
 4. virus
Signing turned
 3. negative
thePatients
informed
Novelwho after treatment;
Coroexperiment
consent
have mental confusion,
18-70 yearscriteria:
 Inclusion
 4. patients
 2.withCriteria:
Pregnant
clear consciousness
or lactating women;
Chanjuan Zheng 11 Lingjiao chanjuanz +86 18971 1. Xinhua a 
 5. Signing 3.
thePatients
informed
novelwhocoro
consent
have
experiment
mental confusion,
 - Adult
 Exclusion criteria: (1) Diagnosed with other k
Kequn Chai 234 Gucui ckqmzygzs +86 13906 Tongde Hos 
Inclusion c- (2)
PCR confirmedNovelnoval
Diagnosed withcoronavirus
CoroExperiment
mycoplasma infection
pneumo
 
Inclusion criteria: 1. novel coronavirus:
 - Exclusion
 (1) 1 days Symptoms developed
beforecriteria:
onset, 14 more
1. Exclude
had than
travel 7 days
participants
history or who
res
Huang Yi Xi'an Chesthuang-yi- +86 13319 Xi'an Chest 
 (2) during 2.
theExclude
14 days
Novel those
before
CoroCase
whoonset,
cannot
series
patients
cooperate.
with f
 - PaO2/FiO2 < 200 mmHg
 
Bin Du, MD dubin98@g8610-6915-5036 - Positiv CoronavirusDrug: meth
Wanhong Yin 37 Guoxue doctorwh +86 13518 DepartmentInclusion c Exclusion cnovel coro Gold Stand
Inclusion criteria:
Exclusion
1. Inpatients
criteria: 1.aged
Previous
18 toor80current
years old,
allerm
 2. Confirmed
 2. Patients
patient diagnosed
diagnosedaccording
as severe to
COVID-1
the gu
Bende Liu 1 Culture Aliubende9 +86 13907 First Peopl Cl 3. Patients
Noveldiagnosed
CoroCaseas serie
infection of infl
Inclusion criteria: 1. patients diagnosed as Pneumonia c
Gang Xu 1095 Jiefa xugang@tj+86 13507 Tongji Hos 2. virus
Inclusion turned negative
c Exclusion after treatment;
cNovel CoroCase series
18-70 years
criteria:
 4. patients
 2.
with
Pregnant
clear consciousness;
or lactating women;
Wenguang Xia Exclusion
11 Lingjiao docxwg@1+86 13377 1.Xinhua af 5. Signing
 3. criteria:
thePatients
informed
new with1) Pregnant
corona
consen
mental
experiment or lactating
confusion, woa
with
Inclusion criteria:
 2) 1)
Severe
patients
basicdiagnosed
diseases asthat
Pneumonia
affect survi
c
 2) The 3)
classification
Other problems
was judged thant
as common
doctor's type;
judgm
WANG YUGUANG, LI 23 Back StrZJHTCM@F+86 13902 Beijing Hos 3) Informed
 4)consent.
Patients
novelhave
corodifficulty
control gr in taking TCM
Exclusion criteria: 1. Hypersensitive to suram
Inclusion criteria:
 2. 1.
BodyAgedweight
18 to<4075 years
kg; male or female
Shentu Jianzhong?Wu79 Qingchustjz@zju.e 1.4E+10 The First A 2. Patients 3.
with
Considered
novel
Novelcoronavirus
CoroCase
as severeseries
infection
disease: has
pneuman
Inclusion criteria: (1) RT-PCR detection of the respirator
 (2) Gene Exclusion
sequence criteria:
of the(1)virus
Subjects
in respiratory
who have orany
blo
Yan Kang 37 Guoxue kangyan_ +86 18980 West China (3) (2) Subjects novel who
coro received
Experiment immunosuppr
Exclusion criteria: 1. Pregnant women;
Exclusion criteria:
 2. Patients with1. Combining
a history ofbasic disease
angina pecto
Chaoqian Li 6 Shuangyo25347766 +86 13807 DepartmentInclusion c 2. 3. Malignant
The Novel tumorjudged
researchers or withthat
Coro1:inhalate a history of m
this study
 3. pregnant or lactating women;
 4. suffer from severe mental illness;
Nanshan Zhong 151 Yanjia linling@gir +86 13902 The First A Inclusion 5. H Novel CoroExperiment
Inclusion criteria:
Exclusion
(1) criteria:
Those who (1) Immunodeficiency
meet the diagnosisdise of n
 (2) Inpatients
 (2) aged
Preparing
18 topregnant,
75 years; pregnant and lac
Qianxue Chen 99 Jiefang chenqx666+86 027-8 Renmin Hos (3) VoluntarilyExclusion criteria:
 (3) Patients
receive 1) Patients
Noveltreatment
with
CoroExperiment
allergies who
with themay
(referring
drugbetotra
and
al
Inclusion criteria:
 2) (1)
G-6PD
Confirmed
defect (Favism);
patients (or legal guardi
 (2) Aged 3)
fromPregnancy,
18 to 80 years,especially
male orearly
female;
pregnancy
Yu Hongzhi 890 Jin'gu ykb@tju.e +86 22 58 Haihe hospi (3) Patients 4)with
Patients
positive
Novelwho Corocontrol
detection
continuallyof
gr2019
use immuno
Novel C
 
Inclusion Inclusion
criteria: 1.Criteria:
Exclusion New
criteria:
coronavirus-infected
1. Pregnancy or lactating
pneumon w
 
 2. Meet 2.
the diagnostic
People with criteria
allergies
for community-acqu
or allergies to Xu
Zhong Nanshan / Song151 Yanjia ylsong70@+86 020 3 The First A - 3.
18-75 Severe
 3. Pneumonia years old
Severity
Novel ,no
basic
Index gender
CoroGroup
diseases restriction
(PSI) III-V
1:Xu
thatoraffect survi
 
 - According to Diagnosis and Clinical Manage
;; XingHuan Wang, profe;znyylcsy ;18971387 Wuhan Univ infection(Trial
Pneumonia,
VersionBiological
4), patients are d
Inclusion criteria: 1. Meet the diagnostic criteria of the "
Yao-sheng Zhang/Ting5 Hai-Yun-Cysz3129@1+86 18610 Dongzhimen
the diagnostic
cNovelcriteria
coroCasefor serie
severe cases in th
Inclusion criteria: 1)2019-nCoV-cured patients that over
XiaoWang Qu 102 Luo-Jiaquxiaowa +86 15526 The First P 2)Sign Exclusion
informed cNovel
consent.
CoroCase serie
Hongzhou Lu 9th Floor, luhongzho +86 21-37 Jiangxi Qin Inclusion criteria:
1. Aged
criteria:
the diagnostic
cNovel>=181. years;
Patients
criteria who havecases
CoroCombinatio
for confirmed been
 2. Severed
 2.
COVID-19
Patientspatients,
who havematched
receivedthe
invasive
requirev
 RR>=30 3.
times/min;
Patients with shock;
Wang Shaogang 1095 Jiefa lingqing1 +86 15827 Tongji Hos Rest 4. Patients Novelcombined
CoroCasewith
serieorgan failure
Inclusion criteria:
Exclusion
(1) criteria:
Comply (1)withIt the
is difficult
diagnostic
to administ
criteria
Donghui Huang 53 Jidajin 13600001 +86 0756- Guangdong (2) Agree Exclusion
 (2) criteria:
to paPregnant Exclusionascriteria
Novel CoroExperiment
women, well asfor the se
patients
 1. Have a history of drug dependence or
Inclusion criteria:
 2. (1)
female
Inpatients
patients
aged who50areandpregnant
over, regar
or l
Lu Hongzhou 2901 Caolaluhongzho +86 18930 Shanghai Pu (2) Persons
 3.diagnosed
People
Novelwith
Corosevere
2019-nCoV NCPinfection: re
Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion Exclusion cNovel CoroSevere gro
XIONG YAN 363 Furongluyibingli +86 18328 West ChinaInclusion c Exclusion cNovel
criteria:CoroExercise
1. The clinicalp classification
 1) Respiratory failure occurs and require
Inclusion criteria:
 2) 1.
Shock
Agedoccurs;
18 to 70 years old, inpatients,
Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny 2. Patients
 3)
with
Combined
severe
Novelnovel
CoroExperiment
failure
coronavirus
of infection:
Inclusion criteria: 1. Voluntarily sign the Consent Form;
 2. MaleExclusion
or female criteria:
aged 18 1. and
Females
over;who are pregna
Zhaohui Tong 8 Workers 13910930 +86 13910 Beijing Cha 3. According
 2. to
Males
the
Novel
"Diagnosis
or females
CoroLow-dose
and
whoTreatment
havegr a birth
Sche
pla
Hongyi Chen 167 HongduChenhongy+86 13807 Nanchang N 2. Pneumonia
Exclusionpatients
cPneumonia
with new
Ganovo
coronavirus
/r infecti
Inclusion criteria: 1. aged 18-70 years male or female;
Tang Jianyuan 2. 2019
39 Shi-Er-Qtangjiany +86 13910 Hospital o Inclusion new coronavirus
c Exclusion nucleic acid test positive;
cNovel CoroExperiment
 3. meet Exclusion
the national
criteria:
diagnosis
1. severe
criteria;
vomiting and diffi
 4. subjects
 2.
onset
pregnant
withinand8 days
nursing
(severe
women;
cases can be
Ke Hu 99 Zhangzhhukejx@16+86 18971 Renmin Hos 5. subjects 3.
or subjects
a Novelreceived
CoroExperiment
lopinavir/ridonavir,
Inclusion criteria: 1. In line with the diagnosis and treatm
Qingping Wu 1277 Jiefa wqp1968@+86 13971 Union Hosp< Exclusion cNovel Corocase series
Inclusion criteria:
Exclusion
Subjects
criteria:
whoSubjects
met allwho
of the
meet
following
one of
 1. Male 1.
or female
pregnant
patients
or lactating
aged 16 women;
to 75 years;
 2. willing
 2.
to sign
Malignant
informed tumors,
consent;
patients with othe
Jian Bo and Chuanzhu 28 Fuxing Rboj301@si +86 13801 Chinese PL 3. Based 3.
on the
Those
criteria
Novel
whofor
CoroExperiment
have
suspected
r cases of COVI
Gong Shouping 157 West 5shpingg@1+86 13709 The SecondInclusion Exclusion cNovel CoroCase serie
Exclusion criteria: 1. Patients who have been
 2. Patients with mental illness have been
Jiang Hong Inclusion criteria:
650 Xinsongjhong.pku +86 15301 Shanghai GInclusion c 3. (1) Meet
Minors NCPNcritical
Anxiety; diagnosis criteria
pneumonia
 (2) Volunteer
Exclusion
to criteria:
participate
1. Patients
in this study,
with other
cooperate
serio
 (3) The 2.
selected
Pregnant
patients
orwere
lactating
basically
women;
stable, cons
Fang Lei 1200 Cailu fanglei58 +86 021-5 Faculty of (4) No 3.
seriousPamentNovel CoroControl gr
Inclusion criteria: 1. Aged 18 to 80 years (inclusive);
 2. People
Exclusion
who hadcriteria:
ineffective
1. Theprotection,
physician decides
i.e.: th
Feng WANG 151 Yanjia 41247573 +86 13710 The First A 1) living,
 2.
studying,
People
Novel
working
whoCoroInterventi
have
together
allergic
with,
reactions
or having
o
Qing Zhou 238 Jiefan qingzhou. +86 13971 Renmin HosInclusion Exclusion cNovel CoroSevere gro
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. Patients
60 years with
old; other serio
 2. Inpatients
 2. who
Pregnant
meetor thelactating
diagnostic
women;
criteria for m
Fang Min 110 Ganhe fangmin1 +86 18930 Tuina Inst 3. Understand
 3. PaandNovel
agreeCoroControl
to gr
CHEN Xinyu 95 Shaoshachenxinyu +86 13807 The First A Inclusion c Exclusion cNovel CoroControl gr
Inclusion criteria: 1. Female of after menarche;
Shixuan Wang 1095 Jiefa sxwang@tj+86 027-8 Tongji Hos Inclusion criteria:
1. Volunteer
criteria:CoroCase
the pneumonia
cNovel 1.to
Plan
participate
diagnosisforseries
pregnant,breast
and in the stud
treatment pl
 2. Aged 2.
18-65Hospitalized
years, male foror female;
other reasons within
 3. Weight
 5.
>= 40kg
Combined
and <=100kg,
with serious
and BMI
diseases
>= 18kg/m
of he
Jing Liu 52 Meihua liujing25@ +86 13844 The Fifth A 4. Medical
 6.
staff
Hasduring
anxiety
fever,the
runn
annovel
Casecoronavirus
series (COVI
Exclusion criteria: (1) Hyperthyroidism;
Patients can not follow-up
Gong Shouping c (2)
157 West 5shpingg@1+86 13709 the SecondInclusion criteria: 1.Favism;
Aged
 Investigator 18-80 years; inappropriate
CoronaviruHumanistic
considering
 (3)
 2. Within
Exclusion
1 weekPregnancy;
criteria:
of onset;1. Any situation that does n
 3. Meet (4)
 2. Abnormal
the diagnostic
The patient coagulation,
criteria
may be of common,thrombocytop
transferred severe
to a na
Xiaoguang Tong 6 Jizhao RoTongxg@y +86 13820 Tianjin Hu Inclusion
(5)
 3. (1)
People
InNovel
Those linewith
whowith medical
ethics,
Corocontrol
have ozone
sign
continuedgr atowritten
allergy or
in
use imm
 (2) Patients
 (6)
with
Severe
positive
anemia;
detection of new coronav
 (3) Chest
 (7)
CT confirmed
Hypocalcemia;
pulmonary lesions;
Chen Xiangdong 1277 Jiefa xiangdong +86 15071 Union Hosp (4) Hospitalized patients
with fever or respirat
Inclusion criteria:
Exclusion
(1) criteria:
Adult aged (1) >=18
The PIyears
considers
and agrees
that tht
Exclusion criteria:with
 (2) Laboratory-confirmed
 (2) Patients 1.2019-nCoV
Patients
serious who
liver are particip
infection
disease,bygr
re
Baofeng Yang 194 Xuefu yangbf@em+86 133 0 Heilongjian (3) Chest 2.
 (3) Pregnant
imaging
Patients
Novel or lactatinglung
(CT) confirmed
wiCoroExperiment women;
damage: mul
Inclusion criteria:
 3. Subjects
ALT / AST> who 5 ULN,
meetneutrophils
the following <0.5,
condpl
 1. Will 4.
sign written
Expectedinformed
survivalconsent.
is less than
Adolescents
1 week;
Huji Xu 415 Fengyaxuhuji@sm+86 13671 Shanghai C 2. Ch 5. Patients Noveldiagn
CoroExperiment
Lianru Gao 6 Fucheng Rlianru666 +86 18600 The Sixth Inclusion c Exclusion cNovel
criteria:CoroExperiment
1)One of the following con
Inclusion criteria:
 Respiratory
1) Aged >=distress,
18 years;RR >= 30 times/min
 2) In line
 At
with rest,
the diagnostic
oxygen saturation
criteria ofis "new
less than
corona
93
Xin Zheng 1277 Jiefa Xin11@hot+86 18602 Union Hospi 3) Severe
 Atrial
pneumonia
Novel
arterial
index
Coroexperiment
oxygen
(PSI) pressure (PaO2)/o
Exclusion criteria: Patients who is enrolled in
 who had diagnosed as macular degenera
Zhuoli Zhang 8 Xishiku S zhuoli.zh +86 13901 The First h Inclusion c who was Novel
allergic
Corohydroxychl
to 4-aminoquinoline co
Exclusion criteria: 1. Previous cheset trauma
Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion 2. Previous
Novelsevere
CoroLight
emphysema
grou and chro
Haifa Xia, Xiangdong 1277 Jiefa xiangdong +86 15071 Union HospInclusion c Exclusion cNovel Corogeneral an
Inclusion criteria: 1. The neonates delivered by the moth
Jun Tang 20 Third S tj1234753 +86 18180 West China 2. The Exclusion
newborn,whose
cNovel mother
CoroCOVID-19
had no pdiagnosis of
Inclusion criteria: 1. Aged >18 years;
 2. Laboratory (RT-PCR) confirmed infection with 20
Lyu Dongqing 1 Tongyanglvdq@enz +86 13867 Enze Hospi 3. LungExclusion
involvementnovel
confirmed
coro Gold
with
Stand
chest imaging.
Exclusion criteria: 1. Involving
Aged <18 in other drug c
years;
Peng Yudong 1277 Jiefa am-penici +86 13886 Union HospInclusion criteria:
 2. 1.
Pregnant
Severe
Patients patients
or
Novelwith breastfeeding;
Corocommon diagnosed
systemic gro with
disease andnov
se
 2. Aged 3.
35 years
Presence
old to of
74other
yearsserious
old; diseases tha
 3. Patients
 4.
or Expected
authorized lifefamily
is lessmembers
than 24 hours;
volunteer
Junbo Ge 180 Fenglinjbge@zs-ho -6.4E+07 ZhongshanInclusion
 criteria:
 5. 1. aged
Allergy >=18
Novel
to ALA years;
Corocontrol
or d gr
 2. Gender
Exclusion
limitation;
criteria: 1. patients with dysphagia
 3. Patients
 2.
must
Patients
be able
with
to autoimmune
sign informeddiseases,
consent oa
Peng Hu 301 Yancha189176831+86 18917 Shanghai 10 4. Be willing
 3.toH provide
novel stool
coro Mild
and blood
Groupsamples on
Inclusion criteria:
Exclusion
1. The
criteria:
age at1. the
In the
time
opinion
of signing
of the
theres
in
Yin Zhenyu 201-209 HuYinzy@xmu+86 13950 Zhongshan 2. The 2.
changeAccord
of typical
Novel CoroChloroquin
viral pneumonia in lung wa
 2. RT-PCR
Exclusion
positivecriteria:
for 2019-nCoV
1. Investigator
or Confirmed
makes alung
dec
Yin Zhenyu Room 507, Yinzy@xmu+86 13950 Zhongshan 3. The 2.
clinicalAs
symptoms
judged
Novel CoroHydroxychl
byare
investigator
slight, andhistoric
there isornoc
Inclusion criteria: 1. The diagnosis conforms to the diagn
 2. Clinical
Exclusion
classification
criteria:is1.normal,severe
Highly allergicorconstituti
critical;
Xuebing Yan 9 Kunpeng yxbxuzho +86 15205 Affiliated Inclusion criteria:
 3. Subject
 2.
aged1.
TheMale
>=18
Novelor CoroExperiment
doctor female,
believes18-95 years old;
that there are oth
 2. 2019 new coronavirus nucleic acid test positive;
 3. Diagnosed
Exclusion
as moderate
criteria: 1. to
Malignant
severe cases
disease
of new
in the
c
Robert Chunhua Zhao5 Shantiao zhaochunh+86 010-6 institute 4. Wi 2. The pneumoniti
clinical prediction
experiment
is that there is n
Inclusion criteria: 1. Aged >=18 years old female;
 2. A history of fertility or sexual activity
Shixuan Wang 1095 Jiefa sxwang@tj+86 02783 Tongji Hos 3. Meet Exclusion
the pneumonia
cNovel CoroGold
diagnosis Standa
and treatment pl
Zhou Min 1095 Jiefa minzhou@t+86 15002 DepartmentInclusion c Exclusion criteria: (1) Subject
Novel CoroCase has a history of
series
Inclusion criteria:
 (2)(1)
Female
Age 18-70
patientsyears
of childbearing age d
 (2) Clinical
 (3)
symptoms,
Highly allergic
signs, and
constitution
lung CT suggest
or history
ch
Luo Zhigang 35 Jiefang 70688539 +86 13907 Second Hos (3) Clinical
 (4)
symptoms,
Coagulation
Novel CoroCase
disorders
serie
such
Exclusion criteria: 1. The serious NCP patient
Inclusion criteria:
 2. 1.
Those
Patients
withor severe
his/her
hypo-immunity
legal representa
due
Dong Liang 1377 Jiao- dl5506@1 +86 18560 Qilu Hospi 2. Those< diagnosed Novel
withCoroExperiment
mild or moderate novel co
Exclusion criteria: 1. The physician decides th
Inclusion criteria:
 2. 1.
People
18 years
witholdheart
<= age
disease
<= 60such
years
as old
card
Zhan Zhang 99 Zhangzhdoctorzha +86 18062 Renmin HosInclusion
 2. Whocriteria:
are in1.
 3. PeoAged
close 18-90
Novel
contact years;
CoroA1:Hydroxy
with suspected cases, c
 2. With risk factor of COVID-19;
 3. Access to nCapp platform;
Chunxue Bai 180 Fenglinbai.chunxu+86 18621 Zhongshan 4. to beExclusion
able to complete
cNovel CoroTraining:N
a 1 year follow up.
Tao Li 
28 South Dxuntao26@+86 18980 West ChinaInclusion Inclusion
c ExclusionCriteria:
criteria:Corocollege
cNovel 1)One of thestfollowing con
 
Inclusion criteria:
 Respiratory
1) Aged >=distress,
18 years; RR >= 30 times/min
 1. At
 2) In line Age
with=18
theyears
rest, at time
diagnostic
oxygen of signing
saturation
criteria Informed
ofis "new
less than 93C
corona
Xin Zheng 1277 Jiefa Xin11@hot+86 18602 Union Hospi 
 3) Severe Artial
pneumoniaarterial
Novel index
Coroexperiment
oxygen
(PSI) pressure
class for II(PaO2)/ox
 2. Laboratory (RT-PCR) confirmed infection wi
 
Bin Cao, Professor caobin@zr 1.08E+09 3. Lung involvement
2019-nCovDrug:
confirmed Remdwith chest ima
Inclusion criteria: (1) Patients with mild who are in comp
 (2) Aged Exclusion
more thancriteria: 1. Patients
18 years old; who are particip
Tang Jianyuan 2.
39 Shi-Er-Qtangjiany +86 13910 Affiliated (3) Informed Pregnant
Exclusion
consent
cNovel ofor lactating
patient.women;
CoroGroup
the 1:Tr
Inclusion criteria:
 3. 1.
ALTThe/ AST>
patients
5 ULN,whoneutrophils
were diagnosed <0.5, pl
w
 2. Aged 4.
18 to Expected
85 years; life<1 week;
Hongliang He 17 Lujiang 44271370 +86 15956 The First A 3. IL-1ÃŸExclusion
 5.
elevatedcriteria:
Definite
Novel
(using 1. critically
diagnosis
Corocontrol
Elisa method,ill
grpatients
of asthma-re
using thebase
sa
Inclusion criteria:
 2. 1.
Patients
Aged >=60with years;
eye diseases (such as ca
 2. Patients
 3.confirmed
Severe liver
withdisease
novel coronavirus
(such as AST pneum
>3U
Feng Cao 28 Fuxing Rfengcao88 +86 13911 Chinese PL Inclusion criteria:
 3. Those 4. 1)
without Male
Patients
broad
Noveland female, 18-70 years old;
Coroexperiment
 2) SevereExclusion
patientscriteria:
(in any1)case:
Casesrespiratory
with severe distress,
vomiti
 3) Within 2)
12 days
Pregnant
after and
illnesslactating
onset; women;
Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 4 3) The Novel
subjectsCoroExperiment
received specific antivira
Inclusion criteria: (1) nurses with working years >=1 yea
Exclusion
 (2) registered criteria:
nurses who(1)are Positive
advanced forand
qualified other
to patho
practice;
trainee n
Caixia Xie 32 West Se8999578@+86 13699 Sichuan Ac (3) nurses (2)
whoRespiratory
nurses
volunteered
NO during failure
to
Case occurs,
series requiring
theparticipate
investigation in this stum
perio
Inclusion criteria:
 (3)(1)People
Aged with
18-65metalyears;
or pacemaker;
 (2) Virus (4)
nucleicactive
acid tuberculosis;
test is positive;
Chen Hong 1095 Jiefa chenhong1+86 13296 Tongji Hos (3) Lung (5)
CT showed
Massive
Novel
multiple
pulmonary
CoroExperiment
patchy, lumpy ground
 
 Inclusion
1. Age =18 Criteria:
years at time of signing Informed C
 
 -2.people who (RT-PCR)
Laboratory lived in orconfirmed
out of China at prese
infection wi
 Inclusion
spreadCriteria:
of COVID-19
; Bin Cao, Professor;Yincaobin@zr +01084206264; 3. Lung involvement2019-nCoVDrug:
confirmed Remd with chest ima
 - age more than
- without gender18 years
and age oldrestriction
 
;; Jiahong Dong, M.D;Xi ;fengxiaob ;+86 1322 Beijing Ts - accord with the clinical
Susceptibil diagnosis
Other: mobi and/ or eti
 Inclusion
of Novel Criteria:
coronavirus pneumonia (COVID-19
 
Bing Sun, MD ricusunbi 8.6E+13 
< 1.1.For Agethe
=18 2019-nCoV
years;
COVID-19; infection
Drug: Methgroup
 
 2.Inclusion
Laboratory Criteria:
(RT-PCR) diagnosis of common p
; Jinglin Xia, MD;Jingli ;xiajingli ;0577-555 First Affil Inclusion Criteria:
fifth edition COVID-19
of the Chinese
Drug: Guidelines
thal for Di
 Diagnosed with 2019-nCoV infection (with d
 -1.High risk ofisCOVID-19
CT image characteristic of viral pneumon
;;;; Kunling Shen, MD,Ph ;;;xubaop ;;;8610596 Beijing Chi 1. Respiratory
2019-nCoV
or blood samples tested pos
 -2.RT-PCR
2019-ncovtestinfection
result of (positive
SAR2-CoV-19 nucleic acid te
 
Yang Jin, MD whuhjy@si 8.61E+12 Exclusion Criteria:
3. In compliance 2019with
NoveBiological
the 2019
 
 - Not available for RT-PCR test result of SAR2
;; Chunxue Bai;Chunxue ;bai.chunx ;+8618621 Shanghai Re COVID-19 Other: nCa
Inclusion criteria:
Exclusion1) confirmed
criteria: 1)or patients
suspected in coma,
casesunable
of ne
 
 2) beInclusion
able
 2) Criteria: with
to understand
patients themental
content illness
of this
or study,
advers
Dong Shang 9 West Secshangdong+86 18098 Institute o 
 3) voluntarily
 3) patients
participate
Novelwith
CoroControl
in serious
this studydiseases
grand obta
such as
 - The neonates
Inclusion criteria: 1. Diagnosedwith COVID-19,or
Novel coronavirus neonates
pneumb
 
 2. Aged 18 to 65 years;
Yang Yi 4 Garden H15326774 +86 18971 Hubei Hosp Exclusion
 3. The Exclusion Criteria:
time intervalcNovel
between
CoroControl
symptom gr onset and ra
 - The neonates with major anomalies
 - Men and women Neonatal aged 18 to 75 years (inclus
Infection;Pe
 - In line with the new coronavirus infection p
; Jianqi Lian, MD;Sicao liangjq@f +86-13571892829;+8 Inclusion
1.(trial Criteria:
Agedversion
between 18 and
2019-nCoVs
4) issued Dby70the
rug: years,
MeplH extremes in
 
 -2.Patients with pulmonary
Fever (armpit temperature fibrosis
=37.3after
Â° C,stand
or m
Hongzhou Lu, Master lunliweiy 021-37990333 Inclusion Criteria:
temperature 2019 NovelDrug: Xiyan
 - Age 18-65
 - The patients who were diagnosed with the c
; Chenghai Liu, PhD;Chechenghaili 8621-20256521; - factors)
2019-nCoV and severe acid
Pulmonary
nucleic cases
Drug: ofN-ac
new coronaviru
negative in respirato
 
 - Aged 18 to 85 years;
; Ying Fu;Wan-Jin Chen fuying199 +86;+1386061359 < CoronaviruDrug: Fing
Inclusion criteria: (1) Aged 20-45 years old;
RongJin Lin 20 Chazhong Exclusionand
nplrj@126 +86 13809 The First A (2) Understand criteria:
cNovel 1. to
willing Cannot
CoroCase take medicine
participate
series by
in this clin
 
Inclusion Inclusion
criteria: Criteria:
 2. 1.
Those
Agedwho 18 to
are75allergic
years men
to bismuth
and wome pot
 
 2. Inpatients
 3. with
Critical
novel
patients
coronavirus(SARS-CoV-2)
meet one of the follow in
Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny Inclusion
 3. Agree1. (1)
Age Criteria:
and=18
sign years;
Respira
Novel
the informed
CoroExperiment
consent form.
 
 -2.Admitted to intensive
The laboratory (RT-PCR)care unit (ICU),
confirmed Peking
the diag
; Jinglin Xia, MD;Jingli ;xiajingli ;0577-555 First Affil Inclusion Criteria:
CoVID-19 (refer
COVID-19to theDrug:
fifth plac
edition of the Ch
 - Adult (aged over 18 years)
 1. Age 18 to 80.
Qinggang Ge, M.D. qinggangg 86-10-82266699 - AnticipateCritically
a length IofOther:
ICU stayNut(LOS) of m
 2. Confirmed COVID-19 diagnosis(including th
 
;; Yuguo Chen, Dr;Jiaojia;jiaojiao ;(086)053 Qilu Hospit 3. Accord withCoronaviruDrug:
any of the following:
Beva ? Respirat
Inclusion criteria: 1. confirmed clinical records in the dat
 2. inpatients have confirmed clinical diagnosis and r
Kunlun He 28 Fuxing Rhekl301@a+86 010 6 Key Labora 3. the CT Exclusion
imagescNovel
are complete,
coroGold theStand
image quality m
Inclusion criteria:
Exclusion
Thiscriteria:
study intends
(1) Exclude
to select
influenza
surveillanc
virus,
Yan Hao; Xiaoping Lu 1095 Jiefa haoyaner +86 13971 Tongji Hos Inclusion criteria:
Exclusion
 (2)1.Exclude
 1. Epidemi aged
criteria:
between
Novel 1. Heart
18-70
pneumonia rate:
CoroMonitor years
caheart
caused old;
byrate <4
atypic
 2. clinical
 2.
dignosied
New myocardial
2019-nCovischemia
pneumonia or arrhythm
and clin
 3. Cured 3.
within
Severe
one month
liver and
of kidney
discharge;
dysfunction or
Nijun 20 Chazhongnijun1000 +86 19890 The First A 4. consious,em
 4. Oxygen2019-nCovone
saturation <=93%
group:R
Exclusion criteria: 1. Heart rate: Heart rate <4
Inclusion criteria:
 2. 1.
New
Agedonset
18-80
of myocardial
years; ischemia or
 2. Meet 3.
the diagnostic
Blood pressure:
criteriamean
of "New
arterial
Coronavirus
pressur
 3. Blood 4.
pressure
Body90-150
temperature:
/ 60-100mmHg,
>=38.5 degree
respirato
C;
Ni Jun 20 Chazhonnijun1000 +86 19890 The First A 4. Extrem
 5. BloodNovel
o CoroGroup 1:Eig
Exclusion criteria: 1. Other pneumonia;
 2. Known to be allergic to traditional Chi
Jianzhong Liu 4 Garden Hljzwd@163+86 13307 Hubei ProvInclusion c 3. Women Novel during
CoroExposure
lactation gand pregnan
Exclusion criteria: 1. Patients with serious he
Inclusion criteria:
 2. Moxibustion intervention
Pregnant or lactating study plan f
patients;
Ziqiang Zhang 389 Xincunzzq1419@ +86 18721 Tongji Hosp Participants
Inclusion c Exclusion
 3.inclusion
criteria:
Cancer
Novelcriteria:
(1) Patients
patients.
CoroMild with severe pr
group
 1. Aged (2)
18 to 75
Those
years
with
old;malignant changes in the
 2. Those (3)
that meet
Persons
onewith
or more
a mental,
of theintellectual
following: or
Xiaorong Chang Hanpu Sciexrchang19 +86 0731 Hu'nan Uni (1)In the (4)
pa preg Novel CoroCase serie
Zhongyu Zhou 4 Huayuan 22094479 +86 18672 Hubei ProvInclusion c Exclusion cNovel coroCase serie
Exclusion criteria: 1. Patients who refused to
Weng Jianping 17 Lujiang wengjp@us+86 0551- the First A Inclusion c 2. Patients
COVID-19
developed
Case symptoms
series:NA; caused
Exclusion criteria: 1. Patients with serious he
Lu Yibin Inclusion criteria:
1 Siyi Roadluyb6810@+86 13937 Xinyang CeInclusion c Exclusion
 2. 1. Normal
criteria:
Pregnant and
Novelor 1.lactating
Pneumonia
severeand
CoroLight cases
caused
diagnosed
patients. by o
 2. Viral 2.
nucleicHave
acidcontraindications
test is negative orthat
positive
can not
after
p
 3. Aged 3.
>= 18Mental
years; disorders, cognitive impairme
Ming Wu 17 Lujiang ahslyywm +86 18655 The First A 4. Patients
 4.with
Patients
c Novelwit
CoroCase series
 
Inclusion Inclusion Criteria:
criteria: (1) Comply with the diagnostic criteria
 
 (2) Patients
Exclusion
=18 years
criteria:
of 1.Serious
age with tracheal
basic diseases
intubatio
aff
Yun Lin 1277 Jiefanfrank0130 +86 13986 Union Hosp 1. 2.Obstructi
 (3) Agree Epidemiological
to participate history
the including resident o
Novel CoroExperimenta
in
 Inclusion Criteria: or exposure to suspected pa
Hubei province
 
;; Liang Peng, Doctor;We;xwx1983@;+8613760 Third Affil Inclusion
1. Sympto Criteria:
2. Epidemiological history including
CoronaviruOther: Com resident o
 Hubei province or exposure to suspected pa
 - 1. Male or female, aged at 18 years-65 year
;; Liang Peng, Doctor;We;xwx1983@;+8613760 Third Affil 2. Sympto Coronavirus
 - 2. Pneumonia that is judged by chest radiog
 
; ZHU, Professor;GUO, wulingzhu 00863733029089;008 - 3. LaboratoryNovel
confirmation
CoroBiological:
of NCP in
Exclusion criteria: Allergy to any medicine
Ma Xiaorong 157 West 5maxr0910 +86 13992 the SecondInclusion c Pregnancy CoronaviruCase serie
Inclusion criteria: 1. Confirmed or clinically diagnosed ca
> 1 year;criteria: 1.With vomiting, diarrhea
Rui Pan 136 Jingzh 55815147 +86 13986 Xiangyang C 3. Volunteers.
 2.refusepediatric
to traditional
Case Chinese
serie medicine
Li Caixia N1 Shangchli_caixia@ +86 15268 The FourthInclusion c Exclusion cNovel CoroCase series
Inclusion criteria: 1. Age is not limited;
Yongxiang Yi Exclusion
1 Kangfu Roian0126@1+86 13338 Nanjing Se 2. Confirmed criteria:CoroGold
group:clinical
cNovel 1. AST and
diagnosis ALT>
Stand is in1.5 x ULN
accordan
 2. bilirubin> 1.5 x ULN at visit 1;
Inclusion criteria:
 3. 1.
AtFirst
visit diagnosis
1, calculated
of novel
by Cockcroftâ€“G
coronavirus
Huilan Zhang Exclusion
1095 Jiefa huillanz_ +86 15391 Tongji Hos 2. Epidemiological criteria:
 4. Patients
Novel
history 1.Travel
with Patients
CoroPirfenidon
potential undergoing
history
chronic gen
or residenc
liver d
 2. With trachea dysfunction;
 3. pregnant women, children, age more
Hu Bing 37 Guoxue hubingnj@+86 18980 West ChinaInclusion c 4. Patients Digestive
with difficulty
The experi in intubation.
Inclusion criteria:
Exclusion
1. Suspected,
criteria: (1)mild,
Known normal
to beandallergic
severe
to
 2. Aged (2)
>= 18 years;
Unwilling to cooperate with the infor
Wang Tan 1478 GongnWangtan2 +86 13756 Affiliated 3. Patients
 (3)
whoPatients
voluntarily
novelwith
coropartic
mental
Case serieillness, or cogni
Inclusion criteria:
Exclusion
(1) criteria:
Comply (1) withCritical
the diagnostic
patients; criteria
 (2) Aged (2)
>= 18Patients
years; who can not guarantee com
Huang Luqi; Ruan Lia 16 Nanxiaohuangluqi +86 010-6 China Acad (3) Agree (3)
to participate
Patients
Novelwith
Coroexperiment
in the
severe
trial, primary
and the patient,
respirat
Jihui Lyu 118 Wenqualvjihui@13 +86 010 6 Beijing GerInclusion c Exclusion psychologicCase serie
Exclusion criteria: (1) known or suspected all
Inclusion criteria:
 (2)(1)
women
aged >=18
who are
years;
breast-feeding durin
Shao Fengmin 7 Weiwu Roguyuesun +86 15037 He'nan Prov (2) positive
 (3)
COVID-19
partic
Novelnucleic
CoroCase
acidserie
was detected by
Exclusion criteria: 1. Pneumonia caused by o
Chuxiao Shao 289 Kuocang Exclusion
scx1818@ +86 0578 Lishui CentInclusion 2. Notcriteria:
Novel 1. Pneumonia
receiving
CoroCase
antiviral
serie caused by o
treatment.
Inclusion criteria:
 2. 1.
Clear
Aged bacterial
from 18infection;
to 70 years old;
 2. According
 3. with
Subjects
the clinical
who have diagnosis
used antiviral
of viral pneu
drug
Jianqing Xu Exclusion
2901 Caolaxujianqing +86 18964 Shanghai Pu 3. Positive
 4.
resultcriteria:
There
for
Novel
are 1. Noacid
nucleic
serious malnutrition;
CoroGroupnon-infecti
of2:On
2019-n
Inclusion criteria:
 2. 1.
Patients
novel coronavirus
who had received
pneumonia
antiviral
patie
dr
 2. enteral
 3.
nutrition
patients
support
with hypertriglyceridemia
treatment for at least(TG
5
Lijia Deng 94 West Str27216302 +86 17723 Ganzi Hospi 3. No use 4.
of Fat
patients
emulsion
Novelwith
CoroExperiment
taboo;
seve
Zhenhua Zhang 678 Furongzzh1974cn +86 13215 The SecondInclusion criteria: 1. Front
c Exclusion cNovelline medicalseries
CoroCase staff;
 2. Participate in the prevention and treatment of CO
 3. Voluntary
Exclusion
to finish
criteria:
psychological
1. refuse tosurvey;
participate in t
Ming Chen 136 Jingzh 55815147 +86 13797 Xiangyang C 4. without
 2.
psychological
withpsychologi
mentalhistory.
disorders
Interventio
Inclusion criteria:
Exclusion
1. Upon
criteria:
the1.judgment
The subject
of the
hasresearch
a history
Yongxiang Yi 1-1 Zhongfuhcm20070 +86 13584 Nanjing Se 2. According
 2. to
Thethe
Novel
subject
newCoroCase
type
suffers
of coronavirus
from
serieactive psycho
 2. Underwent
Exclusionchest
criteria:
CT scan
1. CTduring
imagethequality
treatment
does noa
Kaihu Yu 228 Jingui 20662556 +86 13508 Xianning Ce 3. Able 2.
to complete
Pregnant
Novel
theand
corocase
study.
lactating
series
women.
Inclusion criteria: 1. Confirmed or clinically diagnosed ca
>= 2 years;
criteria: 1. With local skin infection
Ming Chen 136 Jingzho55815147 +86 13797 Xiangyang C 3. Volunteers.
 2. Patients
NovelwhoCoroTwo
refusegroups
massage.
Inclusion criteria: 1. be over 18 years of age;
 2. 2019-nCoV infected patients confirmed by viral n
Feng Li 2901 Caoladr_lif08@ +86 18121 Shanghai PuInclusion criteria:
 3. Subjects 1. Patients
Exclusion
and their
cNovel with confirmed
families
CoroCase series newhave
(or guardians) corona
fu
 2. TCM syndrome differentiation is wind-heat syndr
 3. Aged between 18-75 years old, regardless of gen
Liu Hua/Wang Qian 1200 Cailu yyliuhua@ +86 18930 Shanghai U 4. V Exclusion cNovel CoroRoutine tre
Lijia Deng 94 West Str27216302 +86 17723 Ganzi HospiInclusion c Exclusion Novel CoroGold Stand
Exclusion criteria: (1) Age < 18 or > 65;
 (2) Patients with severe heart, brain, lun
Meiping Chu 1215 Guangchump198 +86 15052 Wuxi Fifth Inclusion c (3) Pregnant
Novel CoroExocrine
and lactating women.
g
Exclusion criteria: 1. Patients who are unable
Bin Zhan 16 Railway 40630252 +86 13678 The Thirte Inclusion c 2. Patients
Geriatrics
and healthy
the elderl
people who are n
Inclusion criteria: 1. Aged 18 to 85 years old;
 2. It conforms
Exclusiontocriteria:
the diagnostic
1. Serious
criteria
basicofdiseases
severe an
aff
Kaijiang Yu 23 Youzhengdrkaijian +86 13303 The First A 3. Sign 2.
the informed
Obstruc
Novel
consent
CoroHigh
form.infla
WANG Jing 169 Donghuwangjing9 +86 18186 DepartmentInclusion c Exclusion cjob burnouBurnout po
Jiemin Zhu Room 222, jieminzhu +86 15960 Xiamen UniInclusion c Exclusion Novel CoroCase series
Inclusion criteria: 1. Aged 18 to 75 years old;
Junxue Wang 415 Fengyadocd1@sin+86 18917 Shanghai CInclusion criteria:
 2. Pneumonia 1)patients
Exclusion Any age;
cNovel with
CoroExperiment
new coronavirus infecti
 2) Meet Exclusion
the diagnostic
criteria:standard
1) Liver and
of COVID-19;
kidney dysfunc
 3) Voluntarily
 2) Psychosis,
accept TCM orsyndrome
cognitive impairment;
differentiation
Bi Ying-fei 88 Changlinyingfei19 +86 13920 First Teach 4) Agree 3)
to sign
Those
informed
Novel
whoCoroCase
aconsent.serie
XIONG YAN 363 Furongluyibingli +86 18328 West ChinaInclusion c Exclusion cNovel CoroExperiment
Inclusion criteria: (1) Aged >=18 years;
 (2) Novel
Exclusion
coronavirus
criteria:
pneumonia
(1) Meet the
patients
diagnostic
diagnosecri
Xie Liangdong Chizhuling 25904100 +86 13707 Fifth Peopl (3) The (2)
patientSevere
himself
Novelprimary
participated
CoroExperiment
diseases
in the
thatstudy
affectvol
s
Kaihu Xiao 165 Xinchexiaokh1@1+86 19923 Chongqing Inclusion c Exclusion cCOVID-19 Case series
Inclusion criteria:
Exclusion
1) The
criteria:
confirmed
1) Anypatient
situation
(orwhere
legal gua
the
 2) aged 2)
18 to Allergic
65 years;constitution, allergic to one or
Shao Yi 17 Yongwaifreebee99 +86 13576 The First A 3) The 3)
time interval
Severe
Novel
between
basic
CoroExperiment
diseases
the onset
affecting
of symptom
surviva
Inclusion criteria:
Exclusion
1. Patients
criteria: discharged
1. Pneumoniafromcaused
severebyoro
 2. Adults
 2.
overHave
18 years
contraindications
of age who signed
that can
the not
inform
p
Chengqi He 37 Guoxue hxkfhcq@1+86 18980 West China 3. Study 3.
participants
Mental
Novel
are
disorders,
Coroexperiment
willing cognitive
to accept impairme
random a
Inclusion criteria: (1) Adults aged >=18 years understand
 (2) a novel coronavirus infection confirmed by labo
Wei Yang 37 Yiyuan Shydyangw +86 13845 The Fourth (3) Hospitalized
Exclusion patients
cNovel CoroExperiment
with fever (axillary temper
Li Jiangping 1 Benxi St 10784044 +86 18602 Puren HospInclusion Exclusion cNovel CoroCase series
Exclusion criteria: 1) Children (less than 14 ye
Chen Hao 116 North S10418633 +86 023 6 Chongqing Inclusion c 2) lackNovel
of important
CoroCasecase
series
information (su
Exclusion criteria: 1. Known to be allergic to h
 2. Patients with severe renal insufficienc
Hua Shucheng 71 Xinmin Sshucheng +86 13756 The First H Inclusion c 3. Severe
Novel
liver
CoroExperiment
disease (child Pugh score
Inclusion criteria:
Exclusion
1. Hospital
criteria: workers
1. Patients
with
whodiagnosis
are unable
of n
Yu Jia 99 Zhang-Zyogaqq116+86 18062 Renmin Hos 2. AgedExclusion
 2. criteria:
>=18 Patients
yearsNovel Patients
old.who
CoroCase with
are not any to
series
willing of the fo
partic
Inclusion criteria:
 1. Subjects
Patients who
with meet
previous
the allergy
following
to 4-am
cond
 1. Sign 2.
writtenPatients
informed with
consent.
previous
Adolescents
severe retinal
or pa
o
Wenxiang Huang 1 Youyi Ro wenxiang +86 13883 The First A 2. Chinese
 3. Patients
Novelwith
CoroLow-dose
s g
Inclusion criteria:
Exclusion
1. Patients
criteria: volunteered
1. People with to serious
sign theorinfu
Zhiyong Peng 169 DonghuPengzy5@h+86 18672 Central So 2. Patients 2.
whoHaving
were
cytokine
received
diagnosed
r Case
Vaccine
with
seriethe
in the
common
4 week
Inclusion criteria:
Exclusion
(1) criteria:
Age 18 to (1)80Patients
years old
with(including
known or th
 (2) Respiratory
 (2) Patients
specimen withwereknown
positive
hepatitis
for COVID-1
B, C, A
Liangdan Sun 218 Jixi Ro ahmusld@ +86 13856 First Affil (3) Clinical
 (3)
classification
Patients
Novelwith
coroExperiment
is mild
severe
or moderate
or severetypeclinica
(w
Zhenjie Hu 12 Jiankan syicu@vip. +86 13933 The FourthInclusion c Exclusion cNovel CoroCase series
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. Patients
80 years;with other serio
Zhou Jia Exclusion
110 Ganhe pdzhoujia +86 18017 Yueyang Ho 2. Patients
 2.
with criteria:
Patients
novel
Novelwh Patients with
coronavirus
CoroExperiment any of the
pneumonia who fo
Inclusion criteria:
 1. Subjects
Patients who
with meet
previous
the allergy
following
to 4-am
cond
 1. Sign 2.
writtenPatients
informed withconsent.
previousAdolescents
severe retinal
or pa o
Wenxiang Huang Exclusion
1 Youyi Ro wenxiang +86 13883 The First A 2. Chinese criteria:
 3. Patients
Novelwith1. Known
CoroExperiment
s allergic to hydrox
Inclusion criteria:
 2. 1.
Severe
Informed
renalconsent
impairment
offered;
(eGFR <= 30
 2. Confirmed
 3. Severe
infectionliver
with disease
2019-nCoV
(Child by
Pugh
RT-PCR;
score
Huawei Mao 136 Secondmaohwei@+86 13928 Chongqing Inclusion criteria:
 4. 1.
 3. Compliance Aged
Pre-exist
with 18coro
novel
the to 70Experiment
years old;
intervention of study.
 2. Non-suspected
Exclusion criteria:
and non-confirmed
1. Suspected cases;
cases and con
 3. Front-line
 2.medical
Patientsstaffs
with in severe
designated
heart, brain,
hospitals
liverd
Feng Cao 28 Fuxing Rfengcao88 +86 13911 Chinese PL 4. Participate
 3. People
voluntarily
Novel
who CoroExperiment
and
couldsign
not
thecomplete
informe the st
Inclusion criteria: 1. Patients withmild and moderate no
 2. Patient
Exclusion
coughcriteria:
score > 1;1. Expected to die within 4
Wei Zhang 17 Yongwaizhangweil +86 0791- The First A 3. Aged 2. Patientsnovelwith
coroasthma
Kesutingattack,
sy purulent
Exclusion criteria: 1. Severe liver disease (suc
Inclusion criteria:
 2. 1.
TheAged
patients
18- 80were years
allergic
old; to the comp
Peng Hu 74 Lingjia hp_cq@16+86 13608 The SecondInclusion criteria:
 3. 1.
 2. Pneumonia Male
Patients
patients or
Novel female
with
with newover
Corocontrol 18 years specifi
contraindications
coronavirus
gro of age
infecti
 2. NovelExclusion
coronavirus
criteria:
infection
1. Patients
is confirmed
are allergic
by path
or in
 3. The 2.
diagnosis
Pregnancy
of severe orcoronavirus
lactating women;
pneumonia w
Yaokai Chen 109 Baoyu yaokaiche +86 13638 Chongqing (1) Re 3. Researchers
believe that patients may
Daisy Dexing Zhang 4/F, Schoolzhangdxda +852 2252 JC School Inclusion c Exclusion cBiopsychosGeneral po
Cancelled Cancelled wdxjy@wh 123 Cancelled Inclusion c Exclusion cCancelled

Exclusion criteria: 1. Patients with severe pne
 2. Death is expected within 48 hours;
Liu Dong 1095 Jiefa ld_2069@ +86 13507 Institution Inclusion 3. There novel
is clear
coroevidence
experimenta
of bacterial inf
Exclusion criteria: 1. Meets any contraindicati
Inclusion criteria:
 2. 1.
Meets
Staff any
of tongji
contraindications
hospital willing
of Jinyeb
to par
Liu Dong 1095 Jiefa ld_2069@ +86 13507 Tongji HospInclusion criteria:
 2. Aged >=18 1.
 3. Aged
Pregnant
years.
novel>=18
coroyears
women, Caseatseries
time of
lactating signingse
women, I
 2. Patients
Exclusion
with confirmed
criteria: 1. cases
Patients
meeting
with identified
the follow
 (1) Epidemiology
 2. Patients
history;
with server diseases of the bl
Shen Ning 49 Huayuanshenning1 +86 15611 Peking Univ (2) Clinical
 3.
manifestations
Patients
Novelwith
Corohydroxychl
(epidemiological
identified severehistory
liver di
Inclusion criteria:
Exclusion
1. Age
criteria:
18 to1 75
Patients
Yearsmale
with identified
or female as
 Inclusion
 2. Diagnosed Criteria:
 2 Patients
with COVID-19,according
with server diseases to of
"Newthe Co
blo
Shen Ning 49 Huayuanshenning1 +86 15611 Peking Univ 
Inclusion criteria:
 3. Sever 3 (1) 18â€“65
COVID-19,
Patients
Novel
except
with years of and
age;
Corohydroxychlo
identified
shock severe
ICU care
liver
wit
dis
 1.Exclusion
Recruited
 (2) Diagnosed subjects
ascriteria:
mild to (1)include
Patientsall
moderate adult
COVID-19;
are patients
diagnosed
 confirmed
 (3) Be (2)
willing to 2019-n-CoV
Patients
sign informed infection.
are pregnant
consent;or breastfeedin
Yaokai Chen 109 Baoyu yaokaiche +86 023-6 Chongqing 
 (4) The (3)
clinicalPatients
assessment
NovelhaveCoroarm
and
aspartate
condition
A:Ribav aminotransfe
of the sub
 Inclusion
2. NEWSCriteria:
of =1 upon recruitment
 
;; Ivan FN Hung, MD FR ;ivanfn@g ;+862 225 The Univer Inclusion
1. Male or Criteria:
female, aged at 18Lopin
Novel CoroDrug: years (including
 
 -2.Aged between
Laboratory 18 and 80 of
confirmation years (Including
2019-nCoV 18
infe
; Lei Shi, MD,PhD;Lei S shilei302 86-10-66933333;86-1 chain reaction
2019(RT-NovelBiological
 - One of them:
XIAN SHEN, phd The 2nd Af 1. Laboratory
Novel(RT-PCR)
Cor Drug: andBrom
clinical symptom
 1.Willingness of study participant to accept thi
 Inclusion Criteria:or female, aged at 18 years (in
consent; 2.Male
; Jie-ming Qu, MD.,PhD;jmqu090 ;+86-21-6 Ruijin Hosp confirm CoronaviruBiological
 1. Subjects or their legal representatives have
 agree not to participate in other clinical stud
; Ronghua Jin;Huiguo D;dinghuig ;+86-1391 Beijing You a Novel CoroDrug: Carri
Yunxia Zuo 37 Guoxue zuoyunxia +86 18980 DepartmentInclusion c Exclusion cNovel CoroCase series
Wang Hailong Inclusion criteria:

165 Xinchewangjinlo +86 15923 Three GorgInclusion c Exclusion1. Aged
cNovel> 18 years; serie
CoroCase
 2. COVID-19
Exclusioncoronavirus
criteria: 1.
nucleic
Children
acidand positive
pregnant
(incluw
 3. Chest 2.
imagingSerious
has clear
cardiopulmonary
viral pneumonia diseases
changes
(ch
Li Shusheng 1095 Jiefa shushengl +86 13971 Department 4. Respirat 3. 2019 novelCase serie
Inclusion criteria: 1. Diagnosed Novel coronavirus pneum
18 to 90criteria:
years; 1. Pregnant and lactating w
Mei Heng 1277 Jiefa hmei@hust+86 13886 Union HospInclusion
 3. Signcriteria:
 2. COVID-19
the written
Patients
Novel group:
informed
with
Corocase
mental
consent
series
illness.
before the stu
 1. Age>Exclusion
= 18 years criteria:
old, noCOVID-19
gender restriction;
group:
 2. Patients
 1. with
Patients
covid-19without
determined
self-awareness;
by gold stand
Hu Liu 107 Huanhudrliuhu@g +86 13866 Anhui Can 3. TotalExclusion
 2.
bilirubin criteria:
Patients
<=1.5
Novelwho (1)used
UNL, Combined
CoroGold
aspartate
drugs withcanhighaffe
Standaminotransfe
that blo
Inclusion criteria:
 (2)1.Combined
Aged 18 to with
75 years;
malignant tumor or a
 2. Real-time
 (3)fluorescence
Pregnant orRT-PCR
lactating detection
women;of nucle
Xu Zhihua Mianyang C11217338 +86 18508 Mianyang CInclusion criteria:
 (4)1.Suffer
 3. Sequencing ofLaboratory
virus
Novelgenes confirmed
Coroexperimenta infection
in respiratory tractwith
spe
 2. Clinical classification is mild or common;
 3. LungExclusion
involvement criteria:
confirmed
1. Patients
withwithchest serious
imaging;pri
Chuantao Zhang 39 Shi-Er- 10357887 +86 13880 Affiliated 4. Hospitalised
 2. Pawith: Novel
Fever:
Coroexperiment
axilla temperature >= 3
Inclusion criteria:
Exclusion(1) criteria:
Aged >=18 (1) years;
Patients allergic to antiv
 (2) novel (2)
coronavirus
Pregnant pneumonia
or lactating novel
women;coronavirus
Xiaoyang Lu 79 Qingchuluxiaoyang +86 13605 The First A (3) Patient
 (3) Patients
Novelwhose
CoroCase GPTserie
or total bilirubin
Exclusion criteria: 1) Patient or family membe
 2) Patients with previous or existing hist
Zhang Huafen 79 Qingchuzhanghuaf +86 13757 The First A Inclusion c 3) The Novel investigator
CoroCase believes
serie that the pati
Inclusion criteria: Patients diagnosed with COVID-19
 Mild group
Ying binwu 37 Guoxue binwuying +86 18980 West China Diagnosed Exclusion
patients
cNovel
classified
CoroPatients
as mild and
w ordinary t
Inclusion criteria: 1. Adult patients confirmed by 2019-n
 2. Patients
Exclusion
with clear
criteria:
manifestations
1. Patients with of pulmonary
cardiopulm
Li Shusheng 1095 Jiefa shushengl +86 13971 Tongji Hosp 3. Patients
 2. requiring
Pregnant
Novel
oxygen
women.
CoroCRRT
therapy group
or mechanical
Exclusion criteria: 1) < 18 years old or >=80 y
 Inclusion Criteria: and lactating women;
 2) pregnant
Wang Hongyang 
225 Changhhywangk@v+86 13801 The Third AInclusion c 3) patientsNovelwith
CoroCase
mentalseries
illness.
 - Who agree to participate in the study and si
 
Chen Xiao 627 Wuluocxfn817@1+86 13986 Central Th Inclusion Exclusion
Exclusion Criteria:
cNovel CoroCase series
 
 Inclusion
- ConfirmedCriteria:
NCIP patients
;; Yan Liu;Xiaotian Sun;Y;xiaotian ;+86-0106 The Fifth Novel CoroDiagnostic
 (1) Age = 18 years. (2) Clinically diagnosed patie
 pneumonia include: on the basis of meeting th
; Huilan Zhang, PD;Huil huilanz_7 15391532171; following Novel CoroDrug: pirf
 
 - all patients suspected of 2019 novel corona
 
 Exclusion Criteria:
 - patients' data are not available.
 1. Adult male CTorScores
femaleOther:
patients
CT aged 18-85 y
 
 2. The newly diagnosed COVID-19 patients wh
; Shuiping Zhou, PhD;Yi;heyi@tasl ;86-022-8 Tasly Pharm Exclusion
the "Guidancecriteria:
of 1. pregnancy;
CoronaviruDrug:
Diagnosi T89
Inclusion criteria:
 2. 1. blood
agedpurification
>=18 yearstreatment
old; prior to a
 2. laboratory
 3. patients
conformed hadSARS-CoV-2
other indications
infection;
for bloo
Xiaowei XU 79 Qingchuxxw69@12+86 13605 The First A 3. critically
 4.ill allergic
and Novel
require
to CoroExperiment
dimethyl
intensivesulfoxide
care.
Exclusion criteria: (1) known or suspected all
Inclusion criteria:
 (2)(1) women
aged >=18
who areyears;
breast-feeding durin
Li Suyun 19 Renmin 38797527 1.39E+10 The First A (2) positive
 (3)COVID-19
partic
Novel nucleic
CoroAzvudine
acid was Pdetected by
CHEN Xinyu 95 Shaoshachenxinyu +86 13807 The First A Inclusion criteria: Must
c Exclusion meetCoroControl
cNovel all of the following
gr criteria
 1. aged 18 to 75 years male or female;
 2. BodyExclusion
Weight 40-100kg,
criteria: 1.and
according
BMI >=18kg/M2;
to the clinical
Wang Hao Zhiyin Ave wanghaohh+86 13901 Huo-Shen-S 3. to meet Note:
the diagnostic
those
Novel who
CoroCase
criteria
comply
in
serie
the
withfourth
an editi
Guojun Zhang 1 Jianshe zlgj-001@ +86 13673 The First A Inclusion c Exclusion cNovel CoroExperiment
Inclusion criteria: 1. Patients who were diagnosed with n
Jiang Shujuan Exclusion
, Jinan, S docjiangs +86 15168 Department 2. Patients criteria:to
who agreed
cNovel 1.enrollment.
Age <14
CoroCase years;
series
 2. Pregnant;
Inclusion criteria:
 3. 1.
Patient
Meetsis2019
irritable
novel
during
coronavirus
NIV treatme
pneu
Shusheng Li 1095 Jiefa shushengl +86 13971 Eergency / 2. Under 4.
non-invasive
Intubation-mechanical
Novelventilation,
CoroGroupfinger
2:co
ventilation
oxygenwit
sat
Ye Gu 85 Heping Ssylykjk@1 +86 18502 Shenyang S 2. Pneumonia
Exclusionpatients
cNovelwith
CoroExperiment
new coronavirus infecti
Ye Wan 1999 Guank41743383 +86 13806 Xiamen MedInclusion criteria:

c Exclusion(1) cNovel
Aged 18CoroMedical
years or older, st male or fem
 (2) Real-time
Exclusionfluorescent
criteria: (1)
RT-PCR
Known of or
pharyngeal
suspectedswa all
 (3) Clinical
 (2)
classification
Mild and severe
is common patients.
or severe;
Yuanrong Dai 109 Xueyua13968888 +86 13857 the Second (4) Signed
 (3)
informed
Combined
Novel
c CoroExperimenta
with severe liver disease (
Exclusion criteria: 1. Patients who are allergic
 2. Patients who are diagnosed with adre
Chen Zhenshun 169 Donghuchzs1990@+86 13627 Zhongnan HInclusion c 3. Severe Novel
immunosuppression,
CoroEarly corti one of th
Inclusion criteria:
Exclusion1) confirmed
criteria: 1)orpatients
suspectedin coma,
casesunable
of ne
 2) be able
 2)
to understand
patients with themental
contentillness
of this
or study,
advers
Wei Yao 9 West Sec41148433 +86 17709 Dalian Med 3) voluntarily
 3) patients
participate
Novelwith
CoroControl
in serious
this study
diseases
grand obta
such as
Exclusion criteria: (1) Female patients during
Inclusion criteria:
 (2)(1) Patients
Patientsallergic
aged from
to lipoic
18 to
acid
75oryears
similo
Chen Chunbo 101 Weimigghicu@16+86 13922 Maoming Pe (2) Mild (3)
patients Patients
with
Novelconfirmed
who
CoroLipoic
are taking
COVID-19
acidpart in accordin
clinica
Exclusion criteria: 1. Patients with mild and c
Inclusion criteria:
 2. 1.Acute
Real-time
respiratory
fluorescent
diseaseRT-PCR
causeddetec
by n
Xiuming Song 528 ZhanghXiumingso +86 13817 Shuguang Ho
 2. Confirmed
 3. Patients
as aNovel
novelwith
CoroControl
coronavirus
diabetes and pneumonia
gr hypertensi com
Exclusion criteria: (1) Chronic obstructive pul
Inclusion criteria:
 (2)Patients
Cardiorenal
with insufficiency;
new type of coronavirus
Liu Yi 324 Jing-Wu
15168888 +86 18660 Shandong P (3) Pregnant
women
Inclusion criteria:
Exclusion
Thiscriteria:
study intends
(1) Exclude
to select
influenza
surveillanc
virus,
Yan Hao; Xiaoping Lu 1095 Jiefa haoyaner +86 13971 Tongji Hos 1. Epidem
 (2) Exclude
Novelpneumonia
Coromonitor caused
ca by atypic
Exclusion criteria: 1. COVID-19 suspected or c
 (1) Those who refuse to cooperate;
Kang Yan Inclusion criteria:
37 Guoxue Kangyan@s+86 18980 West ChinaInclusion (2) 1.Pregnant
Exclusion COVID-19 women;
suspected or
cNovel CoroPatients i confirmed p
 1.1 Diagnostic
 (3)Patients
criteria for
withsuspected
mental disorders
cases; and co
 1.1.1 History
 2. of
non-COVID
Epidemiology:
healthy residents:
Xufang Sun 1095 Jiefa s_186277 +86 18627 Department Exclusion criteria:
 (1) ThoseNovel
who 1)refuse
<14 years
CoroCOVID-2019
t of age;
Inclusion criteria:
 2) 1.
pregnant
Have any women;
of the following epidemio
 (1) travel
 3)
history
ICUor hospital
residence
stayhistory
<24 hours;of Wuhan and
Minghao Fang 1095 Jiefa Fangmh@tj+86 15071 Emergency (2) close 4)
contac
The 2019
necessary
novelCase
clinical
series
information is in
Inclusion criteria:
Exclusion
1. Aged
criteria:
>181.years
Patients
old; without comple
Rui Zeng 37 Guoxue dongze.li +86 028-8 Department 2. patients
 2.
diagnosed
GiveNovel
up treatment
COVID-19.
CoroNoveland
coro
discharge patie
Inclusion criteria: 1. Criteria for inclusion of confirmed p
 (1) Comply
Exclusion
with criteria:
the diagnostic
(1) Patients
criteria
during
of "Pneumon
pregnan
 (2) Above
 (2)
2 years
Complicated
old; liver, kidney, and metab
Zhang Wei 42 Wenhuazhagnweij +86 13505 Affiliated 2 (3) Have Novel
other
CoroPRE-GROUP1
serious primary cardiovas
Yanling Shi Departmentakidney_d +86 0577 The First A Inclusion Exclusion cNovel CoroACEIs/ARB
Jie Luo 32 Renmin 18219024 +86 0719 Shiyan TaihInclusion c Exclusion cLung injurytreatment g
Inclusion criteria: (1) All confirmed and diagnosed SARS-
Yong Huo No.8 Xishikdrhuoyon +86 13901 Peking Univ (2) Voluntarily
Exclusionagree
cNovelto enter
CoroCase
the trial
serieand sign the
Inclusion criteria: 1. Eligible patients were adults ((aged
 2. Were identified as laboratory-confirmed COVID-1
Wu Caineng 16 Jichang wucainen +86 13580 The First A 3. ThoseExclusion
who need cNovel
intubation
CoroGroup
in ICU,
2:SM
and with no s
CAI YU 473 Hanzhecaiy_kf@1 +86 18702 Wuhan Four Inclusion c Exclusion cNovel
criteria:CoroExperiment
(1)People who complicated
Inclusion criteria:
 (2)(1)people
Chinese
whoresidents
can't usewho
smart
experienced
phones
 (2) People
 (3)people
aged betweenwho18 can't
andrecognize
65 years orold;clearly
Zhongyuan Xia Exclusion
238 Jiefan wenqin-1 +86 13808 Renmin Hos (3) People criteria:
 (4)people
have electronic
sleep
who 1.can't
Any situation
softwarewhere
disorcross-secti
socialunderstand such theW
Chinese
as
Inclusion criteria:
 2. 1.Patients
Aged >=18
who years;
have used interferon or
 2. Clinically
 3.diagnosed
No clinicalpatients
manifestations
with COVID-19,
and chest inclu
im
Huilan Zhang 1095 Jiefa huilanz_7 +86 15391 DepartmentInclusion criteria:
 (1) real-time 1. Written
 4. fluorescent
KnownNovel informed
allergy consent from
CoroInterferon
RT-PCR
or hypersensitivity
detection of SARSpati
to in
over 18 criteria: 1. Respiratory failure expla
 3. Fullfill
 2.
the diagnostic
Comorbidities
criteria
including
of critically
lupus,illvasculi
2019-n
Xuemei Li 1 Shuai-Fu-lixmpumc +86 13911 Peking Uni 2019-nCoV
 3. diagnosis
Concurrent
Novel
confirmed
CoroCase
use of byserie
the combination
Chengxian Guo 138 Tongzigchxyy@1 +86 0731- The Third XInclusion Exclusion cNovel criteria:CoroCase
1. The clinical
seriesclassification
Inclusion criteria:
 1) 1.Respiratory
Aged 18 tofailure
70 yearsoccurs
old;and require
 2. Patients
 2)with
Shock
pneumonia
occurs; infected by new corona
Bende Liu 1 Culture Aliubende9 +86 13907 First Peopl 3. Confirmed
 3) cas
Combined
Novel CoroCase
failure of serie
Inclusion criteria: (1) registered nurse;
 (2) to combat the new coronavirus pneumonia of th
Pang Yong-li 600 Tianhepangi88@1+86 15626 The Third AInclusion criteria:
 (3) volunteer 1)
Exclusionto Confirmed
participate or
cNovel CoroCasein clinically
thisseries diagnosed pa
study.
 2) Those who have been identified by Chinese med
 3) Inpatients
Exclusion
agedcriteria:
18 to 751) Patients
years male with
ormild,
female;seve
Zhijun Fang 100 Cross fangzjnj@ +86 13372 Affiliated Inclusion
 4) Vocriteria:
 2) 1. Written
According informed
Novel CoroControl consent
gro from
to the researcher's pati
judgme
over 18 years;
criteria: 1. Respiratory failure expla
 3. Fullfill
 2.
the diagnostic
Comorbiditiescriteria
including
of critically
lupus,illvasculi
2019-n
Xuemei Li 1 Shuai-Fu lixmpumc +86 13911 Peking Uni 2019-nCoV 3.diagnosis
Concurrent
Novelconfirmed
CoroCase
use of byserie
the combination
Bin Li 110 Ganhe 18930568 +86 18930 Yueyang HoInclusion criteria:

c Exclusion
1. Aged>=
criteria:18,
cNovel 1. Critical
male or
CoroCase case
female;
serie with the fol
 2. Fever,
 
axillary
i. Patients
temperature
with respiratory
> 37.3 degrees;
failure and n
 3. Consistent
 ii. with
Patients
the clinical
with shock;
diagnosis of COVID-19
Ye Feng/ Yang Zifeng/151 Yanjia yefeng@gi +86 13710 The First A 4. Patients
 who
iii. Patients
sign
Novel
informed
with
Corogroup
other
consent
organ
A:Arform
failures
freely
ana
Cao Guoqiang 10 Changji cgq1963@ +86 023 6 Daping HosInclusion c Exclusion cNovel CoroCase series
Inclusion criteria: 1. Conform to the western medicine in
 2. Conform to the diagnostic criteria of TCM wind-h
Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital o 3. OverExclusion
18 yearscinfluenza
old Experiment
Exclusion criteria: 1. A coma, MODS or death
Inclusion criteria:
 2. 1.
ThePatients
estimated
confirmed
survivalwith
timenovel
is <7coron
days
Jin Yang 1277 Jiefa whuhjy@si+86 13554 Union Hosp 2. Those 3.
without
The broad-spectrum
novel
patient's
coromedical
Mild COVID
antibacterial,
history is not de
Inclusion criteria:
Exclusion
1. Aged
criteria:
>= 18
1. Patients
years and with<= 75
other
years;
mali
 2. Patients
 2.
clinically
Severediagnosed
cardiovascular
as novel
and coronavirus
metabolic d
Jianfeng Zhou 1095 Jiefa zhougene@+86 027 8 Department 3. Severe/critical
 3. Patients
pat
novelwith
coroclinical
Experiment
symptoms of bra
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18(1) to Combining
75 years old; basic diseas
 (2) Real-time
 (2)fluorescent
Malignant tumor
RT-PCRorforwith
respiratory
a historyor
of
Lunxu Liu No.37 Guoxlunxu_liu@+86 18980 West China (3) The (3)
sequencepregn
Novel
of virusCoroTreatment
genes in respiratory or blo
Inclusion criteria: 1.No age restriction.
 2. Clinically
Exclusion
confirmed
criteria:
2019-nCoV
1. Patientsinfected
withoutpatients
any clin
Jianfeng Zhou 1095 Jiefa zhougene@+86 027-8 Department 3. Patients
 2.
with
Patients
willingness
novelnotcoro
providing
and
Caseability
series
written
to sign
informe
the in
Inclusion criteria: 1. patient with novel coronavirus pneu
 2. patients with type 2 diabetes;
betweencriteria:
18-80 years
1.diabetic
old; ketoacidosis, hy
ZHOU JIAN 600 Yishan zhoujian@s+86 18930 Shanghai Si 4. With 2.previous
effective flash
Novelhistory
glucose
CoroCase
ofmonitoring
cardiovascular
series dise
Inclusion criteria: 1. Confirmed and suspected patients u
 2. Medical
Exclusion
staff of
criteria:
anesthesiology
1. Generaldepartment
anesthesia cont
surg
Zongze Zhang 169 Donghuzhangzz@w+86 13971 Zhongnan H 3. Voluntary
 2.participation
Medical
Novelstaff
Coropatient
inwith
the contact
testgr
andhistory
sig out
Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital o Inclusion Exclusion cnovel coro Experiment
Inclusion criteria: 1. No physical discomfort;
16 yearscriteria:
old andIfabove;
one of the following situ
Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Hospital o 3. Take (1)
the medicine
Hasnovel
fever,
recommended
coro
cough,
Experimenta
fatigue,
by this
stuffy
researc
nose
Inclusion criteria: 1. Those who meet the diagnostic crit
 2. Over 18 years old (including 18 years old), male o
Zhong Nanshan/Zhang385 North Xjiactm@16+86 0311- Shijiazhuan 3. At the Exclusion
time of enrollment,
suspected Routine
the patient
tr had any of
Inclusion criteria:
Exclusion1. Adult
criteria:
aged1. >=18years
Any situation old;that make
 Inclusion
 2. Patients
 2. Criteria:
infected
Known with
allergy
neworcoronavirus
hypersensitivity
confirme
reac
Zhang Dingyu 1 Yintan R 18138863 1.35E+10 Wuhan Jiny 
Inclusion
 3. In criteria:
the state1.
 3. ofPatients
Increase
no
Novel
oxygenwith atconfirmed
inCorointerventio
alanine rest, new corona
aminotransferase
the patient's SP
 
 2. Above- COVID-19
18 yearspositive patients over the age of 1
old (inclusive);
 
 3. At the time of enrollment, the patient had any of
Zhong Nanshan/Zhang385 Xinshi jiactm@16+86 0311 Hebei Yilin Exclusion
 4. Voluntarily
Exclusion Criteria:
sign
cNovel
writtenCoroRoutine
i tr
 
 - Patients who are currently intubated.
Thomas C Pitts, M.D. Drpitts@h 6.47E+09 Inclusion criteria: 1. The
 patient signed Eculizumab
CoronaviruDrug: an informed con
 2.The age of the patient is 18 or more than18 years
 Inclusionpatients
 3. COVID-19 Criteria:diagnosed by PCR;
Cao Bin Cherry Bloscaobin_be 1.39E+10 China-Japa 
 4. Nucleic
Exclusion
acid posi
cnovel coro Experiment
 - The participants were diagnosed as pneumo
 Inclusion
notice Criteria:
on printing and distributing the diagn
; Hongzhou Lu, Ph.D;Holuhongzho +86-021-37990333;+8 Pneumonia,Drug: Hydr
 - The participants were diagnosed as pneumo
 notice on printing and distributing the diagn
Hongzhou Lu, Ph.D luhongzho -3.8E+07 Exclusion criteria:
Pneumonia,1. Complicated
Drug: Daru active tube
Inclusion criteria:
 2. 1. pregnant
Pneumonitis
and lactating
patientswomen;
infected with
 2. Meet 3.
the standard
Combining of TCM
severe syndrome
cognitivedifferentiati
and ment
Wang Dazhong 33 Huanghe13803818 +86 13803 Zhengzhou 3. SignExclusion
 4.
the informed criteria:
Clinical
Novel 1. The patients
consent.
researchers
CoroCase who
seriearerefused
partic to
Inclusion criteria:
 2. 1. Male
Patients
The and
patients female
of stomatology
were out aged 18-65 years;in
ofdepartment
contact;
 2.
 1. Clinically
The 3.
visitingdiagnosed
The
datapatientswithwas
of patientsCorona
could Virus
unable Disease
betobacktracked20
receive th
Jingzhi Ma 1095 Jiefa majingzhi +86 13871 Tongji Hos 3.
 2. Increased
The Exclusion
pati interleukin-6;
 4. Thecriteria:
Novel
patients 1.was
Cases
CoroCase u of severe vomiting
series
 4. Sign 2.
the informed
Allergicconsent;
to Favipiravir or tocilizumab;
 5. Subjects
 3. whoPregnant
can take andmedicine
lactatingorally;
women;
Guiqiang Wang 8 Xishiku S john1312 +86 13911 Peking Univ 6. Agree 4.
to collect
Subjects
Novel
cl received
CoroGroup specific
1:Faantiviral dru
Wang He 33 HuangheWH9400@1+86 15937 ZhengzhouInclusion c Exclusion cpsychologi Observatio

Inclusion criteria:
Exclusion
1. Suspected
criteria: 1.COVID-19
CT imagingpatients
data with
withpoc
Lu Guangming 305 East Z cjr.lugua +86 13951 Jinling Hos Inclusion criteria:
 2. Patients
 2. Stage
Exclusion
confirmed I and
criteria:
Incomplete
Novel iietiological
(1)
with healthy
CoroCase subjects
beforeserie
the
etiological application
ordetection
clinical ando
data.
 Stage 3: (2) malignancies;
 1. Clinical manifestations:
 (3) the presence of severely impaired im
Feng Gao 1095 Jiefa 13971587 +86 13971 Tongji Hos (1)
InclusionFever;
c Exclusion criteria:
 (4) 7 days
Novel Stage
before 1 and stage
CoroOrdinary
admission Crow2:major
subjecs
 Inclusion
 (2) normal
 StageCriteria:
or decreased
3: white blood cells;
 
 (3) CT pulmonary
 1. Patients
exudation;
who cannot
Or a suspected
cooperatepatien
with t
Shiyue Li 151 Yanjia lishiyue@ +86 13902 The First A 
 2. I - Wuhan residents;
Novel CoroCase series
 
 - novel coronavirus pneumonia was found to
 LaboratoryCOVID-19;E
tests revealed
Other:leukocyte
sev or lymp
Exclusion criteria: 1. A pregnant or lactating w
Wang Tan 1478 GongnWangtan2 +86 13756 Affiliated Inclusion c 2. WithNovel
otherCoroPopulation
major diseases, such as se
Exclusion criteria: (1) Past medical history of
Inclusion criteria:
 (2)1.Patients
Patientsinfected
diagnosed
withashuman
severeimmun
or criti
Xie yuanlin 311 Yingpa12867794 +86 13975 The First H According
 (3)
to the
Patients
"New
Novelwith
Coronavirus
CoroMSC
malignant
group:
Pneumonia
tumors: Pati
Exclusion criteria: 1. not qualified for novel c
Inclusion criteria:
 2. 1.
Pregnant
novel coronavirus
or lactatingpneumonia
women who diagn
are
Zhu Bo 3 Yunxing 27477014 +86 13995 Xiangyang 2. age 3.
unlimited,
Patients
male
Novelwith
and
CoroCase
female
severeserie
primary
unlimited.
diseases
Zhang Sheng 1095 Jiefa aloof3737 +86 18971 Tongji Hos Inclusion c Exclusion cNovel CoroCase serie
Inclusion criteria: 1. Aged >=18 years Chinese people;
Xu Jie 280 Mohe Rdr.xu@ali +86 13501 Shanghai N 2. Clinical
Exclusion
diagnosis
cNovel
of 2019
CoroCase
- nCoVserie
suspected cases
Inclusion criteria:
Exclusion
1) Comply
criteria:with
(1) Patients
the diagnostic
who were
criteria
even
Guoqin Sun 241 Peng-L70798689 +86 18971 Wuhan Thir (2) Complete (2)clinical
Patients
Novel data
whose
CoroGroup
of patients.
data could
1:Tr not be ob
 
Inclusion Inclusion
criteria: 1.Criteria:
Exclusion Critical
criteria:patients
1. Pregnant
with women;
COVID-19 confi
 
 2. airway 2.
intubation
Combined withwith
mechanical
severe basal
ventilation
diseasesis
Shusheng Li 1095 Jiefa Shushengl +86 13971 Tongji Hos - 3.
The
Agedparticipants
 3. voluntarily 18-75
Patients
joined years
Novelthis were
withold;
CoroCase
study
lungdiagnosed
with
tumor,
serie as COVID-1
informed
interstitial
consefi
 
 - Participants receivedwith
Pneumonia patients anti-SARS-CoV-2
new coronavirusinactii
;; Yahong Chen, MD;Hon;Chenhong;86138070 Ascletis Ph RT-PCR and 2019-nCoVDrug:
clinical manifestations.
Gano The diag
 Inclusion
- WrittenCriteria:
the informed consent.
 
;; Hongzhou Lu, Ph.D;Ho;luhongzh ;+86-021- Shanghai Pu 1. Age = 18 years;
Coronavirus
 2. Clinically diagnosed patients with new type
Jianping Zhao, Ph.D. Zhaojp88@ 1.35E+10 1.accordance
Age =18
Inclusion criteria: years
1. including
COVID-19;
with theconfirmed,
criteria
Drug: Recosuspected
for suspectedpatic
 
 2. residence in Jingzhou for more than 14 days duri
 
 3. Aged 2. Laboratory
16-65 years;(RT-PCR) confirmed infection wi
Deng Xiaopeng 47 Taqiao R49637569 +86 13872 Jingzhou M Inclusion
 4. self-volunteered.
Exclusion criteria.
cNovel CoroCase serie
 3. PaO2/FiO2 < 300 or SpO2 below 93% breat
 1. 2019-nCov (SARA-Cov-2) nucleic acid positi
;; Chong Lei, MD, PhD;L ;;crystall ;;+86-186 Fourth Mil Inclusion
Exclusion Criteria:
CritCoronaviruDrug: Nitri
 Inclusion
2. Older Criteria:
than 18 years old and younger than 7
 1. Aged >=18 years;
Xiuling Shang Fujian Prov -3.Nurses
Meet the who work > 37criteria
Pneumonia
diagnostic hours of
Caused per week in me
byCOVID-1
 2. Novel coronavirus pneumonia patients diag
 3. The patient COVID-19
himself participated
Drug: Lopin in the stud
 - Nurses with one or more comorbidities
 
; Mark B Loeb;Mark Lo ;loebm@mc;90533400 McMaster U - Nurses CoronaviruDevice: Me
Inclusion criteria:
Exclusion
(1) criteria:
mild / general
(1) Patients
patients
whowho
cannot
meetgut
 (2) Aged (2)
>=18 Patients
years; more than 7 days after diagn
Li Xugui 279 Luoyu spine672@+86 13807 Hubei 672 (3) Obtain (3)
patients'
Patients
COVID-19
informed
with severe
Experimenta
consent.
primary respirat
Exclusion criteria: 1. Discharge cases that can
Xu Shuyun 1095 Jiefa sxu@hust. +86 13517 Tongji Hos Inclusion c 2. Discharge
Novel CoroCase
cases withseries
language and ot
Prof. Christopher CK LDepartmentchris.kcla +852 3505 The ChinesInclusion c Exclusion cNovel CoroCase series
Li Lanjuan 79 Qingchuljli@zju.ed +86 13906 The First A Inclusion c Exclusion cCOVID-19 The triple
Inclusion criteria: 1. Aged >=18 years;
 2. Endotracheal intubation patients with positive nu
Wen Jianli 98 Fenghuazywenjian +86 15186 The Third A 3. Patients Exclusion
with off-line
cNovel CoroCase
extubation. serie
Inclusion criteria:
Exclusion1. Aged
criteria:
18-65
1. Medical
years, gender
workerwithout
who is lid
 Inclusion
 2. Meical 2. Criteria:
workers
Occupation
normalisworking
not medical
duringwokers
the period
suc
Fengbin Liu 16 Jichang liufb163@ +86 020-3 the First 
 3. Auqired
 3.theMedical
informed
Somatopsyc
consent
Observatio
and willing to be a
 1.Exclusion
age range:
Inclusion criteria: 1. Aged10-19;
criteria:
>=181. years
Pregnancy;
old;
 
 2. Symptoms
 2. Patients
of novel with
coronavirus
advancedinfection;
malignant tum
Wen Jianli 98 Fenghuazywenjian +86 15186 The Third A 
Inclusion 2. 3.
 3. Positivefull-time
criteria: 1.
nucleic students
positiveness
Suspected
Novel
acid test inofof
these
CoroCase
cases. targets
nucleic
novel
serie acidhigh or m
of COVI
coronavirus.
 
 2. newly-onset pneumonia in a CT scan;
 3. nationality:
 3. typical symptomsChina;of pneumonia, i.e., fever, coug
Jiang Xie 2 Anzhen Ro frank7820 +86 13161 Beijing Anz 
 4. live Exclusion
in Wuhan cNovel
in the past
CoroCase series
 4. exposure context: COVID-19;
 
 2. Patients with other malignant disease
 3. Patients with known psychiatric disord
Honghua Ye 41 Xibei St yehonghua+86 13505 HwaMei Hos Inclusion c 4. PatientsNovelwiCoroControl gr
Inclusion criteria: 1. Volunteers who have understood an
>=18 years;
criteria: 1. Viral pneumonia with ot
 3. Patients
 2.
diagnosed
Patients with
are not
acute
suitable
severefor2019-nCoV
immunog
 (1) Laboratory
 3. Participation
(RT-PCR) confirmed
in other infection
studies; with 20
Xiang Cheng 1277 Jiefa nathancx@+86 15972 Union hosp (2) Lung 4.
in Other Novel
circumstances
CoroExperiment
in which the inve
Peng Sun 1111 XianxSP2082@sh+86 18121 Tongren HoInclusion c Exclusion Novel CoroCase serie
Inclusion criteria:
Exclusion
Patients
criteria:
mustPatients
meet who
all ofmeet
the following
any of t
 1. Patients
 1.
admitted
The clinical
to hospital
data are
from
insufficient
December and20th
Lingli Dong 1095 Jiefa tjhdongll +86 18672 Tongji Hosp 2. Patients
 2.
identified
The Rheumatic
ageas
ofany
the rheumatic
patient
Case series
is below
disease
12acco
yea
Qian Guoqing 59 Liuting guoqing.q +86 15888 Ningbo FirsInclusion c Exclusion cCOVID-19 Case serie
Inclusion criteria:
Exclusion
(1) criteria:
Patients(1) diagnosed
CT resultwith
is negative;
COVID-19
Xu Haibo 169 Donghuxuhaibo11 +86 13545 Wuhan Univ Inclusion criteria:
 (2) There are 1.
 (2) CT patients
Incomplete
image with
Novelexamination
CoroGoldnovel
clinical coronavirus
data.
Stand
data and manifpne
 2. Fever,Exclusion
respiratory
criteria:
tract1)and
Ordinary
other symptoms,
covid-19 pneumthe
Inclusion
 3. Agedcriteria:
18 to1.
 2) 80Patients
Patients aged
years;with fromto
allergy 18traditional
to 80 years;Chi
Bangjiang Fang 725 Wanpinfangbji@1 +86 18917 Longhua Hos 2.
 4. conformed
Exclusion
Signed
 3) to criteria:
informed epidemic
Patients
Novel
cons
with1.history;
people
CoroGroup
malignant who tuare allergic
2:Tr
 3. fever 2.
and respiratory
the researcherssymptoms;
judged that the comp
 4. normal 3.
or decreased
those wholeukocyte
cannot take count
drugsin peripher
through
Qun Luo Exclusion
151 Yanjia luoqunx@ +86 13710 State Key L 5. conformed to criteria:
 4. any imagi
Fibrosis (1)
a patients
significant clinical
Experimentallergic
or la to the
 (2) infants and young children unable to
Inclusion criteria:
 (3)1.patients
Intervention group:
with unconsciousness or los
Yang Si-Jin 182 Chunhulykyk3160 +86 15228 Affiliated (1)
InclusionAged 18 to 50 Novel
c (4 years;CoroCase series
 (2) Diagnosed
Exclusion ascriteria:
a depression
(1) other
or anxiety
psychiatric
by Diagno
disord
 2. Non-intervention
 (2) complicating
group: with sever medical diso
Yuan Yang 1095 Jiefa yuanyang7+86 13995 Tongji Hos (1 (3) takingNovelantidepressants,
CoroGroup 1:mi psychoactive
Jingfeng Zhang Room 711, jingfengz

B +86 15706 Hwa Mei Ho Inclusion c Exclusion criteria: 1. Pregnant
Novel CoroCase or lactating wo
series
Inclusion criteria:
 2. 1.
Patients
Male or with
female
malignant
patients
tumor,
aged other
16-75
 2. Willing
 3.
to sign
Patients
informed
who consent;
have recently or are par
Dou Qifeng 88 Jiankan douqifeng +86 13503 the First A 3. novel 4.
coronavirus
There Novel
was
novel
CoroHigh
evidence
coronavirus
dose
of drug
group:routin
is highly
add nov
Exclusion criteria: 1. Exclude medical staff wh
 2. Exclude medical staff who worked in t
Yan Hao, Xiaoping Lu 1095 Jiefa haoyaner +86 13971 Tongji Hos Inclusion c 3. Exclude Novel
if the
CoroCase
medical
series
staff and family
Inclusion criteria: All patients who meet one or two of th
 Epidemiological history:
Luo Xiaoping 1095 Jiefa xpluo@tjh.+86 027-8 Tongji Hos 1. travelExclusion
or residence
cCOVID-19
historyCase
of Wuhan
series or other are
Inclusion criteria: The mild cases were defined as those
Tiejun Wang 116 Zhuodatiejunwan +86 13277 Department 1) respiratory
Exclusion failure
cNovelrequiring
CoroCase mechanical
serie ventilat
Exclusion criteria: 1. Aged > 75 years old and
 2. Patients who are contraindicated or a
JIAN PENG 216 Guansh13758526 +86 13907 Wuhan thirInclusion 3. Patients Novelwith
Coroexperimenta
previous tumor, severe
Exclusion criteria: (1) Female patients during
Inclusion criteria:
 (2)(1)Patients
aged between
with allergy
18 and
to Exocarpium
75 years oldC
Hu Linhui 101 Weimihulinhui@l+86 13580 Maoming Pe (2) Common
 (3)type
Pa Novel
patients
CoroExocarpium
with confirmed COVID-1
Inclusion criteria: (1) Patients with Novel coronavirus pn
 (2) Inpatients
Exclusion aged
criteria:
>18 years
(1) Death
old; is expected withi
Jing-Guo Cheng Wenzhou Me wzwsjcjg@+86 13857 WenZhou Me (3) Patients
 (2)
KnowBasic
Novel
the
diseases
inform
Corocontrol
such asgrprimary immu
Exclusion criteria: 1) Age < 14 years;
Inclusion criteria:
 2) 1)Pregnant
The diagnosis
women; meets the diagnostic
Zhigang He 1095 Jiefa 10976858 +86 18827 Eergency / 2) Patients
 3)
receiving
Incomplete
Novel
NIVcoroNIV
or
information
MV treatment.
group:of necessary
Xia Tian 241 Peng-Lhcwy100@+86 13871 Wuhan ThirInclusion c Exclusion cNovel CoroCase series
Zhengrong Mao 19 Renmin maozheng +86 18695 The First A Inclusion c Exclusion cNovel Coro Case seri
Inclusion criteria: 1. COVID-19 patients with positive SAR
Liming Xia 1095 Jiefa Lmxia@tjh.+86 13607 Tongji Hos Inclusion criteria:
 2. ViralExclusion
1. Above
pneumonia criteria:
cNovel 7CoroGold
years
1. Tooold,
manifestation young
understand
Stand
on to understan
CT. the p
 2. Meet 2.
the diagnostic
Non-neoplastic
criteriacoronary
of the COVID-19;
pneumonia p
 3. Clear 3.
consciousness
Impaired and
consciousness,
stable vital affecting
signs; its u
Yibin Hao 33 Huanghehaoyibin0 +86 15903 Zhengzhou 4. V 4. Those Novel
whoCoroCase
cannot cooperate
series
Exclusion criteria: 1. Previous medication info
TAO WANG 1095 Jiefa wt7636@1+86 13971 Tongji Hos Inclusion 2. The Novel
patients'
CoroGold
medicalStand
records were in
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. Patients
80 yrs; with mental ab
Yingjia Xu 801 Heqingxuyingjia@+86 18017 Shanghai Fi 2. Diagnosed
 2. Patients
as COVID-19
Coronaparticipating
Vir
pneumonia(according
Case serie
in other clinical
to
Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion Exclusion cNovel CoroLight grou
Xin Li 1277 Jiefa 31444082 +86 13797 Union Hospi

Inclusion c Exclusion cNovel Corosevere pat
Inclusion criteria: (1) Currently participating in or respon
Zhang Yue 1120 Lianhzyzy1933@+86 18823 Clinical R (2) Voluntarily
Exclusionparticipate
cnovel coro
in Case
this study.
series
Qingyou Zheng 1333 Xinhuzhengqing +86 18601 Shenzhen HInclusion Exclusion cNovel CoroCase series
Ning Qin 1095 Jiefa qning@vip +86 027-8 Tongji Hos Inclusion Exclusion cNovel CoroGold Stand
Inclusion criteria:
Exclusion
(1) criteria:
patients(1)
who
Aged
were<18
diagnosed
years; to N
Ye Tu 1095 Jiefa whtuye@1+86 18986 Tongji Hos (2) patients
 (2)
whopneumonia
received
Novel CoroCase
with
patients
invasive
series
whose mechanical
novel cor
Inclusion criteria:
Exclusion
1. Those
criteria:
who1. Incomplete
meet the diagnosis
medicalof reco
CO
LIU DONG 1095 Jiefa ld_2069@ +86 13507 Tongji Hosp 2. In-patients
 2. Those
admitted
Novel
which
in
CoroCase
designated
the researchers
series
hospitals.
deemed
Exclusion criteria: 1. Transfers to Huoshen sh
Peng Jian Exclusion
241 Peng-L54116340 +86 18627 The Third Inclusion 2. criteria:
Patient
Novel
with 1.only
Withonecontraindications
Corodischarge laboratory test.o
 2. Pregnant or lactating women;
Inclusion criteria:
 3. 1.
Patients
Aged between
taking other
18 and
urinary
75 years;
trypsin in
Zhaofen Lin,Wanshen 415 Fengyalinzhaofe +86 13601 Shanghai C 2. In accordance
 4. Notwith
Novel
suitable
NCP
CoroExperiment
to
criteria
participate
for severe
in theand
clinic
cr
Inclusion criteria:
Exclusion1. Patients
criteria: who
1. Age<14
were diagnosed
years; as CO
Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. ARDS Exclusion
 2.
patients criteria:
Accompanied
according1) Aged
Novel Corocase
to
bythe <14
other years;
series
Berlin
serious
definition.
organ d
Inclusion criteria:
 2) 1) Pregnant;
Meets COVID-19 diagnosis criteria f
 2) Critically
 3)ill COVID-19
COVID-19 as patients
an complication
who admiteed
on othe
to I
Yi Bian 1095 Jiefa bianyi252 +86 15102 Eergency / 3) length
 4)
of stayInsufficient
inNovel
ICU >=24
CoroCase
medical
hoursinformation.
serie
Exclusion
Subjects1.(1)Patients
must
Infectionwho
withare
understand unable
influenza
the clini
Junming Wang InclusionFever
1095 Jiefa eyedrwjm +86 13886 Tongji hos (2) criteria:
 2.
 (2) 1.
Patients
and/or Patients
Novelwith
Patients who
respiratory
with hemodynamic
agreeserie
CoroCase to join
mycoplasma
symptoms, instability
the study
normal
pneu or r
 2. Aged 3.
>16 years
Withold;
severe coagulation dysfunction;
 3. Patients
 4.
with
WithCRPactive
morebleeding,
than twiceespecially
the upper intrac
lim
Qin Wang 1630 Dongfqinwang_ +86 13621 Renji Hospi 4. The 5.
severe Pregnant
or critial
Novelpatients
CoroCase with
serie
COVID-19 acco
Zhanlian Huang 600 Tianhezhanlianh +86 13580 The Third AInclusion c Exclusion cNovel
criteria:CoroGold
1. younger than 18 years o
Stand
Inclusion criteria:
 2. 1.
doconfirmed
not fulfill the
withcriteria
COVID-19;
of critical case
 2. ICU 3.
admission;
declared clinical death or discharged a
Hongyu Gao 1095 Jiefa hygao@tjh+86 13886 Department 3. meet 4.
the critically
important
Novel
ill criteria
coroCase
data missing.
according
series to Chines
Inclusion criteria: 1. Patients who were diagnosed as CO
14 yearscriteria:
or more;1. Hemodynamic instability
Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 3. diagnosis
 2.ofIntracranial
ARDS
Novelaccording
Corotransnasal
pressure
to Berlin
>30 mm definition.
Hg or ce
Wu Kaifeng 98 Fenghuakiphoonw +86 13788 The Third AInclusion Exclusion cNovel CoroGold Standard:Epidem
Exclusion criteria: 1. Patients who refused to
Guo Zhang Inclusion criteria:
6 Taoyuan zhangguog+86 13978 The PeopleInclusion c Exclusion
 2. 1. tumor
criteria:
Patients group:
(1) Thosesymptoms
Noveldeveloped
CoroCase who do not
serie mee
caused
 (1) Aged (2)
>=18 Complicated
years; with severe primary hea
 (2) Diagnosed
 (3) Patients
as a malignant
duringtumor
perioperative
or has aperiod
history
Zhihua Wang, Xiangli 1095 Jiefa zhwang_hu+86 13607 Tongji Hos (3) The (4)
diagnosis
Immune
and
Noveltreatment
dysf
Coronon-cancer
of new coronavirus
Liang Wang 1095 Jiefa wang6@tjh+86 13971 Tongji Hos Inclusion c Exclusion cNovel CoroCase series
Inclusion criteria: 1. Confirmed case: any one of the epid
 (1) epidemiological history:
Wang Hua-bing 241 Peng-L27322554 +86 15377 Wuhan 3rd 1) travel
Exclusion
history cNovel
or residence
CoroCase
history
series
of
Yuan Yadong 215 Hepingyuanyd11 +86 15833 The SecondInclusion c Exclusion cNovel CoroCase series
Xiong Chen 169 Donghuzn_chenxi +86 13995 Zhongnan HInclusion c Exclusion cAnxiety; N Case series
Exclusion criteria: (1) Other viral pneumonia
Inclusion criteria:
 (2)(1)
Serious
novel mental
coronavirus
illnesspneumonia
or history of
nove
de
Burenbatu 1742 Huolinmbrbt89 +86 18804 Affilated H (2) According
 (3)to
Susthe
Novel
diagnostic
CoroCasestandard
serie of "lung in
Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong PInclusion c Exclusion cNovel Corocase series
Inclusion criteria:
Exclusion
(1) criteria:
Corresponding
1. Withtoother
diagnosis
serious
standa
prim
Li Xiaodong 856 Luoyu lixiaodon +86 13908 Hubei Prov (2) Imaging
 2.manifestations
Severe
Novel
primary
coroControl
Fibrous
dis cable-like
gr shado
Exclusion criteria: 1. Aged<14 years;
Inclusion criteria:
 2. 1.
Pneumothorax;
Patients who were diagnosed as CO
Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. ARDS 3.
patients
Severe
are
Novel
asthma
defined
Corocase
or
According
COPD.
series to the Berli
Exclusion criteria: 1. Patients who are not wil
Hui Zhong 37 Guoxue zhonghui3 +86 18980 West ChinaInclusion c 2. Patients
End-stage
withoutCase
theseries:
ability to fill in th
Lihui Wang 13 North Q84961499 +86 13832 Cangzhou PInclusion Exclusion Novel CoroCase serie
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. Renal
80 years;
replacement thera
 2. Diagnosed
 2. Relative
as COVID-19
/ absolute
pneumonia
contraindications
(according too
Jing Chen 12 Wulumuqmoney_09 +86 13816 Huashan Ho 3. ad 3. Pregnant
Novelwomen,
CoroCase participating
series in oth
Lijia Demi 94 West St27216302 +86 17723 Ganzi HospiInclusion c Exclusion cNovel CoroCase series
Inclusion criteria:
Exclusion
Pneumonia
criteria: 1.
cases
Suspected
with suspected
patients unab
SARS
Guangtao huang 149 Dalian haitao314 +86 18085 Affiliated A comprehensive
 2. Pneumonia
Novel
analysis
CoroGold
caused
was conducted
by
Stand
other based
pathogen
on
Inclusion criteria: (1) Aged >18 years old;
Xia Hong 1 Xiyuan Pl97023653 +86 13699 Xiyuan Hos (2) canExclusion
completecNovel
the wechat
Coro4questionnaire
groups:N indepen
GuoLin Song 32 Feishan ant00099 +86 13985 The SecondInclusion Exclusion cNovel CoroCase series
Hong Wang 1229 Gudun hongwang +86 0571 Zhejiang H Inclusion Exclusion cNovel Corotwo groups
Inclusion criteria: 1. confirmed with COVID-19;
 2 oldererExclusion
than 65criteria:
years; 1. declared clinical death o
Cuntai Zhang 1095 Jiefa ctzhang04 +86 15927 Department 3. meet 2.
the critically
important
Novelill criteria
coroCase
data missing.
according
series to Chinese
Inclusion criteria:
Exclusion1. over
criteria:
18 years
1. Investigator
old; believes tha
 2. Patients
 2.diagnosed
Not suitablewithforCovid-19
inclusion
pneumonia
in subjects
(th(
Zhi Zhang 100 Hainin 16683890 +86 13621 Shanghai Fi 3. Have 3.
64-row Patients
high-resolution
Novelwho CoroCase
cannotCTseries
ausc
examination of t
Inclusion criteria: 1. Conforming to the Chinese and Wes
 2. Aged between 18 and 65 years old;
Xiaodong Li 856 Luoyu lixiaodon +86 13908 Hubei Prov 3. Signing Exclusion
the generalized
cNovel CoroGroup
informed2:Weconsent
Inclusion criteria: 1. Patients who were diagnosed as CO
 2. ARDS patients according to the Berlin definition;
Fenglin Liu 12 Lieshishxkyylfl@1 +86 13953 Shandong P 3. Patients
Exclusion
in ICUcNovel
met the Corocase
VAP criteria
seriesand were no
Exclusion criteria: 1. There were symptoms b
Inclusion criteria:
 2.
Exclusion1.
Patients
Confirmed
Patients with
criteria: 1. cases:
who malignant
werepositive
Aged<14 tumor;
diagnosed
years; nucleic ac
as CO
Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. Aged 3.
Severe 25-65
 2.
ARDS Pregnant
years old;women;
Accompanied
patients
Novel CoroECMO
according
by otherto
group
serious
the Berlin
organ
defid
Inclusion criteria:
 3. Asexual
 4. 1. Male
difference;
HIV and female, older than 18 yea
positive;
 2.
 4. Patients
Clinical
 5.with
stage confirmed
Critical
(light,stage
common COVID19;
(ARDS type);
with multiple orga
Zhenlin Zhao Floor 10, B zhaozl200 +86 13828 Shenzhen R 3.
 5. Need to continue
Immunology
 6. The theCorocommon
standard:
Novel antivirus
peripheral bloodtherapy;
peripheral lymphocyte
blood
typ lymphoc
w
 4. Agree Exclusion
to sign the
criteria:
informed1. Cases
consent;
with severe vomiti
 5. Able 2.
to ingest,
Pregnant
absorband andlactating
toleratewomen;
oral medicatio
Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 3. The Novel
subjects CoroExperiment
participated other clinica
Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong PInclusion c Exclusion cNovel Corocase series
Inclusion criteria: 1. Aged 15-79 years;
Huanqin Han Inclusion
57 South Rhuanqinh +86 13828 Affiliated 2. criteria:
Patients 1. The
Exclusion
with patient
COVID-19
cNovel signedStand
CoroGold
confirmed anby informed
testing con
for
 2. patient aged >=18 years old;
 3. COVID-19 patients diagnosed by PCR;
Cao Bin 2 Yinghua Scaobin_be +86 13911 China-Japa 4. Nucleic
Exclusion
acid positive
cNovel within
Coroeperimenta
72 hours befo
Exclusion criteria: 1. Those who have not com
Inclusion criteria:
 2. 1.
Researchers
Medical staffwho ofare
designated
unwillinghospital
to parti
Zhongze Lou 59 Liuting lorenzo_8 +86 0574- Ningbo Firs 2. Patients
 3.
with
Thenew-coronary
Novel
investigator
CoroCaseispneumonia
unwilling
serie to infection
contin
Exclusion criteria: 1) < 18 years old or = 80 ye
 2) pregnant and lactating women;
Wang Hongyang 225 Changhhywangk@v+86 13801 The Third AInclusion c Exclusion criteria:
 3) patients
Novelwith(1)severe
pregnant
CoroTwo groupsor breast-feed
primary diseases
Inclusion criteria:
 (2)(1)
ALT/AST
aged 18-80
> 5 times
yearsULN,
old; neutrophils <
 (2) severe
 (3)
(including
definitecritical
diagnosis
risk factors)
of rheumatoid
and critical
imm
Min Zhang NO.85 Wujimaggie_z +86 18121 Shanghai G (3) blood (4)
CRP and
patien
Novel
ESR were
Coroexperiment
more than twice highe
Inclusion criteria:
Exclusion
1. confirmed
criteria: 1.critically
If the patient
ill covid-19;
received a
 2. grouping
 2.criteria:
aged < meet
14 years;
the clinical risk factor com
Minghao Fang 1095 Jiefa fangmh@tj+86 15071 Department (1) the<b length of sNovel CoroExposed gr
HONGGANG LI 13 Hangkonlhgyx@hot+86 13871 Huazhong UInclusion c Exclusion cNovel Coroin hospita

Inclusion criteria:
Exclusion
(1) criteria:
Comply (1)withPatients
the diagnostic
who were
criteria
even
Wei Li 215 Zhongs78440452 +86 18995 Wuhan Hosp
 (2) Complete
 (2)clinical
Patients
Novel
data
whose
CoroIntegrated
of patients.
data could not be ob
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. Critical
75 yearsnewold;pneumonia
Pinhua Pan, Yehong K 87 Xiangya pinhuapa +86 13574 Xiangya Hos 2. The 2.
diagnosis
Known
ofNovel
new-type
allergies
Coroexperiment
coronavirus pneumon
Inclusion criteria: 1. Those who agree to take part in the
 2. AdultExclusion
aged >=18years
criteria: 1.
old,Participation
male or female;
in the stud
Cai Qingxian 29 Bulan R 41180423 +86 13760 The Third 3. The 2.
inpatients
Lowwith
Novel
bodymild
weight
Coroexperiment
or common
pati type of COV
Inclusion criteria: 1. Those who agree to take part in the
 2. Adults
Exclusion
aged >=18years
criteria: 1.old,
Participation
male or female;
in the stud
Zhang Yu 1277 Jiefa whxhzy@1+86 13971 Union Hospi 3. The 2.
inpatients
Withwith
Novel
bleeding
mild
Coroexperiment
or
orcommon
ble type of COV
Exclusion criteria: 1. Exclusion of COVID-19 in
Inclusion criteria:
 2. 1.
Dead
COVID-19
children;
infection;
Wang Xiaowen 100 Hongkob5477@16+86 15907 Department 2. Children 3.
with
Signkidney
Novel
to reject
injury:
CoroInfection
thisHematuria,
project.w Proteinu
Inclusion criteria: 1. Diagnosed Novel coronavirus pneum
 2. Aged 18 to 65 years;
Yang Yi 4 Garden H15326774 +86 18971 Hubei Hosp 3. The Exclusion
time interval
cNovel
between
CoroControl
symptom groonset and ra
Inclusion criteria: 1. patients diagnosed as malignant tum
 2. aged 18 or above;
Baoshan Cao 49 North Gacaobaosha +86 15611 Peking Univ 3. informed
Exclusion
consent
cmalignant
and ability
tumorto cooperate
pati with r
Inclusion criteria: 1. Children aged 0-18 years and met th
 2. Agreed to participant in the study;
Liu Zhisheng 100 Hongkoliuzsc@12 +86 027-8 Wuhan Chil 3. Can Exclusion
cooperatecNovel
with theCorocase
later onseries
follow-up.
Inclusion criteria:
Exclusion
1. From
criteria:
January
1. Pneumonia
1, 2020 tocaused
Marchby
31,o
Chen Lei 26 Yuancunchenlei0n +86 13570 The Sixth A 2. From 2.
JanuarPatients
Novelwith
CoroGold
incomplete
Standdata.
Zunyuan Liu 67 Dongchaly29.love +86 18263 Liaocheng Inclusion criteria: Epidemiological

c Exclusion history:
cNovel CoroGroup A:Se
 1. History of residence or travel in Hubei province w
 2. Exposure history to resident or traveler in Hubei
Hanwei Chen 8 Fuyu Roadocterwei +86 18922 Guangzhou< Exclusion cNovel Coro1:Throat s
Gao Jun 167 Fangdon

13816012 +86 13816 The SecondInclusion Exclusion cNovel CoroControl gr
Song Ying criteria: 1.

439 Xuanhu16473805 +86 13668 YongchuanInclusion Exclusion cMental Those who
heaCase seriesare allergic t
Inclusion criteria:
 2. 1.
Pregnant
The patient
or lactating
signs the
women;
written inform
 2. Aged 3.
18-80Serious
years; basic diseases affecting surviv
xiao wei 8 Hangkong99xw@sin +86 071 6 Jingzhou Fi 3. the novel
 4.coronavirus
Expected
Noveldeath
coroExperiment
novelwithin
coronavirus infection
Exclusion criteria: 1. Cases of patients with tu
Inclusion criteria:
 2. 1.
A case
Compliance
of a pregnant
with NCP
or lactating
diagnostic
womcri
Miao Qing 1 Xiyuan Plmiaoqing5 +86 13910 Xiyuan Hos 2. Aged 3.
>=18 Incomplete
years.
novel corocase.
Chinese me
Exclusion criteria: 1. Cases of patients with tu
Inclusion criteria:
 2. 1.
A case
Compliance
of a pregnant
with NCP
or lactating
diagnostic
womcri
Miao Qing 1 Xiyuan Plmiaoqing5 +86 13910 Xiyuan Hos 2. AgedExclusion
 3. criteria:
>=18 Incomplete
years. (1) Thoseserie
Novel CoroCase
case. who were not tre
 (2) Patients with active tuberculosis;
 (3) Organ transplant patients;
Qingping Shi 287 Changhsir_shi@1 +86 13855 The First A Inclusion (4) Patients
Novelwith
CoroCase
mentalseries
disorders.
Exclusion criteria: (1) asthma requiring daily t
Inclusion criteria:
 (2)(1)
patients
age: 18-75
with years
severeold
mental
(including
illness
thre
an
He jing 16 Jichang sakeonel@+86 13760 The First A (2) compliance
 (3) the
with
novel
risk
the
stratification
comm
pneumonia
treatment
of
diagnosis
exercise
group :Ba
and
reha
du
t
Inclusion criteria:
Exclusion
1. Upon
criteria:
the1.judgment
The subject
of the
hasresearch
a history
Bi Xiaohui 33 Zhongyu52471295 +86 15618 Luohu hosp 2. According
 2. to
Thethe
Novel
subject
newCoroCase
type
suffers
of coronavirus
from
series
active psycho
Zhu Haibing 8 East Fuy zhb-ck@16+86 13826 Central HosInclusion c Exclusion cSleep; Nov Case series
Zhu Fengxue 11 Xizhimenfxzhu72@1+86 13911 Peking UnivInclusion c Exclusion novel coro Gold Stand
Hong tao 17 Yongwaiht2000@vi+86 13803 The First A Inclusion Exclusion cnovel coro experiment
Meizhen Lin 111 Dade Rlmzmay@1+86 18922 The SecondInclusion criteria:

c Exclusion
1. Male
criteria:
cNovelor CoroGroup
female
1. Severaged
cases18-80
1:Ba withyears
shock,ol
 2. Patients
 2.
with
Multiple
confirmed
organ novel
failure;
coronavirus-infect
 3. Diagnosed
 3. Pregnant
as moderate or lactating
cases of women;
COVID-19 with f
Kaijiang Yu 23 Youzhendrkaijian +86 0451- The First H Inclusion criteria:
 4. 1)
 4. Volunta Confirmed
CasesNovel or clinically
withCoroexperiment
malignant diagnosed
disease, autoimpa
 2) Those who have been identified by Chinese med
 3) Inpatients
Exclusion
agedcriteria:
18 to 751) Patients
years male withormild,
female;
seve
Haibin Ni 100 Cross nhb_2002 +86 15312 Affiliated 4) Vo Exclusion criteria:
 2) According 1. the
Patients
Novel CoroPositive
to with
d presence,
researcher's judgme
Exclusion criteria:and
 2. Pregnant 1. Patients
lactatingwho
women;are particip
 2.
 3. Pregnant
People with or lactating
allergies orwomen;
allergies to Xu
Qingling Zhang 151 Yanjia zqling68@ +86 13609 The First A Inclusion c 3.
 4. ALT / AST
Severe > 2-fold
2019-nCoVRoutine
basic diseasesULN;that
tr affect survi
Inclusion criteria:
 4. 1.
Expected
Sign thesurvival
writtentimeinformed
< 1 week;
consent;
 2. Aged 5.
18-80With
yearsserious
old; liver disease;
Wei Xiao 8 Hangkong99xw@sin +86 18972 Jingzhou Fi Inclusion criteria:
 6. (1)Aged
criteria:
the diagnostic
Patients
Novel>=18 (1)years
taking
criteriaKnown
o forold,
coroExperiment orgender
novel suspected
unlimi
to
coronaviru
 (2) Novel
 (2)
coronavirus
Mild or nucleic
critical patients
acid positive
in clinical
in pharyn
clas
 (3) Clinical
 (3)
classification
Severe liver is ordinary
diseases or (such
severe
as child
patien
Pu
Weiping Cai 627 Dongfegz8hcwp@+86 020-8 Guangzhou (4) I < Novel CoroCase serie
Inclusion criteria:
Exclusion
(1) criteria:
diagnosed (1)aspatients
a mild with
and common
severe het
 (2) aged (2)
14 to patients
70 years whose
old; survival time is not ex
Jia Lijun 725 Wanpinljjia@shut +86 13585 Cancer Inst (3) (3) endotracheal
Novel Coro1:meditati
intu
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. Patients
65 years with
old, both
allergic
male
his
Jing Xu Room 319, 18604501 +86 18604 Harbin Peiy 2. The 2.
eligiblePatients
subjects
Novelwith
(male
CoroExperiment
blood
and system
female)diseases
with ferti
Exclusion criteria: 1. Allergic
Extremelyto ill
vitamin
patientsC; wi
 2. 1.
Inclusion criteria: Cardiogenic
Pregnant dyspnea;
Patientsorwith
lactating
confirmed
women; novel coron
Wei Wei 3. Life
1 Fourth N wwei@chin+86 13729 Guangzhou 2. Voluntarily In
sign
theexpectancy<24h;
novel
written
opinion
coroinformed
of
Experiment
the investigator,
consent. pre
Inclusion criteria:
 4. 1.
Pregnant
Aged>=18 and/or
yearslactating
old; female;
 2. Diagnosed
 5. There
as severe
is a and
statecritical
of tracheotomy
patients with or hom
no
Gao Dengfeng 157 Xiwu Rgaomedic +86 15091 The Second 3. Being 6.
treated
Previously
innovel
the ICU.
coro
complicated
Case seriewith in
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.requirements
Serious/critically
of the
ill "New
patie
 2. Aged 2.
18 to With
65 years
pneumonia
male or infected
female; by other vir
Ying Deng 22 Second surewin00 +86 13500 The Sixth AInclusion
 3. Thecriteria:
Exclusion
intervalConfirmed
 3. Withcriteria:
fromNovel
one
theofor
1.following
suspected
Patients
CoroPhosphoric
onset without
case ofto
of symptoms
abnormal any
COVID
clin
enro
 1. Aged 2.
between
Those 18-85
withyears
severeold;
nasal diseases affec
 2. Patients
 3.
with
Inability
newlyto diagnosed
understand andorsuspected
follow reseaCO
Jingzhi Ma 1095 Jiefa majingzhi +86 13871 Tongji Hos 3. Exclusion criteria:
 4. Invasive 1. The clinical
NovelveCoroGold Standaclassification
Exclusion
Inclusion criteria:
 1) 1. criteria:
Respiratory
Aged 1.failure
18 to Allergic
70 years toold;
occursvitamin C;
and require
 2.
 2. Patients
 2) Cardiogenic
with
Shock
pneumonia
occurs; dyspnea;
infected by new corona
Bende Liu 1 Wenhua A 3.
 3) Life
liubende9 +86 13907 First peopl 3. Confirmed cas expectancy<24h;
Combined
failure of
Inclusion criteria:
 4. 1.
Pregnant
Aged>=18 and/or
yearslactating
old; female;
 2. Diagnosed
 5. There
as severe
is a and
statecritical
of tracheotomy
patients with or hom
no
Gao Dengfeng 157 Xiwu Rogaomedic +86 15091 The Second 3. Being 6.
treated
Previously
inNovel
the ICU.
CoroExperiment
complicated wi
Inclusion criteria:
Exclusion
Subjects
criteria:
who1. Serious/critically
meet the all of the ill follow
patie
 1. Meet 2.
the requirements
With pneumonia of theinfected
"New Coronavirus
by other vir
Jinghua Mao 60 Jingjing hbjzyyywl +86 071 6 Jingzhou CeInclusion criteria:
 2. Aged Exclusion
18 1.
 3. Patients
Withcriteria:
Novel
one of who
Iffollowing
subject
meetmeet
CoroPhosphoric the requirement
one of the
abnormal
 2. Aged 1.
18-75Be years
dysphagia
male orand female;
cannot receive drud
 3. Serious
 2.
patient
Complicated
meet onewith of the
pneumonia
following:infected
Jinghua Mao 60 Jingjing hbjzyyywl +86 071 6 Jingzhou Ce 3. Alle Novel CoroPhosphoric
Inclusion criteria:
 2. 1.
Pregnant
Patientsorwith
lactating
confirmed
women;
new corona
Chao Xu 1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily
 3. Insign
thenovel
written
opinion
coro informed
of
High
thedose
investigator,
consent. pre
Inclusion criteria:
 2. 1.
Pregnant
Patientsorwith
lactating
confirmed
women;
new corona
Chao Xu 1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily
 3. Insign
theNovel
written
opinion
CoroExperiment
informed
of the investigator,
consent. pre
Inclusion criteria: 1. Common inpatient, volunteer and f
 2. Patients who are older than 12 years, gender unl
Zairong Wei 149 Dalian 18811699 +86 15208 Affiliated 3. Consenting
ExclusionorcNovel
the guardian
CoroGold of aStand
minor is willing t
Shan Chunlei 1200 Cailu shanclhap +86 18616 Shanghai UInclusion c Exclusion cnovel coro experiment
Inclusion criteria:
 2. 1.Pregnant
Patientsorwith
lactating
confirmed
women;new corona
Chao Xu 1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily 3. Insign
thenovel
written
opinion
coro
informed
of
Experiment
the investigator,
consent. pre
Inclusion criteria:
 2. 1.Pregnant
Patientsorwith
lactating
confirmed
women;new corona
Chao Xu 85 Kefeng 16497276 +86 15018 Guangzhou 2. Voluntarily 3. Insign
theNovel
written
opinion
CoroExperiment
informed
of the investigator,
consent. pre
 
Huang Keqiang 300 Taizih hkq12312 +86 15287 Wuhan Asia Inclusion c- Exclusion
Parents/legal
cNovel guardians
CoroCase orseries
adult participant
 Inclusion
consent Criteria:
for participation in the study.
 
;; Matthew Snape, Profes ;iason.vic ;01865611 University 1. 14-70oryears
- Male Female,old agedProcedure:
Serogroup 0 - 24 years incl
 
 2. 2019 novel coronavirus pneumonia (severe
Jin Yang 1277 Jiefa whuhjy@si+86 13554 Union Hosp Inclusion c Exclusion cnovel coro Case serie
 3. Subjects voluntarily participate in the clinic
 
Faming Zhang, MD; PHD The Second Inclusion
ExclusionCriteria:
criteria: 1. People with high-risk ex
Xin Zheng 1277 Jiefa xin11@hot+86 027 8 Union Hosp Inclusion c- 2.
Adult aged
People >=18years
novelwith
coro old;cohort
high-risk
Two exposure who w
1. Age:18~55 years old, unlimited gender.
 - Diagnosed with 2019-nCoV. Diagnostic crite
 1.Meet the definition
2.2019-nCoV
Laboratory (RT-PCR)
2019-nCoV of confirmed
infection; severe
CT pneumonia(Co
of the infection
lung wi
conform
 manifestations.
1. Shortness of breath,RR=30 bpm;
; Qing Ning, Professor; qning@vip.+8613971521450; 3. 2019-nCoVDrug: ASC0
 1.
2. =In18 years old;
a resting state:SPO2=93%;
 
; Qing Ning, Professor; qning@vip.+8613971521450; Inclusion
2. P Criteria:
3. Diagnosed as serious or critical
2019-nCoVDrug: MethSARI (accord
 Clinical management of 2019-nCoV infected
 Inclusion Criteria: stroke in the past 180 days o
- Acute ischemic
;; Zhiyong Peng, profess;pengzy5@;+8618672 Wuhan Univ 
< Vitamin C; Drug: VC;Dr
 1)2019-nCoV
- Age >/= 18nucleic acid test was positive. 2)C
years old
 of viral pneumonia.
; Mary Carter Denny, MaryCarte 202-444-8532;202-44 Inclusion
- AutomatedCriteria:
Ischemic
Office Blood
S Device:
Pressure
Ho =135 systo
 Inclusion
Exclusion Criteria:
Criteria:
 1. Laboratory diagnosis:
; Qing Ning, Professor; qning@vip.+8613971521450; 1. 2019-nCoV
Patients who nucleic
meet acid
any testAbid
2019-nCoVDrug: was positive.
 - Respiratory specimen is positive for SARS
2. CT of the lung conformed to the manifestati
Yimin Li, PhD, MD The First A - The viralCOVID-19
gene sequencing
Drug: Reco of the respirat
 1. Volunteers
Exclusion who have understood and signe
Criteria:
 
; Qing Ning, Professor; qning@vip.+8613971521450; 2.
1. Age =18 years,
Patients wh gender unlimited;
2019-nCoVDrug: Abido
 
 3. Patients diagnosed with acute severe 2019
< 2019-nCoV;Drug: Immu
 
 - admission to ICU with novel coronavirus p
Patients confirmed
 "Pneumonitis Diagnosis and Treatment Sche
; Yang Jin;Yang Jin whunjy@113554361146;135543 - adult (=18Novel
years CoroCombinatio
old)
 - confirmed case of 2019-nCov infection by 2
Hong Kong Inclusion Criteria:
- polymerase
Laboratory (RT-PCR)
chain reaconfirmed Covid-19 inf
COVID-19
 lower respiratory tract samples;
 1. Age =18 years at time of signing Informed C
;; Lung-Ji Chang, PhD;Lu;c@szgimi. ;+86(755) Shenzhen G - The interval
Pathogen
betweenI Biological:
the onset of symptom
2. Laboratory (RT-PCR) confirmed infection wi
 
;; Wei Zhang;Jiang-Rong;; ;; Jingzhou H A3.subject must
Hospitalisedmeet
with all of theYinH
CoVID-19;CDrug: following
Fever(=36.7? -axillacriteria
or ora
 Key Inclusion Criteria:
study:
 
20-0003 Central Cont KPWA.vacc 1.21E+10 -1.Willing and
Provides able toinformed
written
Corona provide
Vir written informed
Biological
consent prior to
procedures
 
; Gilead Study Director;;GileadCli ;1-833-445Gilead Scie 1. SubjectAcute
- Severe (or legally
COVID-19 authorized
Respiratory representativ
Drug:Syndrome
Remd Corona
to initiation of any study procedures.
 
John Beigel DMIDClinic 1.3E+10 Inclusion
1.
2. Male Criteria:
or female,
Understands andaged
Corona Vir at 18
agrees to years
Other: Pla
comply(including
wi
 
 1.
2. Male or female,
Laboratory 18 years of
confirmation old2019-nCoV
= age = 75yea
infe
;; Fu-Sheng Wang, MD, P;shilei30 ;86-10-669The fifth m chain reactionCorona(RT-Vir Biological
 2. CT image is characteristic of 2019 novel cor
 3. Laboratory COVID-19
confirmation
Biological
of 2019-nCoV infe
 Inclusion Criteria:personnel as defined in DoDI
- DoD-affiliated
 emergency-essential civilian employees and
Sandi K Parriott sandi.k.par301-619-6824 1.Armed
Aged between
Forces w18 and 75 years,
CoronaviruDrug: extremes in
Remdesivir
 2. Patients diagnosed with mild or common ty
Lin Chen chenlin_t 8.61E+12 - guideline
Adult aged >=18yearsDrug:
"Pneumo
COVID-19 old; Huai
 Inclusion
- DiagnosedCriteria:
with CONVID19. Diagnostic criter
 - SARS-Cov-2
Healthy and Covid-19-positive
infection; CT of thevolunteers
SARS-CoV-2;Outcome, lung conform
 - Patients with novel coronavirus pneumonia
 - swab test of between
The interval viral nucleic
theacid.
onset of symptom
;; Lung-Ji Chang;Lung-Ji ;c@szgimi. ;+86(755) Shenzhen G patients. The Treatonset
andofBiological:
symptoms i
 Key Inclusion
Exclusion Criteria:
Criteria:
Qiong Gong, MD. Renmin Hos - Willing
Patien andPneumonitis
able to provide written informed
 - procedures
confirmed
Inclusion mild COVID-19 (NEWS scoring sys
Criteria:
 
; Gilead Study Director;;GileadCli ;1-833-445Gilead Scie Exclusion
Severe Criteria:
- Participant is willing
Acute
COVID-19 and
Respiratory able
Drug: to give Corona
Syndrome
Remd inform
 study and agrees with the study and its cond
 - unable to take oral medication
William Schilling, MD William@t +66 2 203-6333 - Agrees notCOVID19;Co
to self-medicate
Drug: Chlo
wit
- pregnancy or breast feeding
 
Sung-Han Kim, MD.P shkimmd@a 82-2-3010-3114 - Patients with mild and
COVID-19 severe
Drug: Lopicases who ha
 Inclusion Criteria
pneumonia for a case:
according to the "Pneumonitis D
 1. Patients
- Plan who
for New Cmeet
Corona Virthe requirements
Drug: Tetr of the
 1.respiratory
Patients diagnosed
infectionas COVID-19:
symptoms or acute cou
oriol Mitja, PhD oriolmitja 0034 934651072 1. mild patient:
COVID-19fever,respiratory
Drug: Anti and other
 - Blood donors whose
pneumonia can belast donation
seen were bet
on imaging.
 
; Qing Ning, Professor; qning@vip.+8613971521450; Inclusion
Exclusion Criteria:
Criteria:
COVID-19 Drug: Silde
 
 - It conforms
Blood towhose
donors the diagnostic criteria
blood test ofwere
results confi
 Blood DonaOther: Que
 - Age from 18-75, regardless gender.
 
; Haibo Cheng, phD;Lei 36399490 13815857118;139512 - The patient
COVID-19
informedDrug:
consent
TCMand sign the i
 - 1. Age = 18, age = 75, gender unlimited;
 - At leastCriteria:
Inclusion 21 years
 - 2. novel coronavirus diagnosed severe pneu
; Liwei cheng, doctor;X ;xiaoyang ;18986033 Research o -1.plan.
Has stayed
Laboratory
(severeinconfirmed
Singapore
COVID-19
patients for any
at least
COVID19
Biological
meet 2 yearsde
infection
of
 specimen and/or detection of SARS-CoV-2 Ig
Lorenzo Berra lberra@mg 1.62E+10 Inclusion
2. Hospital Criteria:
admission
CoronaviruDrug:
wit Nitri
 Inclusion
- Below Criteria:
21 years
1. Age: 18-80 years old, male and female;
;; Jean Liu, PhD;Jean Liu ;jeanliu@y ;66013694 Yale-NUS C 1.
- Has Agestayed
=18 years at time of signing Informed C
CoronaviruBehavioral
in Singa
 -2.>/= 18 years
Covid-19 old
confirmed cases;
 2. Those who meet the diagnosis of severe ne
;;;; Dong Shang, M.D.;Jia ;;;;franlj ;;;;8610-6 Wuhan Leis -3.confirmed
ICU admission
Comply with any of with
COVID-19;
infection the following:
Drug: Yinh
 - Intubation
- Dyspnea,and RR mechanical
= 30 times /ventilation
min;
Jiaojiao Pang, PHD sddxlcyjz +86 18560089129 1. Clinically diagnosed
COVID-19 with Drug:Corona
Bev Virus Dise
 - Positivity of 2019-nCoV rt-PCR
 2. Increased interleukin-6
Lorenzo Berra, MD lberra@mg 1.62E+10 - PaO2/FiO2SARS ra (SeveDrug: Nitri
3. Sign the informed consent
; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ -4.Presumptive
Subjects who positive
COVID-19
can takelaboratory
Drug: Favi test
medicine o for SAR
 1.with
Age recent
Inclusion =18 years
Criteria:
exposure to laboratory-proven S
 
;; Christopher Tignanell ;;ctignan ;;612-625- University 2. Negative SARS
- Presumptive
Negative CoV-2
positive
Corona rt-PCR testtest
laboratory
Vir Drug: Losa at screenin
for SAR
 with recent exposure to laboratory-proven S
3. Scheduled to work with SARS-CoV-2 infecte
;; Christopher Tignanell ;;ctignan ;;612-625- University - Negative Corona Vir Drug: Losa
 Inclusion
- (1) AgeCriteria:
Exclusion =18 years. (2) Laboratory (RT-PCR) c
Criteria:
 Lung involvement confirmed with chest ima
Lorenzo Berra, MD lberra@mg 1.62E+10 
 - Participants in other clinical trials
 Inclusion
1. AgreesCriteria:
to the collection of oropharyngeal o
; Adeeb M AlZoubi, Ph. adeebalzou+962795337575;+962 - Use of Ste Biological
 -2.Anyone
Male orvolunteer to participate
non-pregnant female adult =18 yea
 
;; SHAOXIAN HU, M.D;YI;yuyikai@ ;+1 (484) Tongji Hosp Inclusion
Exclusion Criteria:
Criteria:
Covid-19;S Drug: Toci
 - ARDS
Anyone associated with COVID-19
non-voluntary infection
to participate
;; FrÃ©deric DUTHEIL;Lis;promo_int;04737549 University - Patients diagnosed with COVID-19
Stress, Psychological
 - Medical necessity for endotracheal intubati
 Inclusion
- AgedCriteria:
between 18-75 years;
;; Jonathan C Javitt, MD ;rbesthof ;+1484254 Relief Ther - Physician determination
Acute RespDrug: that
Avipt
patient is on
 - Patients wenttotosign
- Willing thethe
fever clinic with
informed respira
consent v
 
;; Xiaoju Zhang, PhD;Ziq ;13781919 ;+86-1378 Henan Provi Exclusion Criteria:
Crite
CoronaviruOther: oxy
 - none
; Wenhong Zhang, Doc zhangwenh13801844344;+86 21 Inclusion Criteria:
- 1. Subjects must haveDiagnostic
COVID-19 documented exposur
 test for the virus within 72 hours of the adm
 - All patients >18 years of age with a positive
; Colin Broom, MD;Col ;cbroom@p;832-315- Pulmotect, - inclusion.
2. Su COVID-19 Drug: PUL-
 Key Inclusion Criteria:
 Inclusion
- HealtyCriteria:
age-matched volunteers will be inclu
 
 - (PCR)
Aged between 18 and 60 years.
or other commercial or public health a
 
; Clinical Trial Managem;clinicalt ;844-734- Regeneron - Hospitalized
Able to understand
COVID-19 the
with illne content
Drug: Sari of informed
 consent
 
; Zhu Fengcai;Wang We;jswwj@vip;027-8765 Jiangsu Pr Inclusion Criteria:
- Able and willing
COVID-19 Biological
 
 - pregnant women with laboratory-confirmed
Gabriele Saccone, MDgabriele.s 8.17E+08 Infection VOther: pre
 -1.Adults
Male or healthcare
female, agedworkers
= 18 (HCW)
years OR
 - flu-like symptoms: myalgia, cough, fever, sp
 -2.Chronic
Laboratory patients with at least
confirmation 2 chronic med
of 2019-nCoV infe
Florentino de Araujo florentino +55 19 991232882 - chain
Chest reaction
X-RaysCOVID-19
(RT-PCR) Biological:
from any diagnostic
 Inclusion
- COVID-19 Criteria:
biological tests
;; Maurizio Cipolla, MD ;antonio.g ;+3939200 Medical di - People that CoronaviruDevice:
have been in Vi
- all patients
Exclusion treated for Covid-19
Criteria:
 
;; Alexandru Burlacu, L ;alexandru ;00407444 University 1.
Exclusion SignedCriteria:
- patient rinformed
COVID-19;Pconsent
Diagnostic
 
 2. negative pregnancy
- Chronology test in women
not compatible between the dru
;; Joe-Elie Salem, MD, ;nguyen.le ;00331584 Clinical In CoronaviruDrug: Any
 Inclusion
3. COVID-19 Criteria:
confirmed by rtPCR in any respira
 
; ; ; ; ; ; ; Carmen Hernandez-CÃ¡ ;;;;;;;cmh ;;;;;;;5487 National In -4.Subject (orCOVID-19;S
Severe COVID-19legally diseas
authorized
Drug: Hydrrepresentative
to initiation of any study procedures.
; Florence Ader, MD;Fl ;florence. ;+33 (0)4 7 Hospices Ci 1.
- 1. age >18 years
Subjects
Understands must
Corona oldhave
and a documented
agrees
Vir Drug: comply wipositiv
to Remd
 - hours
Admittedof theto administration
intensive care of study drug
 Inclusion
2. identify Criteria:
the patients infected with novel co
; Colin Broom, MD;Col ;cbroom@p;832-315- Pulmotect, - suspected or
2. SubjectsCOVID-19
whoverified COVID-19
haveDrug:
no requirement
PUL- f
 1.
3. Any gender completed CT examination;
the patient
Nuffield Exclusion Criteria:
;; Departme
Zhang Li Na, MD;Zhao;56212264 ;+8613667 Xiangya Ho 2.
4. Nosignage
thelimit
info
Novel Coronavirus P
nt of Inclusion
- Pregnancy Criteria:
or breastfeeding
Primary 3. Informed consent for participation in the st
;; Care MD. ;robert.fri ;07365634 Uppsala Uni 
Robert Frithiof, - COVID-19 pneumonia patients
PreexistingCOVID-19;Organ Dysfudiagnosed by
Health Inclusion Criteria:
4. Virological diagnosis of Sars-CoV2 infection
Sciences, Exclusion Criteria:
; University
Francesco Perrone, M;f.perrone@ ;+3908159 Istituto Na 1. Should beCOVID-19at least 18Drug:
yearsTocil
of age,
of Oxford - Patients who were younger than 18 years,
 Inclusion
2. Male or Criteria:
female,
Radcliffe - Patients who COVID-19;Acute
had undergo Kidne
Observat -3.Hospitalised
Diagnosed with COVID-19 and confirmed SA
ory 
; Quarter,
Shyamasundaran Kotti;pzheng@ ;(202) 751 Institute o -4.Adults
Able to18signyear
Severe
theor CorDrug:
older CD24
Woodsto 
ck Road - Moderately severe disease (NEWS score = 6
Kun Ye 6 Taoyuan ; yezi5729@+86 18978 The PeopleInclusion
 c Exclusion cNovel CoroCase series
 - SARS-CoV-2 positive nasopharyngeal swab
Nuffield 
; Departme
Olav Dalgard, MD PhD;odalgard ;+47 9261 Akerhus Uni Corona Vir Drug: Hydr
nt of
Primary
United Kingdom Care Inclusion c Exclusion crCOVID-19 (SPatients wi
Health
Sciences,
Julie;Emm Ogburn;All Uni emma.ogbur -;+44 (0)1 ; Inclusion crExclusion crCOVID-19 (S 
Jiao Xianfa 33 Huanghe27835378 +86 13674 ZhengzhouInclusion c Exclusion cNovel CoroCase series
Exclusion criteria: (1) Those who are allergic
CHEN Hui (2) The
58 Shenlonchenhhust +86 13437 Union HospInclusion Exclusion investigator
cNovel CoroCase judges
seriethat the subj
Inclusion criteria:
 (3)(1)
Patients
Patientswith
aged
severe
18-80liver
years;
disease;
 (2) Clear
 (4)
diagnosis
pregnant
of patients
and lactating
with severe
patients;
COVID-19
Meng Jie 138 Tong-Zmengjie@c+86 13607 The Third X (3) Voluntarily
 (5) Those
joinSevere
the
who
trial
CO
have
and
Pirfenidon
severe
sign thekidney
informed c
Jie Lin 41 Xibei St linjie1992 +86 15258 Hwa Mei Ho Inclusion

Inclusion criteria: 1. Aged
c Exclusion Novel18CoroCase
to 80 years old;
series
 2. Patients diagnosed with novel coronavirus pneum
Inclusion criteria:
 3. Patients (1) criteria:
Exclusion
>=21 Fever patients;
days since 1. Patients
the first who
symptoms
are using
; i
Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny (2) peoples
 4. The Exclusion
 2.who
diagnosis criteria:
need
Patients
of
Novel toCoroCase
(1)
screen
pulmonary
with limited
recent the sample
novel
fibrosis
series coronavir
size;onint
hemodynamic
is based
 (3) patients
 (2)
forLack
possible
of sample
infection
information;
with novel corona
 (4) Age (3)
and gender
unable areornot
failure
limited;
to detect due to hum
Pengfei Pang 52 Meihua pangpf@mai +86 18902 The Fifth A ( (4) Abnormal
Novel CoroDiagnosed
results or failure in detec
Pei Bin 15 Jiefang xyxzyxzx@ +86 18995 Xiangyang Inclusion c Exclusion cNovel coroCOVID-19
Inclusion criteria: 1. Patients who have been diagnosed
betweencriteria:
18 to 80(1) Patients
1.years
Patients
old,whowithare
male severe me
or difficul
female
Luping Lin (2)
627 Dongfe13533550 +86 13533 Guangzhou 3. the subjects Maternal
 2. The patients;
participating
COVID-19
compliance the
experiment
of clinica
medication cannot
 (3) Pediatric patients;
Exclusion
Inclusion criteria:
 (4)Meet criteria:
Suicide 1. Other
thedeath
criteria formajor
cases; mental
confirmed diso
cases
Binru Wang 2.
241 Pengli wanbr2000+86 13554 Wuhan Thir 1. clinical
 (5) Weakness
manifestations:
Transferred affects
Novel CoroGold participation
to hospital
Standhalfwayinand
thef
 3. Communication barriers;
 4. Already participated in regular cogniti
Haihang Yu Zhuangyu Ryuhaihang 8.61E+12 Ningbo KanInclusion c 5. TakeNovel psychotropic
CoroGroup or other
1:ps drugs that
Inclusion criteria:
Exclusion
(1) criteria:
Patients(1)withPatients
mild, common,
who are unwill
and s
 (2) Those
 (2)
who Patients
meet thewithdiagnostic
neocoronary
criteriapneumon
for insom
Jing Li 1 Xiyuan Plxyyylijing +86 15901 Nursing De (3) Those
 (3)
who Patients
meet
novel
thewith
coro
diagnostic
mental
Experiment
criteria
illness who
for insom
hav
Exclusion
To include1) Have other
Patients
confirmed, severe
with
suspected
severe psych
res
an
Fan Li 415 Fengyafanli0930 +86 13564 DepartmentInclusion criteria:
 2)
 (2) Among the1.
Have
Aged suicidal
Children,
patie
Novel11-18 ideation
yearswomen
pregnant
CoroGold middle
and plan
Stand school
and during
stu
lactati
 2. GAD-7 3)
score Not
above
willing
10;to let their legal guardian k
Inclusion criteria:
 3. willing
 4) (1) aged 18-60
to participate
Currently takingyears;
this study
psychiatric
and receive
medicatio
their
Shitao Chen 19 Xin-Jie- kittychen +86 15967 Mental Hea (2) BMI 5
 4. Have in the normal
stable internet
Novel range
and (1+/-20%);
CoroSFBT
quiet space
groupto receive in
 (3) diagnosis
Exclusion
of lung
criteria:
cancer,
(1) had
breast
participated
cancer, cervical
in othe
 (4) ASA (2)
grade I-II;
used albumin and immunoenhancer
Yang Jinfeng 283 Tongzi31597770 +86 13875 Hu'nan Can (5) no (3) hadcancer a history ofGroup
coronavirus
2:th infection
Inclusion criteria: 1. Aged >14years old;
Rengbin Ji 2. The Exclusion
41 Xibei St rengbinji +86 13989 HwaMei Hos criteria: 1. to
Cases
diagnosis c2019-nCOVSARS-COV-2
conforms of severe vomiting
the "Diagnosis and Tre
 2. Pregnant and lactating women;
Inclusion criteria:
 3. 1.
Lopinavir/ridonavir,
Male and female aged ribavirin,
18-75interfero
years o
Zhaohui Tong 8 Worker Stongzhaoh +86 13910 Beijing Cha 2. Patients
 4.
previously
CasesNovel
of diagnosed
r CoroExperimenta
with COVID-2019:
Inclusion criteria: (1) Medical staff in Hubei province;
 (2) People aged between 18 and 65 years old;
Zhongyuan Xia 238 Jiefan wenqin-1 +86 13808 Renmin Hos (3) People
Exclusion
have electronic
csleep disorcross-secti
social software such as W
GAO Hong 29 Bulan R 13603035 +86 13603 Shenzhen T 2. AgedExclusion
older thanNovel
18 years.
CoroCritical gr
Inclusion criteria: (1) Patients with novel coronavirus pn
 (2) Patients with novel coronavirus pneumonia in W
Tang Hao 415 Fengyatanghao_ +86 13816 Department (3) Patients
Exclusion
meetcNovel
the clinical
CoroCase
suspicion
seriesand diagnos
Inclusion criteria:
Exclusion
(1) criteria:
Meet the(1)diagnostic
Critical patients;
criteria for pati
 (2) Aged (2)
18-85TCM
years;diagnosis of yang deficiency syn
Zhongde Zhang 111 Dade Rdoctorzzd +86 13903 Guangdong (3) To agree
 (3)toPatients
participate
NovelwhoCoroExperiment
incannot
the study
guarantee
and signcomp
the
YY Chen 61 West Ji chenyinyi +86 13637 Hu'nan ProInclusion Exclusion cnovel coro Case series
Exclusion criteria: 1. aged >75 years old.
Inclusion criteria:
 2. 1.
after
patients
cardiopulmonary
who meet the resuscitation;
requirement
Zhaohui Tong Exclusion
8 Worker Stongzhaoh +86 13910 Beijing Ch 2. patients
 3.
with scriteria:
accompanied 1. Pregnant
Novel CoroCase
by other womenorgan
series
severe or lactd
 2. Severe liver function damage (child-pu
 3. Severe renal impairment (Ccr<=15ml/
Chunli Liu 151 Yanjia chunli@gir+86 13560 The First A Inclusion c 4. HaveNovel
any coexisting
Coro1:7/5000medical condition
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Those
severe
who and
cannot
critical
recei
CO
 2. Aged 2.
>=18 Patients
years, bothwithmen
allergies
and women;
to certain tradi
Peiyang Gao 39 Shi-Er- gaopy930 +86 18980 Hospital o 3. Agree 3.
to participate
CasesNovel
where
CoroCase
complete serie
diagnosis and t
Exclusion criteria: (1) Reexamine CT;
Inclusion criteria:
 (2)(1)
TheTheCTpatients
image can withnot
covid-19
be analyzed
were cadi
Wei Wang 1095 Jiefa wwang@vi+86 13871 Tongji Hos (2) CT was (3)
positive
Patients
Novel
for the
with
CoroGold
first
pleural
time.
Stand
effusion or atele
Inclusion criteria: 1. Diagnosed COVID-19 patients;
Chen Jian 52 Meihua chenjn@mai
+86 13926 The Fifth H 2. Suspending
ExclusionCOVID-19
cNovel CoroCase
patients. series
Liujie Inclusion criteria:

37 Guoxue liudr@out +86 18980 West ChinaInclusion 1. patients
Exclusion with novel
cNovel Corothe coronavirus pne
patien
 2. Fever,
Exclusion
respiratory
criteria:
tract1)and
novel
other
coronavirus
symptoms, pneum
the
 3. Aged 2)
18 to The
80 years;
age is less than 18 years old or m
Wei Lu 725 Wanpinicuwei@16+86 18917 Longhua Hos 4. Signed
 3)
informed
Patients
Novel
cons
with
CoroExperiment
allergy to traditional Chi
Exclusion criteria: (1) those who do not meet
 (2) pregnant and lactating women;
Inclusion criteria:
 (3)(1)
severe
all patients
basic diseases
with clearly
of the
diagnosed
liver (Chi
Gang Sun 28 Fuxing Rsunok301 +86 13501 PLA Genera (2) agedExclusion
 (4) criteria:
>=18 years,
serious
Novel 1. sNCP
approved
renal
CoroCasebycaused
damage serie bydiseases
thebasic
ethicsother
commi no
 2. WHO grade III or IV pulmonary hypert
Inclusion criteria:
 3. 1.
Malignant
Patients tumor
are eligible
in lung
forand
inclusion
other sys
if t
Ye Xiaoqun 1 Minde Ro51120166 +86 0791 The Second 2. The 4.
patientsLactating
met
Novel
thewomen
CoroExperiment
diagnostic
or screening
criteria ofwomen
2019-n
MINGLI LIU 480 Shuang39595618 +86 13761 Shanghai KInclusion Exclusion Novel CoroCase series
Feng Zhen 17 Yongwaifengzhenl +86 13970 The First A Inclusion c Exclusion cNovel CoroGroup 1:Liu
Changqing Hu 352 Renmin13966906 +86 13966 DepartmentInclusion Exclusion cNovel CoroCOVID-19 p

Inclusion criteria: 1. Patients who were diagnosed with n
Jiang Shujuan 324 Jing-Wdocjiangs +86 15168 Shandong P 2. PatientsExclusion criteria:to
who agreed
cNovel 1.enrollment.
Knownseries
CoroCase allergies to the c
 2. Non-fever non-new coronary pneumo
Inclusion criteria:
 3. 1.
Fever
During
caused
the outbreak
by other non-infectious
of new corona
Peiyang Gao 39 Shi-er- gaopy930 +86 18980 Hospital o 2. Comply 4.
wi Patients
Novelwith
CoroCMtuberculosis,
group:X bronchial a
Inclusion criteria:
Exclusion
(1) criteria:
Aged >=18 (1) years;
Known or suspected all
 (2) 2019-nCoV
 (2) Acute
pneumonia
infectionis diagnosed
of other viruses
according
andtb
Li Shi-yue 151 Yanjia lishiyue@ +86 13902 the First A Inclusion criteria:
 (3) Patient's
 (3) 1)The
> Novel
18
condition years
function
has ofofage;
CoroExperiment
reached
liver and
the standard
kidney was of
 2) identify the patients infected with the new coron
 3) the Exclusion
patient completes
criteria: 1.CTthose
examination;
who cannot comp
Zhang Lina 87 Xiangya zln7095@1+86 15874 Intensive C 4) sign 2.
the informed
the patient
Novel
consent.
Coroobservatio
or his guardian requests to
Exclusion criteria: 1. Those who do not meet
 2. Without the informed consent of the
Sun Hongyuan 88 Changlinsunhongy +86 18222 First TeachInclusion 3. Unable Novel
to Coroconfirmed
cooperate with the informa
Inclusion criteria: 1. Novel coronavirus history before en
 (1) there
Exclusion
were travel
criteria:
history
1. Having
or residential
one of the
history
followin
Lei Genping Plus 2 Wei leigenpin +86 13609 Affiliated (2) During
 2.
theMycoplasma
14 Novel
days before
CoroSuspected
pneumo
onset, there
Exclusion criteria: Exclusion criteria (subjects
Inclusion criteria:
 (1)1.There
novelwas
coronavirus
no rapid pneumonia
immunoassay; confi
Tian Lin 52 Meihua tianlin@ma+86 0756 The Fifth A 2. WillingExclusion
 (2) criteria:
to participate
Subjects inThe
Novelwho
coroCaseclinical
rapid
could classification
immunoassay
series
not cooperate o
resea
wi
 1) Respiratory failure occurs and require
Inclusion criteria:
 2) 1.Shock
Agedoccurs;
18 to 70 years old, inpatients,
Binghong Zhang 99 Zhang-Zzbhong62 +86 13886 Renmin Hos 2. Patients 3)with
Combined
severe
NovelCOVID-19:
CoroExperiment
failure of othconfirmed cases
Huang Hui 41 Erling 39340681 +86 13825 HuiZhou Mu

Inclusion c Exclusion Novel CoroCOVID-19 p
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Patients
COVID-19whoinfection
are usingthw
Qianjin Lu 139 Renminqianlu586 +86 731-8 The 2nd Xi 2. Age- 2.
and sex-matched
ThoseNovel
whoCoroGold
refuse
normaltopeople
Stan
sign the
and
informe
patien
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=181. years
Gestational
old; female patie
 2. The Exclusion
 2. criteria:
person,Patients
who 1. Aged
is diagnosed
with < 7-year-old;
allergic
as constitution,
COVID-19 accorspe
Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos 2.
 3. previous
Patients arrhythmia;
Novelwith
CoroTricholoma
other malignant disease
 3. previous chronic respiratory failure ca
Inclusion criteria:
 4. 1.
hemodynamic
Novel coronavirus
instability;
pneumonia is dia
Hu Xingxing 100 Shizi S huxingxin +86 17327 Jiangsu Pr 2. Respiratory
 5. serateNovel
in calm
CoroExperiment
state >=30 times / min;O
Inclusion criteria: 1. Pharyngeal swabs are used to detec
 2. AgesExclusion
betweencriteria:
18 to 851.years
Patients
malewith
or female;
mental illn
Fan Zhong 8 Huaying gz8hzf@12+86 18122 Guangzhou 3. Su 2. Patients Noveljudged
Corocontrol
by the gr
researchers as
Wei Zhang 17 Yongwaizhangweil +86 13707 The First A Inclusion crExclusion c2019 - nC Case series
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18(1) to Female
65 yearspatients
old; who ar
Bin Zhang/Yinong Ye 81 LingnanFSYYN001 +86 18038 Department (2) Patients (2)
with
ALTmild
Novel
is higher
orCoroA:Long-acti
normal
than type
10 times
who the
have
uppe
bee
Inclusion criteria:
Exclusion
1. Aged
criteria:
between
1. Family
18 and
history
60 years;
of seizure
 2. Able 2.
to understand
Subject allergic
the content
to anyofcomponent
informed cons
of t
Zhu Fengcai 172 Jiangsuiszfc@sina +86 025 8 Jiangsu Pro 3. Able 3.
and willing
WomanNovel
to complete
who
Coro1:Low
is preg
all the
dosesecluded stu
Inclusion criteria: 1. novel coronavirus pneumonia diagn
 2. No contraindications
Exclusion criteria:for 1. Patients
MR examination;
with congenital
Ying-kun Guo 20 South Rgykpanda +86 18180 West China 3. understand
 2. Contraindications
theNovel
potential
CoroGold
risksof/Stand
MRI:
be there are fe
COVID-19
- Has diagnosed as malignant tum

Inclusion criteria: 1. Patients
 2. Stay in hospitallaborator
for 3 days or more;
 3. AgedExclusion y-
18 or above;
criteria: 1. Confirmed or suspected
Hongmei Tao 52 Meihua 13926946 +86 13926 The Fifth A 4. Info 2. KPS confirme
malignant
> 30 points.tumor pati
Inclusion criteria:
Exclusion d SARS-1. Patients
1. Pharyngeal
criteria: swabs and who/ orhave
analcontr
swa
 2. MalesExclusion
 2. CoV-2
criteria:
and females
Patients aged
with(1)mental
Allergic
18 to
to 85illnessfabiravir
years; cannotorcoa
Chuo Li 8 Huaying gz8hlc@12+86 15989 Guangzhou 3. Participant (2)
 (3)(1) as patients
Severe
Aged 18 yearswith or older;
expected surviv
 (2) Voluntarily determin
 (4) Pregnancy;
signed informed consent;
Xinghuan Wang 169 Donghuwangxingh+86 027 6 Zhongnan H (3) Hospitalized
 (5) HIV ed
patients
Novel by CoroExperimenta
positive diagnosed as COVID-19.
PCR, or
other
GuoLin Song 32 Feishan ant00099 +86 13985 The SecondInclusion Exclusion cNovel commerci Coronavirus Pn
Inclusion criteria:
Exclusion al or patients
1. Eligible
criteria: 1. Intubation
were adults
required ((aged
imm
 2. Were 2.
identified public
Pregnancy,
as laboratory-confirmed
severe chronic respiratory2019-nC
Li Bixi 627 Wuluobxlee@soh+86 13397 Central Th 3. Those Exclusion
 3.
who Those
needhealth
criteria:
novel 1. Allergy
intubation
patients
coro to drugs
experiment
has
in intubated
ICU, and withandno excs
Inclusion criteria:
 2. 1. assay and
Pregnant
Female in
patients
lactating
agedwomen
>=18 years and w
 2. SARS-CoV-2
 3.Have any
nucleic
malignant
acid test tumor
positive;
or hypercoagul
Chengyun Liu 1277 Jiefa chengyunl +86 18007 Union Hosp 3. Lung< CT exam specimen
Novel Coro1 the criti
Inclusion criteria:
Exclusion < 72 who
1) Those
criteria: 1) According
have closeto contact
the researc
with
 2) Be over
 2)
18 Those
yearshours old
who(including
are allergic 18 to
years
the old);
known i
Dawei Wang 100 Shizhi cleverwd +86 025-5 Affiliated Inclusion criteria:
Exclusion
 3) Voluntarily signCOVID-19
prior
 3) oPregnant
becriteria:
Novel
written to
enrolled,
or You allcannot
the following
CoroExperiment
la
informed be enrolled
consent. criteria
if y
 1) the 1)
confirmed Med
randomiz
any patient
situation (orthat
legal cannot
guardian)
allowagrees
the pr
 2) Aged 2) DRA
ation.
18-65allergic
years, gender
constitution,not limited;
allergic to more t
Li Lanjuan 79 Qingchuljli@zju.ed +86 13906 The First A 3) the 3) version:
-novel
time intpatients Illness
wcoro Mild Type
20.0
of any (1) any situation in which t
Exclusion criteria:
Inclusion criteria:
 (2)(1) Level:
duration,
allergic
aged 18 LLT
constitution;
to 70 years;
Gong Guozhong 139 Renmingongguozh+86 13873 The Second (2) Light Exclusion
 (3)
and heavy Classifica
and
criteria:
serious
Novel at
patients
basic1. Aged
withless
CoroInterventio
diseases than
newaffecting18 years
coronavirussurviv i
 2. Other tion
least code
one medical diseases such a
serious
Inclusion criteria:
 3. 1.
Not 10051905
of
Aged the
suitable
18 years for gastrointestinal
old and above; admin
Guochao Shi 197 Secondshi_guoch +86 13918 Ruijin Hosp 2. Meet Exclusion
 4.
the novel
Preg Term:
criteria:
following:
Novel
coronavirus 1.pneumonia
CoroExperiment ALT/AST (COVID-1
> 5 time
Inclusion criteria:
 2. 1. Coronavir
Stage
â€ 41.severe Subject
chronic
(or kidney
legally autho
disea
 2. Understands us
 3. Pregnancy
¢Clinical
and agrees or breast
to complyfeeding.
with planne
Christelle DELMAS 8 rue de la rqrc.siege 3.32E+10 INSERM 3. Agrees 4.to the infection
Anticipated
ascollect transfer Trade to another hos
System
Organ
Hossein Khalili Class:
Departmentkhalilih@t +98 21 669Tehran UniInclusion c Exclusion cCOVID-19 Interventi
10000000
4862
;
Amir Hossein JamshidNo 847, Behjamshidi.a +98 21 556Iran UniverInclusion Exclusion cCOVID-19. Interventi
Therapeu
Exclusion criteria:
tic area: - Pregnant woman
JAH VAN Oers jah.vanoer 1.32E+08 Inclusion c -Child
Exclusion lessDiseases
Lower thanrespi12Dyears-old
uring rout
 -Known [C]hypersensitivity
- Virus to chloroquine
 -Feeding Diseases
Jody Brookes Mailpoint jody.broo 2.38E+09 Synairgen Inclusion c -Retinopathy
Exclusion c [C02] Produc
Inclusion criteria:
 -Known
 - Women
deficit inand G6PD men with documen
 - Teenager
 -Refusal
girls andto boys
participate
aged more in the
than study
12 years
IHU MÃ©diterranÃ©e19-21 Boulline.medd 00334 13 7Fondation - Persons -Patient
who have Patients
given theirw Trade
free and informed c
Sven Laudi Liebigstras anaesthesi +49 341 97Klinik fÃ¼r Inclusion c Exclusion c;J12.8 - Ot Interventi
Hossein Khalili Departmentkhalilih@t 9.82E+10 Tehran UniInclusion c Exclusion cCOVID-19 Interventi
Dr Ehsan Aali Bahonar en.aali@g +98 28 333Qazvin UniInclusion c Exclusion cNovel CronInterventi
Farzaneh Dastan Dr. Masih f_dastan@s+98 21 261Shahid BehInclusion Exclusion COVID-19 pInterventio
Hossein Khalili Departmentkhalilih@t +98 21 669Tehran UniInclusion c Exclusion cCOVID-19 Interventi
Dr Hossein Poustchi Shariati Hoh.poustch +98 21 824Tehran UniInclusion Exclusion cCOVID-19. Interventio
Hospital
and ED by
electronic
survey.
Head of
Emergenc
y suspected of Covid-19 (fever
Inclusion criteria: Patients
Enrique Casalino 46 rue Henenrique.ca 3.31E+10 APHP qSOFAExclusion Departme
>=1 (respiratory
cCovid-19
ratec Ã¢?Â¥
Patients22,
susystolic bloo
nt will be
questionn
Hossein Khalili ed.
Departmentkhalilih@t +98 21 669Tehran UniInclusion c Exclusion cCOVID-19 Interventio
 Covi
d-19,
Tetsuya Nakamura 3-39-15 S nakamurt@ -8906 Gunma Univ Preparedi oral admini
Inclusion Exclusion cpatients
ness,
Responsiv
Tetsuya Nakamura 3-39-15 Sh nakamurt@ -8906 Gunma Univ eness, i oral admini
Inclusion Exclusion cpatients
Emergenc
y, Quality,
Masashi Kondo Organiza iImmediate
1-98 Dengamkond@fuji -9981 Fujita Heal Inclusion c Exclusion cCOVID-19
tion,
Formatio
Keibun Liu n,
Takebayashkeiliu040 028-626-5 Saiseikai Inclusion crExclusion cCOVID-19
Resource
s,
Junko Terada Manage
1-21-1, To registry.c 3.32E+08 National CeInclusion crExclusion cCOVID-19
ment,
Interoper
Enrique Casalino 46 rue Henenrique.ca 3.31E+10 Assistance Inclusion Exclusion c abi Head of de
Primary o results da results da results url RetrospectiBridging fl Bridged ty results yes no
mortality Yes 0
inhospital length;inhospital mortality;ECMOYes 0
duration of in hospital;in hospital mortality No 0
Length of hospital stay; No 0
Lung function; Yes 0
Conversion rate of mild and common type paNo 0
Time to disease recovery; Yes 0
SEN, SPE, ACC, AUC of ROC; Yes 0
Fatality rate; Yes 0
Time fo fever reduction;Time of nucleic ac Yes 0
Chest CT findings;Epidemiological history; Yes 0
Length of hospital stay;fever clearance time Yes 0
28-day mortality and 90-day mortality.; No 0
St. George's Respiratory Questionnaire; Yes 0
14 day outcome of the subjects, including: r No 0
Time to Clinical recovery; No 0
Detection specificity is greater than 95%;DetYes 0
The rate of virus inhibition Yes 0
Cardiovascular Death Yes 0
GHQ-12(general health questionnaire-12) Yes 0
PSQI; No 0
imaging feature; Yes 0
Chest imaging (CT); No 0
Length of stay;Length of severe;oxygenationYes 0
Time to complete remission of 2019-nCoV i Yes 0
Virus negative conversion rate in the first Yes 0
Lower Murray lung injury score;Lower MurraYes 0
The incidence of composite adverse outco Yes 0
Completely antipyretic time: completely an No 0
2019-nCoV nucleic acid turning negative time

Yes 0
Sensitivity of detection of NCP;Specificity o Yes 0
ECG;Chest imaging;Complications;vital sign Yes 0
detection of SARS-CoV-2 nucleic acid;SEN; Yes 0
Number of worsening events; Yes 0
clinical features and risk factors;validity and Yes 0
Incidence of co-infection; No 0
Antipyretic time; Yes 0
Cure rate;The cure time;The rate and time aYes 0
Body temperature returns to normal time;P Yes 0
Length of admission;mortality rate; No 0
TCR sequencing;BCR sequencing;HLA sequenYes 0

Time for body temperature recovery;Chest CT
Yes 0
Recovery time;Ratio and time for the generalYes 0
Relief of clinical symptoms and duration; Yes 0
Positive/Negtive;SEN, SPE, ACC, AUC of ROCYes 0
TCM symptom score;Antifebrile time;The time

Yes 0
rate of cure; No 0
Self-rating depression scale, SDS;Self-Rating No 0
the negative conversion ratio;the proportio No 0
PSI; Yes 0
Self-rating depression scale, SDS;Self-Rating Yes 0
pulmonary function;St Georges respiratory Yes 0
Time of viral nucleic acid turns negative;Ant Yes 0
Proportion of patients with a lung injury sc No 0
time and rate of temperature return to normYes 0
Time to clinical recovery; No 0
viral negative-transforming time;30-day causYes 0
The incidence of adverse outcome within 14Yes 0
TCM symptoms efficacy; Yes 0
Antipyretic time;Pharyngeal swab nucleic acYes 0
Time for body temperature recovery;Chest XYes 0
CT of lung;CT and MRI of hip; No 0
CD4+;CD3+;HAMA;HAMD;STAI; Yes 0
Clinical and laboratory indicators;Viral load No 0
Clinical characteristics;TCM syndrome; No 0
CURB-65;PSI score;Mechanical ventilation ti Yes 0
cure rate; No 0
Rate of conversion to severe or critical illnesYes 0
Inpatient mortality; No 0
28-day survival;Inflammatory factor levels; Yes 0
Duration of PCR normalization;Clinical sym Yes 0
Critically ill patients (%); Yes 0
length of stay;length of stay in ICU;Antibio No 0
vital signs (Body temperature, blood pressu Yes 0
Physical and mental health; No 0
pulmonary function;Novel coronavirus pneum

No 0
CT scan of the lungs;Nucleic acid detection oYes 0
blood routine examination;CRP;PCT;Chest CT;

No 0
incidence;mortality; No 0
Chest CT;Routine blood test;liver and rena Yes 0
the condition worsens and develops into seve

Yes 0
Chest CT scan;Nucleic acid of novel coronaviYes 0
Time to leave ventilator on day 28 after rec No 0
ROX index; Yes 0

Physical examination;Nucleic acid;Oxygen Yes 0
Epidemiological history;haematological;Fir No 0
Virus negative conversion rate in the first w Yes 0
Time to completely antipyretic time:comple Yes 0
Lymphocyte subpopulation analysis;CytokineYes

d 0
Incidence of onset at home / designated is No 0
Declining speed of Novel Coronavirus by PCRNo 0
State anxiety; Yes 0
the score of Hamilton depression scale;the sYes 0
PSI; Yes 0
The time when the nucleic acid of the novel No 0
Time to viral negativity by RT-PCR;Time to c Yes 0
Time to conversion of 2019-nCoV RNA resultYes 0
Number of Participants with presence of 20 Yes 0
lung injury score Yes 0
Cure rate;Mortality; Yes 0
body temperature;Whole blood count and five

Yes 0
Patient survival rate; No 0
virus nucleic acid negative-transforming tim Yes 0
Mortality in patients; No 0
pneumonia severity index (PSI);Incidence o Yes 0
The novel coronavirus nucleic acid negative Yes 0

all available outcome; Yes 0
Viral nucleic acid detection;CT Scan of th Yes 0
Time to disease recovery; No 0
The incidence of composite adverse outcomYes 0
TCM syndroms; Yes 0
the rate of remission; Yes 0
the daily treatment intensity; Yes 0
Blood routine tests, Liver function examina No 0
blood routine;urine routines;CRP;PCT;ESR;crNo 0
Time to viral negativityby RT-PCR;Time to c Yes 0
SARS-CoV2 Nucleic Acid Quantification; No 0
menstruation changes;TCM body constitutioYes 0
pulmonary function;Antipyretic time;Time ofYes 0
Body temperature;TCM syndrome integral;Mur

No 0
Distribution of 'B' line around lungs of bot No 0
Lower Murray lung injury score;Lower MurraYes 0
28day mortality; Yes 0
The changes of clinical symptom, laboratoryNo 0
Acute kidney injury; Yes 0
Antipyretic time;Time of virus turning negat Yes 0

clinical cure rate;Incidence of mechanical v No 0
Neutrophil count;Lymphocyte count;Monocyt

Yes 0
viral negative-transforming time;30-day cauNo 0
Clinical symptoms;Blood routine;the viral No 0
CD8+ T cells numbers;CD4+ T cell numbers;NK

Yes 0
Chest CT;Whole blood cell analysis;Recover Yes 0
pneumonia severity index (PSI); No 0
Oxygenation index Yes 0
Release rate of discharge standards for isol Yes 0
NA; Yes 0
Clinical recovery time; No 0
Cortisol;ACTH;Form of Adrenal tissue; Yes 0
TCM symptom score;Becomes negative timeNo

o 0
Severe NCP group: Time to clinical improvemNo 0
M mode echocardiography;two-dimensionalNo 0
Mood index; Yes 0
Improvement of clinical symptoms (Clinical iYes 0
Time to Clinical Recovery; Yes 0
Rate of composite advers outcomes:SpO2,PaNo 0
Quality of life;Anxiety assessment;Depres Yes 0
The days from positive to negative for viral nYes 0
ICU hospitalization days;Death rate; Yes 0

Clinical index; Yes 0
Self-rating depression scale; Yes 0
Self-Rating Anxiety Scale;Self-Rating Depres Yes 0
lung function;ADL;6min walk; Yes 0
Proportion of COVID-19 close contacts who Yes 0
Death;Recovered;Discharged; No 0
Length of hospital stay; Yes 0
TCM syndrome; Yes 0
menstruation changes; No 0
psychological scale;Intestinal flora abundan No 0
recovery time; Yes 0
Chest imaging;RNA test of COVID-19;Time toYes 0
Recovery rate; Yes 0
TTCI (Time to Clinical Improvement); Yes 0
The nucleic acid of the novel coronavirus i Yes 0
Disappearance rate of fever symptoms; Yes 0
oxygen index;max respiratory rate;lung radi Yes 0
Three-dimensional ultrasound;Two-dimensioNo 0
CT image of lung of close contact medical st Yes 0
CoVID-19 Perinatal Outcomes; No 0
Cytokine detection;Lymphocyte subpopulatio

Yes 0
blood cell count;C-reactive protein (CRP);ar Yes 0
SOFA; Yes 0
gut microbiome;Fecal metabolomics;Blood ro

Yes 0
Clinical recovery time;Clinical recovery tim No 0
Clinical recovery time; Yes 0
SARS-CoV-2 DNA;SARS-CoV-2 antibody levels

Yes 0
Improved respiratory system function (bloo No 0
SARS-COV-2 nucleic acid;SEN, SPE, ACC, AU Yes 0
Clinical characteristics; Yes 0
Coronavirus nucleic acid markers negative No 0
Time to Clinical recovery;Butyrate in feces; No 0
Number of patients who have progressed toYes 0
Accuracy; Yes 0
Mental health status; Yes 0
Recovery time; Yes 0
Time to Clinical Improvement (TTCI) [Censo Yes 0
hospital stay;Discharge rate;Site-specific Yes 0
cure rate; No 0
Arterial Blood Oxygen Saturation;TTCR,TimeYes 0
Time to Clinical Recovery; No 0
HSCS;SCSQ;GHQ-12; No 0
the rate of Coronary virus nucleic acid neg Yes 0

Time to Clinical recoveryTime to Clinical Re Yes 0
positive number diagnosed by national guideYes 0
the incidence of treatment failure in 14 day Yes 0
Time to Clinical recoveryTime to Clinical Re Yes 0
The incidence of long-term adverse outcom Yes 0
Oxygenation index (PaO2/FiO2);Pneumonia Ys es 0
Accuracy of nCapp COVID-19 risk diagnosti Yes 0
Psychological status;Treatment compliance;To

Yes 0
Recovery time;Pneumonia psi score; Yes 0
The SARS-CoV-2 infection of neonates born Yes 0
2019 nCoV nucleic acid detection Yes 0
Clinical recovery time Yes 0
High-resolution computed tomography (HRCT)

Yes 0
The change of pneumonia severity on X-ray Yes 0
PCL;PSQI;FSI; Yes 0
Pharynx swabs, lower respiratory tract sampNo 0
Time to Clinical Improvement (TTCI) Yes 0
28-day all cause mortality Yes 0
Partial arterial oxygen pressure (PaO2) to fraYes 0
CT;SEN, SPE, ACC, AUC of ROC; No 0
Epidemiological characteristics;clinical fe No 0
PCL;HRQL;IPAQ;PASE; Yes 0
Post-traumatic stress disorder checklist;Clin Yes 0
Lung CT;TCM symptoms; No 0
Epidemiological and clinical characteristics; Yes 0
mood assessment; Yes 0
pulmonary iconography; Yes 0
Case series:NA; No 0
Epidemiological and clinical characteristics; No 0
walking distance;oxygen saturation;heart raYes 0
Lung CT after 3 days;Lung CT after 7 days;O Yes 0
Survival rate Yes 0
Positive rate of 2019 Novel Coronavirus RN Yes 0
Number of participants with treatment-rela Yes 0
Inhospital time; Yes 0
temperature;respiratory symptoms; Yes 0
blood RNA; Yes 0
SEN, SPE, ACC, AUC of ROC; No 0
K-bld questionnaire survey;Refers to the pu Yes 0
During the operation, the patient's volume oYes 0
Critically ill patients (%);Mortality Rate; No 0
The time to 2019-nCoV RNA negativity in patYes 0
GHQ-20; No 0
Sputum/nasal swab/pharyngeal swab/lowerYes

res 0
cure rate;virus negative rate;time of virus n Yes 0
Viral load;Clinical features;Inflammation;P No 0
NRS 2002 score;BMI;triceps skinfold thickn Yes 0
Blood Routine;Liver function;Blood electrol No 0
Psychological questionnaire; Yes 0
Time to disease recovery;Exacerbation (tranNo 0
imaging feature; Yes 0
Temperature;Respiratory symptoms; Yes 0
Clinical indicators; Yes 0
Clearance rate and time of main symptoms (fYes 0
SEN, SPE, ACC, AUC of ROC; Yes 0
Lung CT; Yes 0
health status;Mental health status; No 0
Inflammation factor; No 0
no; Yes 0
Quality of Life;Epidemic Prevention Medica No 0
Rate of composite advers outcomes: SpO2, PNo 0
Clinical symptoms;TCM syndrome;Lung imagin

No 0
Mood index; No 0
Clinical recovery time;Pneumonia Severity InNo 0
Clinical symptoms;Test result;Examination r Yes 0
Routine physical examination;Vital signs: b Yes 0

pulmonary function; Yes 0
temperature;respiratory rate;Blood oxygen No 0
INR;PT;TT;APTT;FIB;DD; Yes 0
ROC;calibration curve; Yes 0
viral negative-transforming time;30-day causYes 0
exposed factors;latent period;preventive m Yes 0
Negative conversion rate of 2019-nCoV nucleYes 0
the relive of CRS; No 0
COVID-19 nucleic acid detection time from po

Yes 0
Clinical characteristics; No 0
Length of hospital stay;Discharge time of ge No 0
Negative conversion rate of COVID-19 nucleiYes 0
Time to clinical recovery; Yes 0
Blood routine examination;Chest CT;Arteria Yes 0
cough; Yes 0
time to recovery.; Yes 0
SOFA score; Yes 0
Quality of life;Socio-demographcis and otheNo 0
Cancelled; Yes 0
Validity observation index; Yes 0
The proportion of patients diagnosed with Yes 0
Time to Clinical Recovery, TTCR; Yes 0

TTCI (Time to Clinical Improvement); Yes 0
The time to 2019-nCoV RNA negativity in patNo 0
Time to negative NPS Yes 0
Size of lesion area by chest radiograph or C Yes 0
Time to clinical recovery after treatment Yes 0
Adverse reaction (AE) and severe adverse reYes 0
Negative conversion (%) of 2019-nCOVRNA in

Yes 0
intrusion;avoidance; No 0
Worsening condition;Death;Heart fatty acid Yes 0
Lung ultrasound index;Right ventricular funcYes 0
Immunity function;cytokines;viral load; Yes 0
Volatile organic compounds, VOCs;SEN, SPE Yes 0
Clinical therapeutic course;Pathogenic dete No 0
Time to Clinical Recovery (TTCR); Yes 0
ALT; Yes 0
Unplanned shutdowns; Yes 0
Pulmonary image findings;Relevant clinical Yes 0
Chest imaging;Oxygenation index;ExtravascuYes 0
viral load;virus genotyping;Classification of Yes 0
A cycle threshold value (Ct-value); No 0
Screening accuracy Yes 0
K-BILD;blood gas;Finger pulse oxygen;chest Yes 0

7-day mortality Yes 0
The proportion of patients with normal leveYes 0
Mortality; No 0
Sputum/nasal swab/pharyngeal swab/lowerYes

res 0
TCM syndrome; Yes 0
Cure rate; No 0
Tempreture;Virus nucleic acid detection; No 0
clinic outcome; No 0
28-day mortality;ICU 14-day mortality; Yes 0
Rate of composite advers outcomes: SPO2, PNo 0
PSS-14; Yes 0
Real-time fluorescent RT-PCR detection of pNo 0
The time of duration of COVID-19 nucleic acNo 0
Psychological status; No 0
Progression rate from mild to critical/severeYes 0
fever clearance time;Effective rate of TCM No 0
Pulmonary function;6 minutes walking distaNo 0
Child Stress Disorders Checklist evaluation; Yes 0
length of stay;length of stay in ICU;Hospita No 0
Nuclei acid test of SARS-CoV-2 of conjuncti No 0
in-ICU mortality;mortality of 28 days; No 0
In-hospital mortality;Hospital mortality; No 0

disease incidence;Duration of PCR normaliz No 0
ratio of severe cases; Yes 0
PaO2 / FiO2 or respiratory rate (without ox No 0
Cardiac injury;Death in hospital and/or EndoYes 0
SpO2 during intubation;the total time of in Yes 0
MRC breathlessness scale;6MWD; No 0
Pittsburgh sleep quality index; Yes 0
Incidence of side effects; Yes 0
28 day mortality; Yes 0
Clinical characteristics; Yes 0
Clinical symptom improvement rate: improvYes 0
Mental status;Social support; Yes 0
lasting time of fever;lasting time of novel No 0
28 day mortality; Yes 0
cure rate;duration of hospitalization;days o Yes 0
Main symptom relief time; Yes 0
Epidemiological and clinical characteristics; No 0
CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine eNo 0
Patients' general information: epidemiologi Yes 0
Safety; No 0
Clinical symptoms;Blood routine;BiochemicalNo 0
Cytokines; No 0
time in range; Yes 0
CT image of lung; Yes 0
Severe conversion rate;Oxygenation index;2No 0
Inccidence of 2019-nCoV pneumonia; No 0
Clinical symptoms (fever, weakness, cough) Yes 0
Clinical improvement time of 28 days after rNo 0
Clinical symptoms (fever, weakness, cough) Yes 0
Drug: Eculizumab Yes 0
the number of days between randomised gro

Yes 0
The mortality rate of subjects at weeks 2;TheYes 0
The virological clearance rate of throat swa Yes 0
Improvement of symptoms; No 0
nosocomial infection ratio of SARS-Cov-2; No 0
Clinical cure rate; No 0
Symptom Checklist 90; Yes 0
chest CT images; No 0
Laboratory inspection index;Oxygen therap No 0
CT; No 0
Success rate of intubation;Infection rate of Yes 0
Confirmed 2019-ncov pneumonia; No 0
Oxygenation index (arterial oxygen partial p No 0
2019-ncov-RNA;Chest CT;Routine blood tes No 0

RT-PCR test for SARS-CoV-2; Yes 0
Single cell sequencing; No 0
Mortality rate; No 0
cytology;proteomics;chest X-ray;OxygenatioNo 0
Rate of composite adverse outcomes Yes 0
Numbers of participants with different Clini Yes 0
The incidence of side effects;The incidence oYes 0
mental health status and influence factors; No 0
SARS-free patients at 14 days Yes 0
The time interval of Nucleic acid detection Yes 0
Clinical recovery time Yes 0
RT-PCR confirmed COVID-19 infection Yes 0
Average discharge time;WBC;ALT, AST, gama-

No 0
Clinical outcomes after discharge; No 0
Transmission dynamics of COVID-19 in HongNo 0
white blood cell;lymphocyte;creatinine;CRP No 0
Length of stay in ICU;Diaphragm movement No 0
Chinese health status scale;Self-rating AnxieYes 0
CK-MB;CTnI;neuron-specific enolase,NSE;BUN;
No 0
Death; No 0
The prevalence and incidence changes of Yes 0
serum albumin;siderophilin;prealbumin;lungNo 0
Time to Clinical Improvement (TTCI); No 0
SAA;Detection of respiratory pathogen ser No 0
Clinical features; Yes 0
Epidemiological features; No 0
Precision;SEN, SPE, ACC, AUC of ROC; No 0
HRCT pulmonary fibrosis score; No 0
temperature;Systemic symptom;RespiratoryNo 0
PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACT
Yes 0
Abnormalities on chest CT;Exposure to sourcNo 0
High dose group:routine treatment + MSc (2 x10^6 / kgNo 0
Epidemiological characteristics;SARS-CoV-2 IYes 0
Maternal and neonatal morbidity; No 0
Discharge rate; No 0
blood RT;ABG;blood clotting function;liver aNo 0
Cough Score;Expectoration score; No 0
The time for the positive nucleic acid of t No 0
Dose of analgesic and sedative drugs;28-dayNo 0
Liver function; No 0
ymphocyte subsets; No 0
sensitivity;SPE; No 0
SCL-90 scale; Yes 0

cure rate;propotion of progression;SEN, SP No 0
all-cause death;fatal arrhythmias; No 0
Two-dimensional ultrasound;M mode echoca

No 0
age;sex;comorbidities;chest-CT examination;No 0
Psychological assessment; Yes 0
SARS-CoV-2; No 0
RNA of 2019-nCov;SPE, SEN, ACC, AUC of R Yes 0
Laboratory inspection index;Imaging examinNo 0
time and rate of cure; proportion and time No 0
discharg time; No 0
blood gas;SOFA score; Yes 0
Pulmonary function;Cardiac function;neural No 0
Mortality of ICU 28-day; No 0
Ocular Symptoms; No 0
CRP;IL-6;TNF-alpha;IL-8; Yes 0
false positive rate of SARS-CoV-2 IgM antib No 0
in-ICU mortality; Yes 0
PaO2;PaCO2; No 0
Gold Standard:Epidemiological history + CT + clinical No 0
Epidemiological characteristics;clinical fe No 0
lynphocyte;cytokine;cancer history;order of No 0
Quantitative CT characteristic; No 0
blood biochemistry; No 0
mortality;effective rate; No 0
anxiety; No 0
nucleic acids probing;blood routine;blood b No 0
Outcome; No 0
CT Scan-Chest; No 0
mortality;ICU hospital stay;mechanical ventiNo 0
Levels of anxiety, stress and depression; No 0
28-day prognosis; No 0
death;Number of failure organs;Length of hoNo 0
Blood oxygen saturation; Yes 0
Sensitivity, specificity and accuracy; No 0
PSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian No 0
Clinical characteristics according to TCM; No 0
the clinical, laboratory and the radiologic chYes 0
Critical illness ratio; Yes 0
ascultation; No 0
Medical imaging improvement rate in patienNo 0
ICU hospitalization days;The recurrence rateNo 0
Inpatient mortality;ICU hospital stay; No 0
Shorten the duration of the disease;Antipyr No 0
Time to Clinical Recovery; No 0

Tempreture;cough;dyspnea;Blood Routine;At
No 0
detection of SARS-CoV-2 RNA;SEN, SPE, ACCYes 0
Time to clinical recovery after randomizatio No 0
SDS;SAS;PSQI; Yes 0
Lymphocyte grouping; No 0
chest computerized tomography;Nucleic acidNo 0
14-days mortality;28-days mortality; Yes 0
SARS-CoV-2 virus;sex hormones;sperm qualiNo 0
Mortality rate;Common-severe conversion rat

No 0
Lung CT; Yes 0
Time to Virus Eradication; Yes 0
Time to Virus Eradication; No 0
temperature;heart rate;respiratory rate;blo No 0
Recovery time;Pneumonia psi score; No 0
impact on the treatment of tumor patients; No 0
Clinical characteristics;Clinical outcomes; No 0
In-hospital mortality;ACC, SEN, SPE, ROC; Yes 0
cough;agitation; Yes 0
CT image features;Fever;Throat swab virus nYes 0
Status of immune function;The time of nucleiYes 0
Comprehensive psychological assessment;Me

No 0
The percentage of patients who convert to mNo 0

Imaging; Yes 0
Disease Severity;Imaging;Syndrome FeatureYes 0
treatment effect; No 0
treatment group :Ba duanjin; No 0
Time to disease recovery;Time and rate of Yes 0
sleep status and related factors of insomnia No 0
Lung ultrasound;Chest computed tomography

Yes( 0
The time when the nucleic acid of the novel Yes 0
GAD-7; Yes 0
Time and rate of novel coronavirus become Yes 0
lasting time of fever;lasting time of novel No 0
Complete Blood Count;CRP;blood coagulatioNo 0
Endotracheal intubation rate;mortality;RatioYes 0
The negative conversion rate and negative cYes 0
Self-rating depression scale;self-rating anxi Yes 0
Temperature returns to normal for more thaYes 0
IFN-gama;TNF-alpha;Blood routine index;TimYes 0
Ventilation-free days;mortality; Yes 0
Time of conversion to be negative of novel cNo 0
detection of SARS-Cov-2 nucleic acid;SEN, A Yes 0
Clinical symptom improvement rate: improvYes 0
Ventilation-free days;mortality; Yes 0

Time of conversion to be negative of novel cYes 0
Mortality rate; Yes 0
Positive/Negtive;False positive of rate ; Yes 0
Oxygen Inhalation Frequency;Oxygen IntakeYes 0
DEATH; No 0
Feasibility of developing a UK based sero epYes 0
Patientsâ€™ general information: epidemioloYes 0
Number of participants with improvement Yes 0
2019-nCoV RNA;2019-nCoV antibody;Chest Yes 0
Death;Mechanical Ventilation;Occupancy rate

Yes 0
Rate of comprehensive adverse outcome Yes 0
Rate and time of entering the critical stage Yes 0
Ventilation-free days Yes 0
Feasibility of blood pressure self managemenNo 0
Rate of disease remission;Time for lung rec Yes 0
Time course of body temperature (fever);VirYes 0
Time for lung recovery;Rate of disease remi Yes 0
Time to Clinical Improvement (TTCI) Yes 0

recovery Yes 0
28 day mortality Yes 0
Lower Murray lung injury score;Clinical im Yes 0
Mean clinical recovery time (hours) Yes 0
Frequency of solicited local reactogenicit Yes 0
Proportion of Participants Discharged by Da Yes True parent
Percentage of subjects reporting each severiYes 0
Improvement time of clinical critical treat Yes 0
Blood oxygen saturation;Size of lesion area Yes 0
Drug: Remdesivir Yes 0
Mortality rate Yes 0
all-cause mortality Yes 0
Proportion of subjects with positive T cell Yes 0
survival status No 0
Proportion of Participants With Normalizat Yes True parent
Number of symptomatic COVID-19 infectionYes 0
Viral load Yes 0
Survival rate Yes 0
Effectiveness of chemoprophylaxis assessedYes 0
Time of entering the critical stage;Rate of e Yes 0
Differences of attitude about blood donatio Yes 0
The relief / disappearance rate of main sy Yes 0

Disppear time of ground-glass shadow in th Yes 0
Reduction in the incidence of patients wit Yes 0
Assessment of COVID-19 situation;DepressioYes 0
changes in the ratio of PaO2 to FiO2 from b Yes 0
Proportion of patients whose oxygenation Yes 0
Change of arterial oxygenation at 48 hours Yes 0
Clinical cure rate Yes 0
Hospital Admission Yes 0
Sequential Organ Failure Assessment (SOFA)Yes 0
COVID-19 diagnosis Yes 0
The risk factors analysis for the death;The Yes 0
RT-PCR results;CT Scan;Clinical outcome Yes 0
Proportion of Participants With Normalizat Yes 0
Stress Yes 0
PO2;Mortality Yes 0
Incidence of respiratory failure Yes 0
Sensitivity, spectivity turnaround time of Yes 0
Prevention of COVID-19 Yes 0
Change in viral expression in association to Yes 0
Percentage of patients reporting each severitYes 0
Safety indexes of adverse reactions Yes 0
Maternal and perinatal outcomes Yes 0

Disappear time of ground-glass shadow in t Yes 0
Number of patients with contrasting results Yes 0
COVID-19 negative X-Rays;COVID-19 positiv Yes 0
Renal failure Yes 0
All-cause hospital mortality Yes 0
Percentage of subjects reporting each severiYes 0
Severity of COVID-19 Yes 0
characteristics of cardiopulmonary ultrasou Yes 0
Acute Kidney Injury Yes 0
One-month mortality rate Yes 0
Rate of Acute Kidney Injury Yes 0
Improvement of COVID-19 disease status Yes 0
25(OH)D; No 0
Rate of decline in SARS-CoV-2 viral load Yes 0
Time from COVID-19 tes

4/1/2021 Yes 0
The need for hospital ### Yes 0
T lymphocyte subsets; Yes 0
Neonatal outcome; No 0
HRCT score; No 0
Abnormalities on chest CT; Yes 0
Pulmonary function evaluation;Changes in blNo 0
Metagenomics Sequencing; No 0
demographic information;exposure history;clNo 0
syndrome;nucleic acid of nCoV-19; No 0
PT-PCR test;SEN, SPE, ACC, AUC of ROC; No 0
Pittsburgh sleep quality index;Self-rating an Yes 0
insomnia;anxiety;depression;comfort; No 0
SEN, SPE, ACC, AUC of ROC; No 0
GAD-7;STAI-Y (C); Yes 0
postoperative complication;occupancy rate of

No 0
Serum SARS-COV-2 RNA;Swallow swab SARSNo 0
improvement or recovery of respiratory symNo 0
Pittsburgh sleep quality index;hospital anxi No 0
T lymphocyte count; Yes 0
Clinical Characteristics, Treatments and Pro No 0
Inflammation absorption on Chest CT; Yes 0
clincical characteristics; No 0
hospital mortality; No 0
The biochemical indicators; No 0
fatality rate;the ratio of patients transform No 0
CT image;sensitivity;Specificity;Time efficienYes 0
Clinical characteristics and risk factors; No 0
Nucleic acid; No 0
Quantitative table of main symptom grading;No 0

nuclear acid test of faeces;nuclear acid tes No 0
Changes of serum inflammatory factors;PatieYes 0
Blood routine test; No 0
Maximal inspiratory pressure;Respiratory mYes 0
Venous Thrombosis; Yes 0
Body temperature returns to normal time;A No 0
The change of TCM syndrome integral of defiYes 0
auto B line method;Semi-automatic manual Ymes 0
traditional Chinese medicine symptom; No 0
Incidence of COVID-19 pneumonia;COVID-1 No 0
Immune response multiomics; No 0
Improvement of clinical symptoms (Clinical iYes 0
Time to negative conversion of severe acut Yes 0
RNA;DNA; No 0
Albumin;Cellular immune indicators (total No 0
PO2/FiO2;ROX INDEX; No 0
novel coronavirus nucleic acid; Yes 0
detection of virus nucleic acid; Yes 0
COVID-19 nucleic acid negative conversion rNo 0
adverse reactions 7 days post injection; No 0
First pass perfusion i;Delayed enhancemen Yes 0

psychological states; No 0
RNA of Coronavirus; Yes 0
Clinical recovery rate of day 7; No 0
prognosis; No 0
the lowest SpO2 during intubation; Yes 0
SP02;lesions of lung CT;temperature;Blood Yes 0
Compared with the control group, the posit Yes 0
The time required for RNA Yin conversion o Yes 0
novel coronavirus nucleic acid clearance rat No 0
Viral nucleic acid test; No 0
Timepoint(s) of evaluation of this end point:Yes 0
Complications of the treatment. Timepoint: No 0
Response to the treatment (Significant clini No 0
28-day mortality Yes 0
Main Objective: To assess whether SNG001 is

Yes 0
Timepoint(s) of evaluation of this end point No 0
genetic and epigenetic risk profiles Yes 0
Complications of the treatment. Timepoint: No 0
Cough. Timepoint: Daily. Method of measureNo 0
Clinical response to therapy. Timepoint: D No 0
Response to the treatment (improvement ofNo

p 0
Clinical recovery (composite) within 14 daysYes 0

ED time interval [Time ### Yes 0
Adverse drug reactions. Timepoint: Every otNo 0
expected value and 95% CI of ratio of C-reacYes 0
expected value and 95% CI of ratio of C-reacYes 0
Proportion of subjects with clearance of S Yes 0
1.Date of ECMO disco ### No 0
none ### Yes 0
Prepredness measureme ### Yes 0

Ictrp Covid-19

Uploaded by

Copyright:

Available Formats

You might also like

Ictrp Covid-19

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ictrp Covid-19

Uploaded by

Copyright:

Available Formats

TrialID Last Refreshe Public title

A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019

A Medical Records Based Study for the Effectiveness of Extracorporeal Membrane

Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus

A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel

A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of

Evaluate the effectiveness of Traditional Chinese medicine in the treatment of novel

Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay

NCT042559 17-Feb-20 2019-nCoV Outbreak and Cardiovascular Diseases

A Survey of Psychological Status of Medical Workers and Residents in the Context of

Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV

Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused

The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and

An observational study for Xin-Guan-1 formula in the treatment of novel coronavirus

Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-

A randomized, open-label study to evaluate the efficacy and safety of low-dose

A comparative study on the sensitivity of nasopharyngeal and oropharyngeal

A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the

A medical records based study of novel coronavirus pneumonia (COVID-19) and

Chinese medicine prevention and treatment program for novel coronavirus

Application of Regulating Intestinal Flora in the Treatment of Severe Novel

Immune Repertoire (TCR & BCR) Evaluation and Immunotherapy Research in

Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia

A randomized controlled trial for honeysuckle decoction in the treatment of patients

Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus

A randomized, open-label, controlled clinical trial for azvudine in the treatment of

An observational study on the clinical characteristics, treatment and outcome of novel

A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-

Study for clinical characteristics and distribution of TCM syndrome of novel

A randomized controlled trial of integrated TCM and Western Medicine in the

Clinical Application of ECMO in the Treatment of Patients with Very Serious

Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a

Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus

Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus

A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus

Impact of vitamin D deficiency on prognosis of patients with novel coronavirus

Epidemiological investigation and clinical characteristics analysis of novel coronavirus

Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus

A clinical observational study for Xin-Guan-2 formula in the treatment of suspected

Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-

Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV

NCT042685 24-Feb-20 Immunoregulatory Therapy for 2019-nCoV

Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy

Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia

A prospective, open-label, multiple-center study for the efficacy of chloroquine

Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-

Randomized controlled trial for traditional Chinese medicine in the prevention of

A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian

Study for establishment of correlation between virological dynamics and clinical

Effects of novel coronavirus pneumonia (COVID-19) on menstruation, TCM body

Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia

Study on ultrasonographic manifestations of new type of novel coronavirus

The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of

Combination of traditional Chinese medicine and western medicine in the treatment

Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the

Multicenter randomized controlled trial for rhG-CSF in the treatment of novel